<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Treatments for Morton's neuroma - Matthews, BG - 2024 | Cochrane Library</title> <meta content="Treatments for Morton's neuroma - Matthews, BG - 2024 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD014687.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Treatments for Morton's neuroma - Matthews, BG - 2024 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD014687.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD014687.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Treatments for Morton's neuroma" name="citation_title"/> <meta content="Barry G Matthews" name="citation_author"/> <meta content="Queensland University of Technology (QUT)" name="citation_author_institution"/> <meta content="barry@informpodiatry.com.au" name="citation_author_email"/> <meta content="Colin E Thomson" name="citation_author"/> <meta content="The Royal Infirmary of Edinburgh and St John’s Hospital Livingston" name="citation_author_institution"/> <meta content="Michael P Harding" name="citation_author"/> <meta content="University of South Australia (City East)" name="citation_author_institution"/> <meta content="John C McKinley" name="citation_author"/> <meta content="Royal Infirmary of Edinburgh and Royal Hospital for Sick Children" name="citation_author_institution"/> <meta content="Robert S Ware" name="citation_author"/> <meta content="Griffith University" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="2" name="citation_issue"/> <meta content="10.1002/14651858.CD014687.pub2" name="citation_doi"/> <meta content="2024" name="citation_date"/> <meta content="2024/02/09" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD014687.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD014687.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD014687.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Anesthetics, Local; Atrophy; *Morton Neuroma [therapy]; Pain; Quality of Life" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014687.pub2&amp;doi=10.1002/14651858.CD014687.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014687.pub2&amp;doi=10.1002/14651858.CD014687.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014687.pub2&amp;doi=10.1002/14651858.CD014687.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014687.pub2&amp;doi=10.1002/14651858.CD014687.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014687.pub2&amp;doi=10.1002/14651858.CD014687.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014687.pub2&amp;doi=10.1002/14651858.CD014687.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014687.pub2&amp;doi=10.1002/14651858.CD014687.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014687.pub2&amp;doi=10.1002/14651858.CD014687.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014687.pub2&amp;doi=10.1002/14651858.CD014687.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014687.pub2&amp;doi=10.1002/14651858.CD014687.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014687.pub2&amp;doi=10.1002/14651858.CD014687.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014687.pub2&amp;doi=10.1002/14651858.CD014687.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014687.pub2&amp;doi=10.1002/14651858.CD014687.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014687.pub2&amp;doi=10.1002/14651858.CD014687.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014687.pub2&amp;doi=10.1002/14651858.CD014687.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014687.pub2&amp;doi=10.1002/14651858.CD014687.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014687.pub2&amp;doi=10.1002/14651858.CD014687.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014687.pub2&amp;doi=10.1002/14651858.CD014687.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014687.pub2&amp;doi=10.1002/14651858.CD014687.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014687.pub2&amp;doi=10.1002/14651858.CD014687.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014687.pub2&amp;doi=10.1002/14651858.CD014687.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014687.pub2&amp;doi=10.1002/14651858.CD014687.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014687.pub2&amp;doi=10.1002/14651858.CD014687.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774054000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774081000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000"}};Liferay.authToken="tkZQC4GK";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD014687\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD014687\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD014687\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD014687\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1559916434000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","de","zh_HANS","zh_HANT","ms","fa","fr","pl"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD014687.pub2",title:"Treatments for Morton\u0027s neuroma",firstPublishedDate:"Feb 9, 2024 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Neuromuscular Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738735355000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=tkZQC4GK&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD014687.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD014687.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD014687.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD014687.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD014687.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD014687.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD014687.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD014687.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD014687.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD014687.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Zusammenfassung in einfacher Sprache&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;pl&quot;,&quot;title&quot;:&quot;Streszczenie prostym językiem&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;淺顯易懂的口語結論&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;riskOfBias2&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Risk of bias&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Risk of Bias&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD014687.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD014687.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD014687.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD014687.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>3853 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD014687.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD014687.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD014687.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD014687.pub2/full#CD014687-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD014687.pub2/full#CD014687-sec-0112"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD014687.pub2/full#CD014687-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD014687.pub2/full#CD014687-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD014687.pub2/full#CD014687-sec-0014"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD014687.pub2/full#CD014687-sec-0015"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD014687.pub2/full#CD014687-sec-0054"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD014687.pub2/full#CD014687-sec-0100"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD014687.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD014687.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD014687.pub2/appendices#CD014687-sec-0121"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD014687.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD014687.pub2/references#riskOfBias2"> Risk of bias </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD014687.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD014687.pub2/media/CDSR/CD014687/supinfo/CD014687-dataPackage.zip?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD014687.pub2/media/CDSR/CD014687/supinfo/CD014687-dataPackage.zip?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD014687.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD014687.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD014687.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD014687.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD014687.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD014687.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2024 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD014687.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Treatments for Morton's neuroma</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD014687.pub2/information#CD014687-cr-0004"><i class="icon corresponding-author fa fa-envelope"></i>Barry G Matthews</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD014687.pub2/information#CD014687-cr-0005">Colin E Thomson</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD014687.pub2/information#CD014687-cr-0006">Michael P Harding</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD014687.pub2/information#CD014687-cr-0007">John C McKinley</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD014687.pub2/information#CD014687-cr-0008">Robert S Ware</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD014687.pub2/information/en#CD014687-sec-0131">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 09 February 2024 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD014687.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD014687.pub2">https://doi.org/10.1002/14651858.CD014687.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD014687-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD014687-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD014687-abs-0013">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD014687-abs-0008">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD014687-abs-0010">Français</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD014687-abs-0004">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD014687-abs-0001" lang="en"> <section id="CD014687-sec-0001"> <h3 class="title" id="CD014687-sec-0001">Background</h3> <p>Morton's neuroma (MN) is a painful neuropathy resulting from a benign enlargement of the common plantar digital nerve that occurs commonly in the third webspace and, less often, in the second webspace of the foot. Symptoms include burning or shooting pain in the webspace that extends to the toes, or the sensation of walking on a pebble. These impact on weight‐bearing activities and quality of life. </p> </section> <section id="CD014687-sec-0002"> <h3 class="title" id="CD014687-sec-0002">Objectives</h3> <p>To assess the benefits and harms of interventions for MN.</p> </section> <section id="CD014687-sec-0003"> <h3 class="title" id="CD014687-sec-0003">Search methods</h3> <p>On 11 July 2022, we searched CENTRAL, CINAHL Plus EBSCOhost, ClinicalTrials.gov, Cochrane Neuromuscular Specialised Register, Embase Ovid, MEDLINE Ovid, and WHO ICTRP. We checked the bibliographies of identified randomised trials and systematic reviews and contacted trial authors as needed. </p> </section> <section id="CD014687-sec-0004"> <h3 class="title" id="CD014687-sec-0004">Selection criteria</h3> <p>We included all randomised, parallel‐group trials (RCTs) of any intervention compared with placebo, control, or another intervention for MN. We included trials where allocation occurred at the level of the individual or the foot (clustered data). We included trials that confirmed MN through symptoms, a clinical test, and an ultrasound scan (USS) or magnetic resonance imaging (MRI). </p> </section> <section id="CD014687-sec-0005"> <h3 class="title" id="CD014687-sec-0005">Data collection and analysis</h3> <p>We used standard Cochrane methodological procedures. We assessed bias using Cochrane's risk of bias 2 tool (RoB 2) and assessed the certainty of the evidence using the GRADE framework. </p> </section> <section id="CD014687-sec-0006"> <h3 class="title" id="CD014687-sec-0006">Main results</h3> <p>We included six RCTs involving 373 participants with MN. We judged risk of bias as having 'some concerns' across most outcomes. No studies had a low risk of bias across all domains. Post‐intervention time points reported were: three months to less than 12 months from baseline (nonsurgical outcomes), and 12 months or longer from baseline (surgical outcomes). The primary outcome was pain, and secondary outcomes were function, satisfaction or health‐related quality of life (HRQoL), and adverse events (AE). </p> <p><b>Nonsurgical treatments</b> </p> <p><b><i>Corticosteroid and local anaesthetic injection (CS+LA) versus local anaesthetic injection (LA)</i> </b> </p> <p>Two RCTs compared CS+LA versus LA.</p> <p>At three to six months:</p> <p>• CS+LA may result in little to no difference in pain (mean difference (MD) ‐6.31 mm, 95% confidence interval (CI) ‐14.23 to 1.61; P = 0.12, I<sup>2</sup> = 0%; 2 studies, 157 participants; low‐certainty evidence). (Assessed via a pain visual analogue scale (VAS; 0 to 100 mm); a lower score indicated less pain.) </p> <p>• CS+LA may result in little to no difference in function when compared with LA (standardised mean difference (SMD) ‐0.30, 95% CI ‐0.61 to 0.02; P = 0.06, I<sup>2</sup> = 0%; 2 studies, 157 participants; low‐certainty evidence). (Function was measured using: the American Orthopaedic Foot and Ankle Society Lesser Toe Metatarsophalangeal‐lnterphalangeal Scale (AOFAS; 0 to 100 points) ‐ we transformed the scale so that a lower score indicated improved function ‐ and the Manchester Foot Pain and Disability Schedule (MFPDS; 0 to 100 points), where a lower score indicated improved function.) </p> <p>• CS+LA probably results in little to no difference in HRQoL when compared to LA (MD 0.07, 95% CI ‐0.03 to 0.17; P = 0.19; 1 study, 122 participants; moderate‐certainty evidence), and CS+LA may not increase satisfaction (risk ratio (RR) 1.08, 95% CI 0.63 to 1.85; P = 0.78; 1 study, 35 participants; low‐certainty evidence). (Assessed using the EuroQol five dimension instrument (EQ‐5D; 0‐1 point); a higher score indicated improved HRQoL.) </p> <p>• The evidence is very uncertain about the effects of CS+LA on AE when compared with LA (RR 9.84, 95% CI 1.28 to 75.56; P = 0.03, I<sup>2</sup> = 0%; 2 studies, 157 participants; very low‐certainty evidence). Adverse events for CS+LA included mild skin atrophy (3.9%), hypopigmentation of the skin (3.9%) and plantar fat pad atrophy (2.6%); no adverse events were observed with LA. </p> <p><b><i>Ultrasound‐guided (UG) CS+LA versus non‐ultrasound‐guided (NUG) CS+LA</i> </b> </p> <p>Two RCTs compared UG CS+LA versus NUG CS+LA.</p> <p>At six months:</p> <p>• UG CS+LA probably reduces pain when compared with NUG CS+LA (MD ‐15.01 mm, 95% CI ‐27.88 to ‐2.14; P = 0.02, I<sup>2</sup> = 0%; 2 studies, 116 feet; moderate‐certainty evidence). (Assessed with a pain VAS.) </p> <p>• UG CS+LA probably increases function when compared with NUG CS+LA (SMD ‐0.47, 95% CI ‐0.84 to ‐0.10; P = 0.01, I<sup>2</sup> = 0%; 2 studies, 116 feet; moderate‐certainty evidence). We do not know of any established minimum clinical important difference (MCID) for the scales that assessed function, specifically, the MFPDS and the Manchester‐Oxford Foot Questionnaire (MOXFQ; 0 to 100 points; a lower score indicated improved function.) </p> <p>• UG CS+LA may increase satisfaction compared with NUG CS+LA (risk ratio (RR) 1.71, 95% CI 1.19 to 2.44; P = 0.003, I<sup>2</sup> = 15%; 2 studies, 114 feet; low‐certainty evidence). </p> <p>• HRQoL was not measured.</p> <p>• UG CS+LA may result in little to no difference in AE when compared with NUG CS+LA (RR 0.42, 95% CI 0.12 to 1.39; P = 0.15, I<sup>2</sup> = 0%; 2 studies, 116 feet; low‐certainty evidence). AE included depigmentation or fat atrophy for UG CS+LA (4.9%) and NUG CS+LA (12.7%). </p> <p><b>Surgical treatments</b> </p> <p><b><i>Plantar incision neurectomy (PN) versus dorsal incision neurectomy (DN)</i> </b> </p> <p>One study compared PN versus DN.</p> <p>At 34 months (mean; range 28 to 42 months), PN may result in little to no difference for satisfaction (RR 1.06, 95% CI 0.87 to 1.28; P = 0.58; 1 study, 73 participants; low‐certainty evidence), or for AE (RR 0.95, 95% CI 0.32 to 2.85; P = 0.93; 1 study, 75 participants; low‐certainty evidence) compared with DN. </p> <p>AE for PN included hypertrophic scaring (11.4%), foreign body reaction (2.9%); AE for DN included missed nerve (2.5%), artery resected (2.5%), wound infection (2.5%), postoperative dehiscence (2.5%), deep vein thrombosis (2.5%) and reoperation with plantar incision due to intolerable pain (5%). </p> <p>The data reported for pain and function were not suitable for analysis. HRQoL was not measured. </p> </section> <section id="CD014687-sec-0007"> <h3 class="title" id="CD014687-sec-0007">Authors' conclusions</h3> <p>Although there are many interventions for MN, few have been assessed in RCTs. There is low‐certainty evidence that CS+LA may result in little to no difference in pain or function, and moderate‐certainty evidence that UG CS+LA probably reduces pain and increases function for people with MN. Future trials should improve methodology to increase certainty of the evidence, and use optimal sample sizes to decrease imprecision. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD014687-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD014687-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD014687-abs-0003">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD014687-abs-0014">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD014687-abs-0009">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD014687-abs-0011">Français</a> </li> <li class="section-language"> <a class="" href="full/ms#CD014687-abs-0007">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/pl#CD014687-abs-0012">Polski</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD014687-abs-0005">简体中文</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD014687-abs-0006">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD014687-abs-0002" lang="en"> <h3>What are the benefits and risks of nonsurgical and surgical treatments for Morton's neuroma (pain in the forefoot on walking)? </h3> <p><b>Key messages</b> </p> <p>• The benefits and risks of nonsurgical and surgical treatments for Morton's neuroma (nerve enlargement in the foot that causes pain on walking) are unclear. </p> <p>• Well‐designed studies are required to determine the benefits and risks of treatments for Morton's neuroma. </p> <p><b>What is Morton's neuroma?</b> </p> <p>Morton's neuroma occurs when a nerve in the ball of the foot (the forefoot, i.e. the area connected to the toes) enlarges and causes pain. Its cause is unknown. Symptoms can include: </p> <p>• burning or shooting pain in the forefoot and toes;</p> <p>• feeling as though you are walking on a pebble or lump.</p> <p>This can affect walking, and so affects people's general well‐being.</p> <p><b>How is Morton's neuroma treated?</b> </p> <p>Nonsurgical treatments include:</p> <p>• shoe inserts (foot orthoses);</p> <p>• moving the bones and soft tissue in the forefoot (mobilisation);</p> <p>• shockwave therapy;</p> <p>• injection of corticosteroid and local anaesthetic (CS+LA) into the swollen part of the nerve (neuroma). </p> <p>Surgical treatments (that require a cut in the foot) include:</p> <p>• removal of the neuroma (neurectomy);</p> <p>• release of the nerve from the surrounding tissue (surgical neurolysis).</p> <p><b>What did we want to find out?</b> </p> <p>We wanted to find out which treatments were better than placebo (a 'dummy' or sham treatment, that looks or feels the same as the treatment being tested), or better than another treatment for: </p> <p>• pain;</p> <p>• function (walking‐related activities);</p> <p>• well‐being; and</p> <p>• satisfaction.</p> <p>We also wanted to find out about any unwanted adverse effects.</p> <p><b>What did we do?</b> </p> <p>We searched for studies that looked at nonsurgical and surgical treatments compared with placebo or another treatment in people with Morton's neuroma. We compared and summarised the results of the studies and rated our confidence in the evidence, based on factors such as study methods and sizes. </p> <p><b>What did we find?</b> </p> <p>We found 6 studies that involved 373 people with Morton's neuroma. Studies lasted from 4 weeks (1 study) to more than 12 months (3 studies), and were conducted in Europe (3), UK (2) and Asia (1). </p> <p>Funding from government or university sources was reported for 2 studies.</p> <p><b>Main results</b> </p> <p><b>Nonsurgical treatments</b> </p> <p>At 3 months to 12 months, an injection of corticosteroid plus local anaesthetic (CS+LA) compared to an injection of local anaesthetic alone (LA): </p> <p>• may make little to no difference to pain (2 studies, 157 people);</p> <p>• may make little to no difference to function (2 studies, 157 people);</p> <p>• probably makes little to no difference to well‐being (1 study, 122 people);</p> <p>• may make little to no difference to satisfaction (1 study, 35 people).</p> <p>Unwanted effects were few in the CS+LA group and included reduction in thickness of the foot fat pad and loss of skin colour. There were no unwanted effects in the LA group. </p> <p>At 3 months to 12 months, an ultrasound‐guided CS+LA injection compared to a non‐ultrasound‐guided CA+LA injection: </p> <p>• probably reduces pain (2 studies, 116 people);</p> <p>• probably increases function (2 studies, 116 people);</p> <p>• may increase satisfaction, (2 studies, 114 people).</p> <p>These studies did not measure well‐being.</p> <p>There was little to no difference between these treatments for unwanted effects, which were few and included reduction in thickness of the foot fat pad and loss of skin colour. </p> <p><b>Surgical treatments</b> </p> <p>One study compared surgical removal of the neuroma via a cut through the top of the foot (dorsal neurectomy) against removal via a cut through the bottom of the foot (plantar neurectomy). </p> <p>At 12 months or more, dorsal neurectomy:</p> <p>• may make little to no difference to satisfaction (1 study, 73 people);</p> <p>• may make little to no difference to serious unwanted effects (1 study, 75 people).</p> <p>This study reported pain and function in a way we could not use, and did not measure well‐being. </p> <p>Unwanted effects occurred in 11 of the 75 people and included:</p> <p>• plantar group: painful scar, foreign‐body reaction;</p> <p>• dorsal group: infection, wound reopening, blood clot in leg vein and plantar reoperation due to pain. </p> <p>Studies investigating foot orthoses (shoe inserts), forefoot mobilisation and surgical neurolysis did not meet our requirements for consideration in this analysis. </p> <p><b>What are the limitations of the evidence?</b> </p> <p>We have moderate to little confidence in this evidence because some studies were small, and there were not enough studies to be certain about the results of our outcomes, especially unwanted effects. We are uncertain about the accuracy of the satisfaction scale used by studies. It is possible that assessors in some studies knew which treatment they were assessing. Some studies used a different number of CS+LA injections, which could have affected the results. Further research may change our results. </p> <p><b>How up to date is this evidence?</b> </p> <p>This evidence is up‐to‐date to July 2022.</p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD014687-sec-0112" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD014687-sec-0112"></div> <h3 class="title" id="CD014687-sec-0113">Implications for practice</h3> <section id="CD014687-sec-0113"> <p>While multiple interventions for Morton's neuroma (MN) have been proposed, there are few randomised clinical trials that have assessed those interventions and only six that met the inclusion criteria for this systematic review. The effectiveness of those interventions, when measured against the outcomes of pain, function, quality of life or satisfaction, remains unconfirmed. </p> <p>A combined corticosteroid and local anaesthetic injection (CS+LA) may result in little to no difference in pain at three to six months when compared with a local anaesthetic injection alone. Although people allocated to receive CS+LA had slightly reduced pain, the reduction was less than the minimum clinical important difference (MCID) with uncertainty about the number of injections required to achieve this pain reduction. The evidence suggests that a CS+LA injection results in little to no difference in health‐related quality of life at three months, or function at three to six months, and may not increase satisfaction at six months. </p> <p>An ultrasound‐guided corticosteroid and local anaesthetic injection probably reduces pain and increases function at six months with moderate certainty, and may increase satisfaction at three to six months compared to a non‐ultrasound‐guided corticosteroid and anaesthetic injection, but there is uncertainty about the number of injections required to achieve this effect. </p> <p>There is low‐certainty evidence that a plantar incision neurectomy may result in little to no difference in satisfaction compared to a dorsal incision neurectomy at 34 months (mean). There is low‐ to very low‐certainty evidence about whether nonsurgical and surgical interventions have an effect on the rate of adverse events. </p> </section> <h3 class="title" id="CD014687-sec-0114">Implications for research</h3> <section id="CD014687-sec-0114"> <section id="CD014687-sec-0115"> <h5 class="title">Trial recruitment</h5> <p>Future clinical trials should consider the combination of MN symptoms and the thumb‐index finger squeeze test and an ultrasound scan (USS) or magnetic resonance imaging (MRI) for participant enrolment in trials. None of these inclusion criteria in isolation provides enough certainty to diagnose a MN. Symptoms associated with a neuroma may be caused by a variety of foot and systemic disorders (<a href="./references#CD014687-bbs2-0038" title="DandoC , CherryL , JonesL , BowenC . The clinical diagnosis of symptomatic forefoot neuroma in the general population: a Delphi consensus study. Journal of Foot and Ankle Research2017;10(1):59. [DOI: 10.1186/s13047-017-0241-2]">Dando 2017</a>). The thumb‐index finger squeeze test has a higher sensitivity than the commonly used Mulder's test to detect a MN (<a href="./references#CD014687-bbs2-0069" title="MahadevanD , VenkatesanM , BhattR , BhatiaM . Diagnostic accuracy of clinical tests for Morton's neuroma compared with ultrasonography. Journal of Foot and Ankle Surgery2015;54(4):549-53. [DOI: 10.1053/j.jfas.2014.09.021]">Mahadevan 2015</a>), and, while an USS or MRI have a high sensitivity for detecting common plantar digital nerve enlargement (<a href="./references#CD014687-bbs2-0026" title="BignottiB , SignoriA , SormaniMP , MolfettaL , MartinoliC , TagliaficoA . Ultrasound versus magnetic resonance imaging for Morton neuroma: systematic review and meta-analysis. European Radiology2015;25(8):2254-62. [DOI: 10.1007/s00330-015-3633-3]">Bignotti 2015</a>), the enlargement may not be symptomatic (<a href="./references#CD014687-bbs2-0092" title="SymeonidisPD , IselinLD , SimmonsN , FowlerS , DracopoulosG , StavrouP . Prevalence of interdigital nerve enlargements in an asymptomatic population. Foot and Ankle International2012;33(7):543-7. [DOI: 10.3113/FAI.2012.0543]">Symeonidis 2012</a>). Trials should also consider any methodological issues created by the inclusion of participants with ipsilateral (more than one neuroma per foot) or bilateral MN and, where they are included, carefully consider the randomisation or intervention implications for more than one MN per person. </p> </section> <section id="CD014687-sec-0116"> <h5 class="title">Validation and standardisation of assessments</h5> <p>Most studies included in this review suffered from a lack of validated outcomes for patient satisfaction. We do not know of any outcome questionnaires for patient satisfaction that have been validated, so we suggest using a validated health‐related quality of life (HRQoL) questionnaire, for example, the EuroQol‐ 5 Dimension questionnaire (EQ‐5D), until one is published. Currently, there are no published minimal clinically important differences (MCID) for pain, function or health‐related quality of life (HRQoL) for MN outcome scores either. We calculated a MCID for pain measured by a pain visual analogue scale (VAS) based on reported values in three papers (<a href="./references#CD014687-bbs2-0046" title="GallagherEJ , LiebmanM , BijurPE . Prospective validation of clinically important changes in pain severity measured on a visual analog scale. Annals of Emergency Medicine2001;38(6):633-8. [DOI: 10.1067/mem.2001.118863]">Gallagher 2001</a>; <a href="./references#CD014687-bbs2-0002" title="Lizano-DíezX , Ginés-CespedosaA , Alentorn-GeliE , Pérez-PrietoD , González-LucenaG , GambaC , et al. Corticosteroid injection for the treatment of Morton's neuroma: a prospective, double-blinded, randomized, placebo-controlled trial. Foot &amp; Ankle International2017;38(9):944-51. [DOI: 10.1177/1071100717709569]">Lizano‐Diez 2017</a>; <a href="./references#CD014687-bbs2-0003" title="HauMYT , ThomsonL , AujlaR , MadhadevanD , BhatiaM . Medium-term results of corticosteroid injections for Morton’s neuroma. Foot &amp; Ankle International2021;42(4):464-8. [DOI: 10.1177/1071100720966332]MahadevanD , AttwalM , BhattR , BhatiaM . Corticosteroid injection for Morton's neuroma with or without ultrasound guidance: a randomised controlled trial. Bone &amp; Joint Journal2016;98-B(4):498-503. [DOI: 10.1302/0301-620X.98B4.36880]">Mahadevan 2016</a>), but, as this has not been validated, it reduces the certainty of the evidence. </p> <p>We are unaware of a neuroma‐specific questionnaire; the development of such a questionnaire that could be used in conjunction with standard pain and function foot scores and generic health scores would improve the ability to combine data in future systematic reviews. </p> </section> <section id="CD014687-sec-0117"> <h5 class="title">Interventions to test</h5> <p>More non‐surgical and surgical trials are needed for all the interventions featured in this review, that is, shockwave therapy versus sham shockwave therapy, corticosteroid plus local anaesthetic injection (CS+LA) versus local anaesthetic injection (LA), ultrasound‐guided CS+LA versus non‐ultrasound‐guided CS+LA, and plantar incision neurectomy versus dorsal incision neurectomy. </p> <p>Registered clinical trials are also required to assess surgical interventions versus nonsurgical interventions (e.g. neurectomy or surgical neurolysis and ultrasound‐guided CS+LA) and to compare different surgical interventions against each other (e.g. neurectomy versus surgical neurolysis). In addition, we could find no randomised clinical trials that assessed the use of sclerosing alcohol interventions, though sclerosing alcohol is used to treat MN. </p> </section> <section id="CD014687-sec-0118"> <h5 class="title">Trial design</h5> <p>Future trials for non‐surgical and surgical interventions for MN need to be better designed methodologically with: clear inclusion criteria; treatment of a single Morton's neuroma; blinding of participants (where practical) and outcome assessors; consistent time points for assessments (baseline, one month, three months, six months and 12 months); and validated outcome measurements for pain (e.g. pain VAS), function (e.g. the Manchester Foot Pain and Disability Schedule (MFPDS) or Manchester–Oxford Foot Questionnaire (MOXFQ)), and HRQoL (e.g. EQ‐5D). They also need to have appropriate statistical power to improve the certainty of the evidence, especially regarding serious adverse event rates. </p> </section> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD014687-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD014687-sec-0008"></div> <div class="table" id="CD014687-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Summary of findings: corticosteroid and local anaesthetic injection (CS+LA) versus local anaesthetic injection (LA) for people with Morton's neuroma</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Corticosteroid and local anaesthetic injection (CS+LA) versus local anaesthetic injection (LA) for people with Morton's neuroma</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> Morton's neuroma </p> <p><b>Setting:</b> outpatient </p> <p><b>Intervention:</b> corticosteroid and local anaesthetic injection (CS+LA) </p> <p><b>Comparison:</b> local anaesthetic injection (LA) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="bottom"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="bottom"> <p><b>Relative effect</b> <br/><b>(95% CI)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="bottom"> <p><b>Number of participants</b> <br/><b>(studies)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="bottom"> <p><b>Certainty of the evidence</b> <br/><b>(GRADE)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="bottom"> <p><b>Comments</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="bottom"> <p><b>Risk with LA</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="bottom"> <p><b>Risk with CS+LA</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Pain:</b> VAS(0 to 100; a lower score indicates less pain) (change from baseline and final values) </p> <p>Follow‐up: 3 months to 6 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean VAS (0‐100) (final values) at 3 to 6 months was <b>15.10 mm</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD <b>6.31 mm lower</b><br/>(14.23 lower to 1.61 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>157<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⨁⨁◯◯<br/>Low<sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The evidence suggests that CS+LA may result in little to no difference in pain when compared with LA in people with Morton's neuroma. The MD is less than the MCID of 15 mm. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Function:</b> assessed with 2 different questionnaires (lower scores indicate improved function) (final values) </p> <p>Follow‐up: 3 months to 6 months</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>The function score in the CS+LA groups (final values) at 3 to 6 months was on average 0.30 SMDs (0.61 lower to 0.02 higher) <b>lower</b> than in the LA groups. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>157</p> <p>(2 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⨁⨁◯◯<br/>Low<sup>a,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>As a rule of thumb, a SMD of 0.2 is considered a small effect, 0.5 a moderate effect, and 0.8 a large effect. </p> <p>CS+LA may result in little to no difference in function compared to LA for people with Morton's neuroma. </p> <p>Converting the SMD back to the AOFAS (0 to 100) gives an estimated MD of ‐3.33 points (95% CI ‐6.77 to 0.22) and for the MFPDS (0 to 100) an estimated MD of ‐7.71 points (95% CI ‐15.68 to 0.51). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HRQoL:</b> EQ‐5D (0 to 1; a higher score indicates improved HRQoL) (final values) </p> <p>Follow‐up: 3 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean HRQoL (0‐1) (final values) at 3 months was <b>0.57 points</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD <b>0.07 points higher</b><br/>(0.03 lower to 0.17 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>122<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⨁⨁⨁◯<br/>Moderate<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CS+LA probably results in little to no difference in HRQoL compared to LA in people with Morton's neuroma. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Satisfaction:</b> Modified Johnson Scale (dichotomised into satisfied and dissatisfied) </p> <p>Follow‐up: 6 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>58 per 100</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>63 per 100</b><br/>(36 to 100) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.08</b><br/>(0.63 to 1.85) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⨁⨁◯◯<br/>Low<sup>d,e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CS+LA may not increase satisfaction compared to LA in people with Morton's neuroma.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Adverse events</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Unable to calculate</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Unable to calculate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 9.84</b> </p> <p>(1.28 to 75.56)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>157<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⨁◯◯◯<br/>Very low<sup>a,f</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>The evidence is very uncertain about the effect of CS+LA on adverse events compared to LA in people with Morton's neuroma. </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>CS+LA: mild skin atrophy (39 per 1000), hypopigmentation of the skin (39 per 1000) and plantar fat pad atrophy (26 per 1000) </p> <p>LA: none.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>AOFAS:</b> American Orthopaedic Foot and Ankle Society Clinical Rating Lesser Metatarsophalangeal‐Interphalangeal Scale; <b>CI:</b> confidence interval; <b>CS+LA:</b> corticosteroid and local anaesthetic injection; <b>EQ‐5D:</b> EuroQol 5 Dimension Instrument; <b>HRQoL:</b> health‐related quality of life; <b>LA:</b> local anaesthetic injection; <b>MCID:</b> minimum clinically important difference; <b>MD:</b> mean difference; <b>MFPDS:</b> Manchester Foot Pain and Disability Schedule; <b>OIS:</b> optimal information size; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio; <b>SMD:</b> standardised mean difference; <b>VAS:</b> visual analogue scale </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty</b>: we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><b>Explanations</b> </p> <p><sup>a</sup>Downgraded once for study limitations: high risk of bias (missing outcome data) in one study.<br/><sup>b</sup>Downgraded once for imprecision: CI included the possibility of no effect.<br/><sup>c</sup>Downgraded once for imprecision: wide CI which crossed both the small (0.2) and moderate (0.5) effect sizes.<br/><sup>d</sup>Downgraded once for study limitations: high risk of bias (missing outcome data).<br/><sup>e</sup>Downgraded once for imprecision: less than OIS (OIS = 186 participants) and a CI that included the possibility of no effect.<br/><sup>f</sup>Downgraded twice for serious imprecision: less than OIS (OIS = 4638 participants) and a wide CI. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD014687-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Summary of findings: ultrasound‐guided injection of corticosteroid and local anaesthetic (UG CS+LA) versus non‐ultrasound‐guided injection of corticosteroid and local anaesthetic (NUG CS+LA) for people with Morton's neuroma</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Ultrasound‐guided injection of corticosteroid and local anaesthetic (UG CS+LA) versus non‐ultrasound‐guided injection of corticosteroid and local anaesthetic (NUG CS+LA) for people with Morton's neuroma</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> Morton's neuroma </p> <p><b>Setting:</b> outpatient </p> <p><b>Intervention:</b> ultrasound‐guided injection of corticosteroid and local anaesthetic (UG CS+LA) </p> <p><b>Comparison:</b> non‐ultrasound‐guided injection of corticosteroid and local anaesthetic (NUG CS+LA) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="bottom"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="bottom"> <p><b>Relative effect</b> <br/><b>(95% CI)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="bottom"> <p><b>Number of participants</b> <br/><b>(studies)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="bottom"> <p><b>Certainty of the evidence</b> <br/><b>(GRADE)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="bottom"> <p><b>Comments</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="bottom"> <p><b>Risk with NUG CS+LA</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="bottom"> <p><b>Risk with UG CS+LA</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Pain:</b> VAS (0 to 100; a lower score indicates less pain) (final values) </p> <p>Follow‐up: 6 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean VAS (0‐100) (final values) at 6 months was <b>47.00 mm</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD <b>15.01 mm lower</b><br/>(27.88 lower to 2.14 lower) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>116<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⨁⨁⨁◯<br/>Moderate<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>UG CS+LA probably reduces pain when compared with NUG CS+LA for people with Morton's neuroma. The MD is less than the MCID of 15 mm. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Function:</b> assessed with 2 different questionnaires (lower scores indicate improved function) (final values) </p> <p>Follow‐up: 6 months</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>The function score in the UG CS+LA groups (final values) at 6 months was on average 0.47 SMDs (0.84 lower to 0.10 lower) <b>lower</b> than in the NUG CS+LA groups. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>116</p> <p>(2 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⨁⨁⨁◯<br/>Moderate<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>As a rule of thumb, a SMD of 0.2 is considered a small effect, 0.5 a moderate effect, and 0.8 a large effect. </p> <p>The evidence suggests UG CS+LA probably increases function when compared with NUG CS+LA for people with Morton's neuroma. </p> <p>Converting the SMD back to the MOXFQ (0 to 100) gives an estimated MD of ‐21.95 points (95% CI ‐39.23 to ‐4.67), and for the MFPDS (17 to 51) an estimated MD of ‐5.12 points (95% CI ‐9.16 to ‐1.90). The effect sizes for both are small to moderate, but we are unaware of a MCID for the MOXFQ or MFPDS. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HRQoL</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>Outcome not measured.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Satisfaction:</b> 4‐point Likert scale (dichotomised into satisfied and dissatisfied) </p> <p>Follow‐up: 3 months to 6 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>45 per 100</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>77 per 100</b><br/>(54 to 100) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.71</b><br/>(1.19 to 2.44) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>114<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⨁⨁◯◯<br/>Low<sup>c,d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>UG CS+LA may increase satisfaction when compared with NUG CS+LA for people with Morton's neuroma. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Adverse events</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>13 per 100</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>5 per 100</b> </p> <p>(2 to 18)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.42</b> </p> <p>(0.12 to 1.39)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>116<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⨁⨁◯◯<br/>Low<sup>e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>UG CS+LA may result in little to no difference in adverse events when compared with NUG CS+LA for people with Morton's neuroma. </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>Adverse events: depigmentation or fat atrophy, or both:</p> <p>UG CS+LA (40 per 1000);</p> <p>NUG CS+LA (127 per 1000).</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval; <b>HRQoL:</b> health‐related quality of life; <b>MCID:</b> minimal clinically important difference; <b>MD:</b> mean difference; <b>MFPDS:</b> Manchester Foot Pain and Disability Schedule; <b>MOXFQ:</b> Manchester–Oxford Foot Questionnaire; <b>NUG CS+LA:</b> non‐ultrasound‐guided injection of corticosteroid and local anaesthetic; <b>OIS:</b> optimal information size; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio; <b>SMD:</b> standardised mean difference; <b>UG CS+LA:</b> ultrasound‐guided injection of corticosteroid and local anaesthetic; <b>VAS:</b> visual analogue scale </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><b>Explanations</b> </p> <p><sup>a</sup>Downgraded once for imprecision: wide CI (&gt; 10 mm).<br/><sup>b</sup>Downgraded once for imprecision: less than OIS (OIS = 128 participants) and wide CI which crossed both small (0.2) and large (0.8) effect sizes.<br/><sup>c</sup>Downgraded once for study limitations: some concerns risk of bias (measurement of the outcome) in both studies.<br/><sup>d</sup>Downgraded once for imprecision: less than OIS (OIS = 128 participants).<br/><sup>e</sup>Downgraded twice for serious imprecision: less than OIS (OIS = 4638 participants) and includes the possibility of no effect. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD014687-tbl-0003"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Summary of findings: plantar‐incision neurectomy (PN) versus dorsal‐incision neurectomy (DN) for people with Morton's neuroma</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Plantar‐incision neurectomy (PN) versus dorsal‐incision neurectomy (DN) for people with Morton's neuroma</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> Morton's neuroma </p> <p><b>Setting:</b> outpatient </p> <p><b>Intervention:</b> plantar‐incision neurectomy (PN) </p> <p><b>Comparison:</b> dorsal‐incision neurectomy (DN) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="bottom"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="bottom"> <p><b>Relative effect</b> <br/><b>(95% CI)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="bottom"> <p><b>Number of participants</b> <br/><b>(studies)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="bottom"> <p><b>Certainty of the evidence</b> <br/><b>(GRADE)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="bottom"> <p><b>Comments</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="bottom"> <p><b>Risk with DN</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="bottom"> <p><b>Risk with PN</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Pain:</b> VAS(0 to 100; lower score indicates less pain) </p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>Pain data reported in a format we could not analyse.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Function:</b> restrictions in daily activities (4‐item Likert scale) </p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>Function data reported in a format we could not analyse.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HRQoL</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>Outcome not reported.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Satisfaction:</b> 4‐item Likert scale (dichotomised into satisfied and dissatisfied) </p> <p>Follow‐up: mean 34 months (range 28 to 42)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>83 per 100</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>88 per 100</b><br/>(72 to 100) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.06</b><br/>(0.87 to 1.28) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>73<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⨁⨁◯◯<br/>Low<sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PN may result in little to no difference in satisfaction when compared with DN for people with Morton's neuroma. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>15 per 100</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>12 per 100</b><br/>(4 to 37) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.95</b><br/>(0.32 to 2.85) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>75<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⨁⨁◯◯<br/>Low<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PN may result in little to no difference in adverse events when compared with DN for people with Morton's neuroma. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval; <b>DN:</b> dorsal‐incision neurectomy; <b>HRQoL:</b> health‐related quality of life; <b>OIS:</b> optimal information size; <b>PN:</b> plantar‐incision neurectomy; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio; <b>VAS:</b> visual analogue scale </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><b>Explanations</b> </p> <p><sup>a</sup>Downgraded once for study limitations: some concerns about risk of bias (measurement of the outcome) due to use of an unvalidated 4‐point Likert scale with two active treatment groups and no reported blinding.<br/><sup>b</sup>Downgraded once for imprecision: less than OIS (OIS = 186 participants) and a CI that included the possibility of no effect.<br/><sup>c</sup>Downgraded twice for serious imprecision: less than OIS (OIS = 398 participants) to rule out risk difference with adverse events between intervention groups and CI failed to exclude values for important harms by crossing the line of no effect. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD014687-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD014687-sec-0009"></div> <section id="CD014687-sec-0010"> <h3 class="title" id="CD014687-sec-0010">Description of the condition</h3> <p>Morton's neuroma (MN) is a common condition that affects nerves in the forefoot. In this condition, a benign enlargement of the common plantar digital nerve (a neuroma) produces painful neuropathic symptoms. This nerve condition presents most frequently in the third webspace (webspaces are numbered from first (adjacent to the big toe) to fourth (adjacent to little toe)), followed by the second webspace, but rarely presents in the first or fourth webspaces (<a href="./references#CD014687-bbs2-0057" title="HughesRJ , AliK , JonesH , KendallS , ConnellDA . Treatment of Morton's neuroma with alcohol injection under sonographic guidance: follow-up of 101 cases. American Journal of Roentgenology2007;188(6):1535-9. [DOI: 10.2214/AJR.06.1463]">Hughes 2007</a>; <a href="./references#CD014687-bbs2-0082" title="ParkYH , LeeJW , ChoiGW , KimHJ . Risk factors and the associated cutoff values for failure of corticosteroid injection in treatment of Morton's neuroma. International Orthopaedics2018;42(2):323-9. [DOI: 10.1007/s00264-017-3707-8]">Park 2018</a>; <a href="./references#CD014687-bbs2-0084" title="PasqualiC , VulcanoE , NovarioR , VarottoD , MontoliC , VolpeA . Ultrasound-guided alcohol injection for Morton's neuroma. Foot and Ankle International2015;36(1):55-9. [DOI: 10.1177/1071100714551386]">Pasquali 2015</a>; <a href="./references#CD014687-bbs2-0005" title="SeokH , KimSH , LeeSY , ParkSW . Extracorporeal shockwave therapy in patients with Morton's neuroma a randomized, placebo-controlled trial. Journal of the American Podiatric Medical Association2016;106(2):93-9. [DOI: 10.7547/14-131]">Seok 2016</a>). When using the term webspace, we are describing the fleshy area that extends from the level of the inter‐metatarsophalangeal joint to the interdigital space. Strictly, the neuroma extends from the intermetatarsal space distally to the interdigital space. </p> <p>The precise cause of MN is poorly understood, with many proposed theories that include: a thicker third common plantar digital nerve compared to the first, second and fourth common plantar digital nerves (<a href="./references#CD014687-bbs2-0025" title="BettsLO . Morton's metatarsalgia: neuritis of the fourth digital nerve. Medical Journal of Australia1940;1(15):514-5. [DOI: 10.5694/j.1326-5377.1940.tb46191.x]">Betts 1940</a>); nerve ischaemia (constriction or obstruction of the blood flow to a nerve) (<a href="./references#CD014687-bbs2-0079" title="NissenKI . Plantar digital neuritis Morton's metatarsalgia. Journal of Bone and Joint Surgery1948;30(1):84-94. [PMID: 18864949]">Nissen 1948</a>); bursitis (inflammation of a fibrous sac that acts as a cushion between the metatarsal heads) (<a href="./references#CD014687-bbs2-0028" title="BossleyCJ , CairneyPC . The intermetatarsophalangeal bursa-its significance in Morton's metatarsalgia. Journal of Bone and Joint Surgery1980;62-B(2):184-7. [PMID: 7364832]">Bossley 1980</a>); narrow webspace (<a href="./references#CD014687-bbs2-0064" title="LevitskyKA , AlmanBA , JevsevarDS , MoreheadJ . Digital nerves of the foot: anatomic variations and implications regarding the pathogenesis of interdigital neuroma. Foot and Ankle1993;14(4):208-14. [DOI: 10.1177/107110079301400406]">Levitsky 1993</a>); tight‐fitting footwear (<a href="./references#CD014687-bbs2-0024" title="BennettGL , GrahamCE , MauldinDM . Morton's interdigital neuroma: a comprehensive treatment protocol. Foot and Ankle International1995;16(12):760-3. [DOI: 10.1177/107110079501601204]">Bennett 1995</a>); and reduced ankle dorsiflexion (<a href="./references#CD014687-bbs2-0023" title="BarrettSL , JarvisJ . Equinus deformity as a factor in forefoot nerve entrapment: treatment with endoscopic gastrocnemius recession. Journal of the American Podiatric Medical Association2005;95(5):464-8. [DOI: 10.7547/0950464]">Barrett 2005</a>). There is inconclusive evidence to support theories of an association between neuroma development and nerve size (<a href="./references#CD014687-bbs2-0050" title="GovsaF , BilgeO , OzerMA . Anatomical study of the communicating branches between the medial and lateral plantar nerves. Surgical and Radiologic Anatomy2005;27(5):377-81. [DOI: 10.1007/s00276-005-0009-4]">Govsa 2005</a>; <a href="./references#CD014687-bbs2-0064" title="LevitskyKA , AlmanBA , JevsevarDS , MoreheadJ . Digital nerves of the foot: anatomic variations and implications regarding the pathogenesis of interdigital neuroma. Foot and Ankle1993;14(4):208-14. [DOI: 10.1177/107110079301400406]">Levitsky 1993</a>), neuroma symptoms associated with tight‐fitting footwear (<a href="./references#CD014687-bbs2-0070" title="MatthewsBG , HurnSE , HardingMP , HenryRA , WareRS . The effectiveness of nonsurgical interventions for common plantar digital compressive neuropathy (Morton's neuroma): a systematic review and meta-analysis. Journal of Foot and Ankle Research2019;12(12):1-21. [DOI: 10.1186/s13047-019-0320-7]">Matthews 2019</a>), and narrow webspace (<a href="./references#CD014687-bbs2-0081" title="ParkYH , JeongSM , ChoiGW , KimHJ . The role of the width of the forefoot in the development of Morton's neuroma. Bone and Joint Journal2017;99-B(3):365-8. [DOI: 10.1302/0301-620X.99B3.BJJ-2016-0661.R1]">Park 2017</a>). Limited evidence of an association between Morton's neuroma and reduced ankle dorsiflexion has been reported (<a href="./references#CD014687-bbs2-0076" title="NaraghiR , BremnerA , Slack-SmithL , BryantA . The relationship between foot posture index, ankle equinus, body mass index and intermetatarsal neuroma. Journal of Foot and Ankle Research2016;9:46. [DOI: 10.1186/s13047-016-0179-9]">Naraghi 2016</a>). </p> <p>The condition is characterised by a benign growth of nerve tissue, and, although it is named after Thomas Morton, the nerve changes that occur were first described in 1835 by Italian anatomist, Filippo Civinini (<a href="./references#CD014687-bbs2-0083" title="PaseroG , MarsonP . Filippo Civinini (1805-1844) and the discovery of plantar neuroma [Filippo Civinini (1805-1844) e la scoperta del neurinoma plantare]. Reumatismo2006;58(4):319-22. [DOI: 10.4081/reumatismo.2006.319]">Pasero 2006</a>). Accordingly, European studies may use the name 'Civinini‐Morton's neuroma' to describe the condition (<a href="./references#CD014687-bbs2-0087" title="SamailaE , ColòG , RavaA , NegriS , ValentiniR , FelliL , et al. Effectiveness of corticosteroid injections in Civinini-Morton's syndrome: a systematic review. Foot and Ankle Surgery2020;27(4):357-65. [DOI: https://doi.org/10.1016/j.fas.2020.05.001]">Samaila 2020</a>). Lewis Durlacher then described the symptoms in 1845 (<a href="./references#CD014687-bbs2-0043" title="DurlacherL . A treatise on corns, bunions, the disease of nails, and the general management of the feet. Simpkin, Marshall and Co, 1845.">Durlacher 1845</a>). In 1876, Thomas Morton, who believed the symptoms were caused by the fourth metatarsophalangeal joint, called the condition 'metatarsalgia'. Morton's treatment for the condition was to remove the joint, the common plantar digital nerve and the adjacent soft tissue surgically (<a href="./references#CD014687-bbs2-0074" title="MortonTG . A peculiar and painful affection of the fourth metatarsophalangeal articulation. American Journal of Medical Science1876;71(35):37-45.">Morton 1876</a>). The condition was first described as 'Morton's neuroma' in 1958 (<a href="./references#CD014687-bbs2-0061" title="LarsonEE , BarrettSL , BattistonB , Maloney CT Jr, DellonAL . Accurate nomenclature for forefoot nerve entrapment: a historical perspective. Journal of the American Podiatric Medical Association2005;95(3):298-306. [DOI: 10.7547/0950298]">Larson 2005</a>). </p> <p>Since 2017, the US National Library of Medicine has mapped the term 'Morton neuroma' within the medical subject headings for indexing articles (<a href="./references#CD014687-bbs2-0078" title="US National Library of Medicine. National Library of Medicine Medical Subject Heading: Morton neuroma. www.ncbi.nlm.nih.gov/mesh/2016292 (accessed 06 July 2023).">NCBI 2021</a>). While there are many common and pathophysiological names for the condition (<a href="./references#CD014687-bbs2-0061" title="LarsonEE , BarrettSL , BattistonB , Maloney CT Jr, DellonAL . Accurate nomenclature for forefoot nerve entrapment: a historical perspective. Journal of the American Podiatric Medical Association2005;95(3):298-306. [DOI: 10.7547/0950298]">Larson 2005</a>; <a href="./references#CD014687-bbs2-0070" title="MatthewsBG , HurnSE , HardingMP , HenryRA , WareRS . The effectiveness of nonsurgical interventions for common plantar digital compressive neuropathy (Morton's neuroma): a systematic review and meta-analysis. Journal of Foot and Ankle Research2019;12(12):1-21. [DOI: 10.1186/s13047-019-0320-7]">Matthews 2019</a>), MN is an accepted misnomer, but has recently become the predominant term. </p> <p>People with MN usually report burning or shooting pain located in the third or second webspaces, often with radiating paraesthesia (abnormal tingling or 'pins and needles' sensation) into the corresponding toes, or a clicking sensation in the forefoot. When weight‐bearing, people with MN often report the sensation of walking on a pebble, lump or stone (<a href="./references#CD014687-bbs2-0038" title="DandoC , CherryL , JonesL , BowenC . The clinical diagnosis of symptomatic forefoot neuroma in the general population: a Delphi consensus study. Journal of Foot and Ankle Research2017;10(1):59. [DOI: 10.1186/s13047-017-0241-2]">Dando 2017</a>). In severe cases, the condition can impact on the person's mobility, ability to pursue activities, and quality of life (<a href="./references#CD014687-bbs2-0006" title="ThomsonCE , BeggsI , MartinDJ , McMillanD , EdwardsRT , RussellD , et al. Methylprednisolone injections for the treatment of Morton neuroma: a patient-blinded randomized trial. Journal of Bone and Joint Surgery. American Volume2013;95(9):790-S1. [DOI: 10.2106/JBJS.I.01780]">Thomson 2013</a>). MN is the most common compressive neuropathy after carpal tunnel syndrome, and in the UK it affects approximately 88 in every 100,000 women and 50 in every 100,000 men who present to their General Practitioner for care (<a href="./references#CD014687-bbs2-0062" title="LatinovicR , GuillifordMC , HughesRA . Incidence of compressive neuropathies in primary care. Journal of Neurology, Neurosurgery and Psychiatry2006;77:263-5. [DOI: 10.1136/jnnp.2005.066696]">Latinovic 2006</a>). </p> <p>The diagnosis of MN can be challenging, with a range of symptomatic and objective findings at presentation (<a href="./references#CD014687-bbs2-0038" title="DandoC , CherryL , JonesL , BowenC . The clinical diagnosis of symptomatic forefoot neuroma in the general population: a Delphi consensus study. Journal of Foot and Ankle Research2017;10(1):59. [DOI: 10.1186/s13047-017-0241-2]">Dando 2017</a>), which include tenderness or pain on palpation of the webspace (<a href="./references#CD014687-bbs2-0069" title="MahadevanD , VenkatesanM , BhattR , BhatiaM . Diagnostic accuracy of clinical tests for Morton's neuroma compared with ultrasonography. Journal of Foot and Ankle Surgery2015;54(4):549-53. [DOI: 10.1053/j.jfas.2014.09.021]">Mahadevan 2015</a>). An ultrasound scan (USS) has been proposed as a cost‐effective and accurate method to confirm the diagnosis of MN, especially in cases where the clinical diagnosis is uncertain (<a href="./references#CD014687-bbs2-0026" title="BignottiB , SignoriA , SormaniMP , MolfettaL , MartinoliC , TagliaficoA . Ultrasound versus magnetic resonance imaging for Morton neuroma: systematic review and meta-analysis. European Radiology2015;25(8):2254-62. [DOI: 10.1007/s00330-015-3633-3]">Bignotti 2015</a>). </p> </section> <section id="CD014687-sec-0011"> <h3 class="title" id="CD014687-sec-0011">Description of the intervention</h3> <p>The treatment goals for MN are minimalisation of pain and improved function. Interventions for MN may be nonsurgical or surgical (involving an incision). A common term used in both nonsurgical and surgical treatments is 'neurolysis', which has multiple meanings including the destruction or dissolution of nerve tissue, and also the surgical release of a nerve caught in an adhesion (the abnormal union of adjacent tissues due to inflammation). To distinguish between these definitions, we have used 'temperature neurolysis' or 'chemical neurolysis' for destruction of nerve tissue, and 'surgical neurolysis' for surgical release of the nerve. </p> <p>Nonsurgical interventions may be divided into noninvasive (non‐skin‐penetrating) treatments and invasive (skin‐penetrating) treatments. Nonsurgical noninvasive interventions used in clinical practice include ultrasound, electrical stimulation, whirlpool (type of hydrotherapy), massage (<a href="./references#CD014687-bbs2-0080" title="NunanPJ , GiesyBD . Management of Morton's neuroma in athletes. Clinics in Podiatric Medicine and Surgery1997;14(3):489-501. [PMID: 9257036]">Nunan 1997</a>), manipulation (<a href="./references#CD014687-bbs2-0031" title="CashleyDG , CochraneL . Manipulation in the treatment of plantar digital neuralgia: a retrospective study of 38 cases. Journal of Chiropractic Medicine2015;14(2):90-8. [DOI: 10.1016/j.jcm.2015.04.003]">Cashley 2015</a>; <a href="./references#CD014687-bbs2-0012" title="GovenderN , KretzmannH , PriceJL , BrantinghamJW , GlobeG . A single-blinded randomized placebo-controlled clinical trial of manipulation and mobilization in the treatment of Morton's neuroma. Journal of the American Chiropractic Association2007;44(3):8-18. ">Govender 2007</a>), nonsteroidal anti‐inflammatory drugs (<a href="./references#CD014687-bbs2-0080" title="NunanPJ , GiesyBD . Management of Morton's neuroma in athletes. Clinics in Podiatric Medicine and Surgery1997;14(3):489-501. [PMID: 9257036]">Nunan 1997</a>), orthoses (shoe inserts) (<a href="./references#CD014687-bbs2-0047" title="GaynorR , HakeD , SpinnerSM , TomczakRL . A comparative analysis of conservative versus surgical treatment of Morton's neuroma. Journal of the American Podiatric Medicine Association1989;79(1):27-30. [DOI: 10.7547/87507315-79-1-27]">Gaynor 1989</a>; <a href="./references#CD014687-bbs2-0054" title="HirschbergGG . A simple cure for Morton's neuralgia. Journal of the American Podiatric Medical Association2000;90(2):100-1. [DOI: 10.7547/87507315-90-2-100]">Hirschberg 2000</a>; <a href="./references#CD014687-bbs2-0014" title="KilmartinTE , WallaceWA . Effect of pronation and supination orthosis on Morton's neuroma and lower extremity function. Foot &amp; Ankle International1994;15(5):256-62. [DOI: 10.1177/107110079401500505]">Kilmartin 1994</a>), and shockwave therapy (SWT) (<a href="./references#CD014687-bbs2-0005" title="SeokH , KimSH , LeeSY , ParkSW . Extracorporeal shockwave therapy in patients with Morton's neuroma a randomized, placebo-controlled trial. Journal of the American Podiatric Medical Association2016;106(2):93-9. [DOI: 10.7547/14-131]">Seok 2016</a>). Nonsurgical invasive interventions include botulinum toxin injection (<a href="./references#CD014687-bbs2-0034" title="ClimentJM , Mondéjar-GómezF , Rodriguez-RuizC , Diaz-LlopisI , Gómez-GallegoD , Martín-MedinaP . Treatment of Morton neuroma with botulinum toxin A: a pilot study. Clinical Drug Investigation2013;33:497-503. [DOI: 10.1007/s40261-013-0090-0]">Climent 2013</a>), radiofrequency ablation (temperature neurolysis) (<a href="./references#CD014687-bbs2-0033" title="ChuterGS , ChuaYP , ConnellDA , BlackneyMC . Ultrasound-guided radiofrequency ablation in the management of interdigital (Morton’s) neuroma. Skeletal Radiology2013;42:107-11. [DOI: 10.1007/s00256-012-1527-x]">Chuter 2013</a>), cryoneurolysis (temperature neurolysis) (<a href="./references#CD014687-bbs2-0045" title="FriedmanT , RichmanD , AdlerR . Sonographically guided cryoneurolysis: preliminary experience and clinical outcomes. Journal of Ultrasound in Medicine2012;31(12):2025-34. [DOI: 10.7863/jum.2012.31.12.2025]">Friedman 2012</a>), and steroid injection (<a href="./references#CD014687-bbs2-0002" title="Lizano-DíezX , Ginés-CespedosaA , Alentorn-GeliE , Pérez-PrietoD , González-LucenaG , GambaC , et al. Corticosteroid injection for the treatment of Morton's neuroma: a prospective, double-blinded, randomized, placebo-controlled trial. Foot &amp; Ankle International2017;38(9):944-51. [DOI: 10.1177/1071100717709569]">Lizano‐Diez 2017</a>; <a href="./references#CD014687-bbs2-0006" title="ThomsonCE , BeggsI , MartinDJ , McMillanD , EdwardsRT , RussellD , et al. Methylprednisolone injections for the treatment of Morton neuroma: a patient-blinded randomized trial. Journal of Bone and Joint Surgery. American Volume2013;95(9):790-S1. [DOI: 10.2106/JBJS.I.01780]">Thomson 2013</a>). Although steroid injection is often the initial nonsurgical invasive treatment for Morton's neuroma (<a href="./references#CD014687-bbs2-0041" title="Di CaprioF , MeringoloR , EddineMS , PonzianiL . Morton’s interdigital neuroma of the foot: a literature review. Foot and Ankle Surgery2018;24(2):92-8. [DOI: 10.1016/j.fas.2017.01.007]">Di Caprio 2018</a>; <a href="./references#CD014687-bbs2-0093" title="ThomasJL , BlitchEL , ChaneyDM , DinucciKA , EickmeierK , RubinLG , et al. Diagnosis and treatment of forefoot disorders. Section 3. Morton's intermetatarsal neuroma. Journal of Foot and Ankle Surgery2009;48(2):251-6. [DOI: 10.1053/j.jfas.2008.12.005]">Thomas 2009</a>), its effectiveness is not established (<a href="./references#CD014687-bbs2-0070" title="MatthewsBG , HurnSE , HardingMP , HenryRA , WareRS . The effectiveness of nonsurgical interventions for common plantar digital compressive neuropathy (Morton's neuroma): a systematic review and meta-analysis. Journal of Foot and Ankle Research2019;12(12):1-21. [DOI: 10.1186/s13047-019-0320-7]">Matthews 2019</a>). </p> </section> <section id="CD014687-sec-0012"> <h3 class="title" id="CD014687-sec-0012">How the intervention might work</h3> <p>Interventions for the treatment of MN provide a diverse range of proposed therapeutic effects, but evidence in the peer‐reviewed literature for many of these effects is limited. From a nonsurgical and noninvasive perspective, it is speculated that mobilisation or manipulation (<a href="./references#CD014687-bbs2-0012" title="GovenderN , KretzmannH , PriceJL , BrantinghamJW , GlobeG . A single-blinded randomized placebo-controlled clinical trial of manipulation and mobilization in the treatment of Morton's neuroma. Journal of the American Chiropractic Association2007;44(3):8-18. ">Govender 2007</a>), and footwear modification (<a href="./references#CD014687-bbs2-0024" title="BennettGL , GrahamCE , MauldinDM . Morton's interdigital neuroma: a comprehensive treatment protocol. Foot and Ankle International1995;16(12):760-3. [DOI: 10.1177/107110079501601204]">Bennett 1995</a>), reduce pain by reducing webspace compression. Foot orthoses may reduce plantar forefoot pressure (<a href="./references#CD014687-bbs2-0039" title="deOliveiraHA , NatourJ , VassalliM , RosenfeldA , JenningsF , JonesA . Effectiveness of customized insoles in patients with Morton's neuroma: a randomized, controlled, double-blind clinical trial. Clinical Rehabilitation2019;33(12):1898-907. [DOI: 10.1177/0269215519873949]">de Oliveira 2019</a>), and SWT may suppress nociceptive nerve fibres and result in pain reduction (<a href="./references#CD014687-bbs2-0005" title="SeokH , KimSH , LeeSY , ParkSW . Extracorporeal shockwave therapy in patients with Morton's neuroma a randomized, placebo-controlled trial. Journal of the American Podiatric Medical Association2016;106(2):93-9. [DOI: 10.7547/14-131]">Seok 2016</a>). </p> <p>From a nonsurgical invasive perspective, corticosteroid injections induce atrophy (wasting away) of the webspace tissue, which possibly decreases compression and inflammation of the nerve (<a href="./references#CD014687-bbs2-0082" title="ParkYH , LeeJW , ChoiGW , KimHJ . Risk factors and the associated cutoff values for failure of corticosteroid injection in treatment of Morton's neuroma. International Orthopaedics2018;42(2):323-9. [DOI: 10.1007/s00264-017-3707-8]">Park 2018</a>). Alcohol injections given to achieve chemical neurolysis may induce neuritis (painful inflammation of the nerve) and Wallerian nerve degeneration until the nerve is destroyed or completely ceases to function (<a href="./references#CD014687-bbs2-0042" title="DockeryGL . The treatment of intermetatarsal neuromas with 4% alcohol sclerosing injections. Journal of Foot and Ankle Surgery1999;38(6):403-8. [DOI: 10.1016/s1067-2516(99)80040-4]">Dockery 1999</a>). </p> <p>From a surgical perspective, nerve excision (neurectomy) is essentially the removal of the nerve or neuroma to alleviate chronic pain (<a href="./references#CD014687-bbs2-0030" title="BucknallV , RutherfordD , MacDonaldD , ShalabyH , McKinleyJ , BreuschSJ . Outcomes following excision of Morton's interdigital neuroma: a prospective study. Bone and Joint Journal2016;98-B(10):1376-81. [DOI: 10.1302/0301-620X.98B10.37610]">Bucknall 2016</a>). Surgical neurolysis aims to decompress the nerve to relieve pain, whilst maintaining normal nerve function and toe sensation (<a href="./references#CD014687-bbs2-0097" title="VillasC , FlorezB , AlfonsoM . Neurectomy versus neurolysis for Morton's neuroma. Foot and Ankle International2008;29(6):578-80. [DOI: 10.3113/FAI.2008.0578]">Villas 2008</a>). Metatarsal osteotomies (cutting of bone) may also decompress the nerve and relieve pain (<a href="./references#CD014687-bbs2-0063" title="LeeJ , KimJ , LeeM , ChuI , LeeS , GwakH . Morton’s neuroma (interdigital neuralgia) treated with metatarsal sliding osteotomy. Indian Journal of Orthopaedics2017;51:692-6.">Lee 2017</a>). </p> </section> <section id="CD014687-sec-0013"> <h3 class="title" id="CD014687-sec-0013">Why it is important to do this review</h3> <p>Currently there is no up‐to‐date review reporting on the certainty of the evidence from high‐quality trials regarding the effectiveness of surgical and nonsurgical interventions for MN. The previous Cochrane review that investigated the treatment of people with MN was published in 2004 and found there was an insufficient number of high‐quality trials to reach firm conclusions about the effectiveness of interventions (<a href="./references#CD014687-bbs2-0100" title="ThomsonCE , GibsonJN , MartinD . Interventions for the treatment of Morton's neuroma. Cochrane Database of Systematic Reviews2004, Issue 3. Art. No: CD003118. [DOI: 10.1002/14651858.CD003118.pub2]">Thomson 2004</a>). Since then, nine systematic reviews have been published that considered a range of interventions for MN (<a href="./references#CD014687-bbs2-0027" title="BondiL , TarantinoU , BondiR , FollieroA . Treatment of Morton's neuroma: the evidence. Journal of Orthopaedics and Traumatology2005;6(4):199-202. [DOI: 10.1007/s10195-005-0110-9]">Bondi 2005</a>; <a href="./references#CD014687-bbs2-0032" title="ChoiJY , LeeHI , HongWH , SuhJS , HurJW . Corticosteroid injection for Morton's interdigital neuroma: a systematic review. Clinics in Orthopedic Surgery2021;21(3):206-11. [DOI: 10.1177/107110070002100304]">Choi 2021</a>; <a href="./references#CD014687-bbs2-0044" title="EdwardsSR , FlemingS , LandorfKB . Efficacy of a single corticosteroid injection for Morton's neuroma in adults: a systematic review. Journal of the American Podiatric Medical Association2021;111(4):1-12. [DOI: 10.7547/20-151]">Edwards 2021</a>; <a href="./references#CD014687-bbs2-0067" title="LorenzonP , RettoreC , ScalviA . Infiltrative therapy of Morton's neuroma: a systematic review of different treatment options. Acta Biomedica2022;92(Suppl 3):e2021556. [DOI: 10.23750/abm.v92iS3.12545]">Lorenzon 2022</a>; <a href="./references#CD014687-bbs2-0068" title="LuVM , PufferRC , EversonMC , GilderHE , BurksSS , SpinnerRJ . Treating Morton's neuroma by injection, neurolysis, or neurectomy: a systematic review and meta-analysis of pain and satisfaction outcomes. Acta Neurochirurgica2021;163(2):531-43. [DOI: 10.1007/s00701-020-04241-9]">Lu 2021</a>; <a href="./references#CD014687-bbs2-0070" title="MatthewsBG , HurnSE , HardingMP , HenryRA , WareRS . The effectiveness of nonsurgical interventions for common plantar digital compressive neuropathy (Morton's neuroma): a systematic review and meta-analysis. Journal of Foot and Ankle Research2019;12(12):1-21. [DOI: 10.1186/s13047-019-0320-7]">Matthews 2019</a>; <a href="./references#CD014687-bbs2-0088" title="SamailaE , ColoG , RavaA , NegriS , ValentiniR , FelliL , et al. Effectiveness of corticosteroid injections in Civinini-Morton's syndrome: a systematic review. Foot and Ankle Surgery2021;27(4):357-65. [DOI: 10.1016/j.fas.2020.05.001]">Samaila 2021</a>; <a href="./references#CD014687-bbs2-0094" title="ThomsonL , AujlaRS , DivallP , BhatiaM . Non-surgical treatments for Morton'sneuroma: a systematic review. Foot and Ankle Surgery2020;26(7):736-43. [DOI: 10.1016/j.fas.2019.09.009]">Thomson 2020</a>; <a href="./references#CD014687-bbs2-0095" title="ValisenaS , PetriGJ , FerreroA . Treatment of Morton's neuroma: a systematic review. Foot and Ankle Surgery2018;24(4):271-81. [DOI: 10.1016/j.fas.2017.03.010]">Valisena 2018</a>). However, none of these reviews has reported on the certainty of the evidence from high‐quality trials for surgical and non‐surgical interventions. This Cochrane review is based on a new protocol (<a href="./references#CD014687-bbs2-0098" title="MatthewsBG , ThomsonCE , McKinleyJC , HardingMP , WareRS . Treatments for Morton's neuroma. Cochrane Database of Systematic Reviews2021, Issue 7. Art. No: CD014687. [DOI: 10.1002/14651858.CD014687]">Matthews 2021</a>), and provides the first comprehensive summary of the certainty of the evidence from high‐quality trials across the breadth of treatments from nonsurgical through to surgical interventions. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD014687-sec-0014" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD014687-sec-0014"></div> <p>To assess the benefits and harms of interventions for MN.</p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD014687-sec-0015" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD014687-sec-0015"></div> <section id="CD014687-sec-0016"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD014687-sec-0017"> <h4 class="title">Types of studies</h4> <p>We considered all parallel‐group trials and cross‐over trials. The number of groups studied in each trial could be two or more. We considered trials where allocation to intervention group was either randomised or quasi‐randomised (that is, allocation using methods that are partly systematic, for example by alternation, use of a case‐record number, or date of attendance). We considered trials whether allocation occurred at the participant level (one participant with one Morton's neuroma (MN)) or at the cluster level (one participant with two or more MN receiving one or more interventions). We considered all studies that were reported as full text, those published as abstracts only, and unpublished data. There were no restrictions regarding language or date. </p> </section> <section id="CD014687-sec-0018"> <h4 class="title">Types of participants</h4> <p>We included study participants with a diagnosis of MN confirmed by one or more diagnostic criteria from each of the history, physical examination and confirmatory test categories described below. </p> <section id="CD014687-sec-0019"> <h5 class="title">History</h5> <p> <ul id="CD014687-list-0001"> <li> <p>Pain located in the first, second, third, or fourth webspace of the foot (<a href="./references#CD014687-bbs2-0005" title="SeokH , KimSH , LeeSY , ParkSW . Extracorporeal shockwave therapy in patients with Morton's neuroma a randomized, placebo-controlled trial. Journal of the American Podiatric Medical Association2016;106(2):93-9. [DOI: 10.7547/14-131]">Seok 2016</a>) </p> </li> <li> <p>Paraesthesia, including pins and needles, shooting pains, or burning sensations in the forefoot or toe(s) (<a href="./references#CD014687-bbs2-0038" title="DandoC , CherryL , JonesL , BowenC . The clinical diagnosis of symptomatic forefoot neuroma in the general population: a Delphi consensus study. Journal of Foot and Ankle Research2017;10(1):59. [DOI: 10.1186/s13047-017-0241-2]">Dando 2017</a>) </p> </li> <li> <p>A weight‐bearing sensation of walking on pebbles, a lump or a stone (<a href="./references#CD014687-bbs2-0038" title="DandoC , CherryL , JonesL , BowenC . The clinical diagnosis of symptomatic forefoot neuroma in the general population: a Delphi consensus study. Journal of Foot and Ankle Research2017;10(1):59. [DOI: 10.1186/s13047-017-0241-2]">Dando 2017</a>) </p> </li> <li> <p>The wearing of tight‐fitting footwear ‐ especially across the forefoot ‐ or high‐heeled footwear aggravates symptoms (<a href="./references#CD014687-bbs2-0038" title="DandoC , CherryL , JonesL , BowenC . The clinical diagnosis of symptomatic forefoot neuroma in the general population: a Delphi consensus study. Journal of Foot and Ankle Research2017;10(1):59. [DOI: 10.1186/s13047-017-0241-2]">Dando 2017</a>) </p> </li> </ul> </p> </section> <section id="CD014687-sec-0020"> <h5 class="title">Physical examination</h5> <p> <ul id="CD014687-list-0002"> <li> <p>Positive thumb‐index finger squeeze test (tenderness or pain with dorsal and plantar compression of the webspace) (<a href="./references#CD014687-bbs2-0038" title="DandoC , CherryL , JonesL , BowenC . The clinical diagnosis of symptomatic forefoot neuroma in the general population: a Delphi consensus study. Journal of Foot and Ankle Research2017;10(1):59. [DOI: 10.1186/s13047-017-0241-2]">Dando 2017</a>; <a href="./references#CD014687-bbs2-0069" title="MahadevanD , VenkatesanM , BhattR , BhatiaM . Diagnostic accuracy of clinical tests for Morton's neuroma compared with ultrasonography. Journal of Foot and Ankle Surgery2015;54(4):549-53. [DOI: 10.1053/j.jfas.2014.09.021]">Mahadevan 2015</a>) </p> </li> <li> <p>Presence of Mulder's sign (also known as Mulder's click, manoeuvre or test, which is a palpable click felt when firm plantar pressure is applied with the thumb over a suspected neuroma while the forefoot is compressed with the other hand) (<a href="./references#CD014687-bbs2-0038" title="DandoC , CherryL , JonesL , BowenC . The clinical diagnosis of symptomatic forefoot neuroma in the general population: a Delphi consensus study. Journal of Foot and Ankle Research2017;10(1):59. [DOI: 10.1186/s13047-017-0241-2]">Dando 2017</a>; <a href="./references#CD014687-bbs2-0069" title="MahadevanD , VenkatesanM , BhattR , BhatiaM . Diagnostic accuracy of clinical tests for Morton's neuroma compared with ultrasonography. Journal of Foot and Ankle Surgery2015;54(4):549-53. [DOI: 10.1053/j.jfas.2014.09.021]">Mahadevan 2015</a>; <a href="./references#CD014687-bbs2-0075" title="MulderJD . The causative mechanism in Morton's metatarsalgia. Journal of Bone and Joint Surgery. British Volume1951;33B:94-5. [PMID: 14814167]">Mulder 1951</a>) </p> </li> </ul> </p> </section> <section id="CD014687-sec-0021"> <h5 class="title">Confirmatory tests</h5> <p> <ul id="CD014687-list-0003"> <li> <p>Ultrasound scan (USS): 5 mm or more transverse thickening of the plantar digital nerve at the webspace that is well defined and grey in appearance (hypoechoic) (<a href="./references#CD014687-bbs2-0038" title="DandoC , CherryL , JonesL , BowenC . The clinical diagnosis of symptomatic forefoot neuroma in the general population: a Delphi consensus study. Journal of Foot and Ankle Research2017;10(1):59. [DOI: 10.1186/s13047-017-0241-2]">Dando 2017</a>; <a href="./references#CD014687-bbs2-0096" title="Van HulE , VanhoenackerF , Van DyckP , De SchepperA , ParizelPM . Pseudotumoural soft tissue lesions of the foot and ankle: a pictorial review. Insights Imaging2011;2(4):439-52. [DOI: 10.1007/s13244-011-0087-2]">Van Hul 2011</a>) </p> </li> <li> <p>Magnetic resonance imaging (MRI): 5 mm or more transverse thickening of the plantar digital nerve that appears to have the same signal intensity (isointense) as muscle tissue, a grey appearance on T1‐weighted images, and a lower signal intensity (hypointense) than fat tissue, which has a white appearance on T2‐weighted image (<a href="./references#CD014687-bbs2-0096" title="Van HulE , VanhoenackerF , Van DyckP , De SchepperA , ParizelPM . Pseudotumoural soft tissue lesions of the foot and ankle: a pictorial review. Insights Imaging2011;2(4):439-52. [DOI: 10.1007/s13244-011-0087-2]">Van Hul 2011</a>) </p> </li> <li> <p>Nerve conduction studies: absent sensory nerve action potentials, decreased amplitude peaks or prolonged peak latency (<a href="./references#CD014687-bbs2-0022" title="AydinlarEI , UzunM , BeksacB , OzdenVE , KaraarslanE , OgeAE . Simple electrodiagnostic method for Morton neuroma. Muscle &amp; Nerve2014;49(2):193-7. [DOI: 10.1002/mus.23899]">Aydinlar 2014</a>) </p> </li> <li> <p>Histological confirmation of excised tissue (<a href="./references#CD014687-bbs2-0048" title="GiakoumisM , RyanJD , JaniJ . Histologic evaluation of intermetatarsal Morton's neuroma. Journal of the American Podiatric Medical Association2013;103(3):218-22. [DOI: 10.7547/1030218]">Giakoumis 2013</a>) </p> </li> </ul> </p> <p>We excluded participants with a history of the following comorbidities or characteristics.</p> <p> <ul id="CD014687-list-0004"> <li> <p>Local tissue injury or disease (e.g. metatarsophalangeal capsulitis, forefoot adventitial bursitis, stress fracture, schwannoma or mononeuropathies such as tarsal tunnel syndrome) </p> </li> <li> <p>Systemic conditions resulting in polyneuropathies (e.g. rheumatoid arthritis, multiple sclerosis, vitamin B<sub>12</sub> deficiency, diabetes) </p> </li> <li> <p>Proximal neural defects (e.g. radiculopathy)</p> </li> </ul> </p> <p>If studies had included a subset of relevant participants, we would have contacted the study authors to obtain data for the subgroup of interest. If we could not source subgroup data, we would have included the study in the review, but not in any meta‐analysis. </p> </section> </section> <section id="CD014687-sec-0022"> <h4 class="title">Types of interventions</h4> <p>We considered trials that compared any surgical or nonsurgical intervention with any control, placebo, nonsurgical or surgical intervention. We considered studies with co‐interventions when they were provided to each group equally. We excluded trials that evaluated interventions following MN surgery. </p> <p>We grouped interventions into one of the following categories.</p> <section id="CD014687-sec-0023"> <h5 class="title">Nonsurgical treatments</h5> <p> <ul id="CD014687-list-0005"> <li> <p>Noninvasive interventions (e.g. mobilisation or manipulation, supportive footwear with a wider fit, metatarsal padding, shockwave therapy (SWT) or foot orthoses) </p> </li> <li> <p>Invasive interventions (e.g. injections of corticosteroid, alcohol for sclerosing or botulinum toxin (<a href="./references#CD014687-bbs2-0034" title="ClimentJM , Mondéjar-GómezF , Rodriguez-RuizC , Diaz-LlopisI , Gómez-GallegoD , Martín-MedinaP . Treatment of Morton neuroma with botulinum toxin A: a pilot study. Clinical Drug Investigation2013;33:497-503. [DOI: 10.1007/s40261-013-0090-0]">Climent 2013</a>); radiofrequency ablation (<a href="./references#CD014687-bbs2-0033" title="ChuterGS , ChuaYP , ConnellDA , BlackneyMC . Ultrasound-guided radiofrequency ablation in the management of interdigital (Morton’s) neuroma. Skeletal Radiology2013;42:107-11. [DOI: 10.1007/s00256-012-1527-x]">Chuter 2013</a>), or cryoneurolysis (<a href="./references#CD014687-bbs2-0045" title="FriedmanT , RichmanD , AdlerR . Sonographically guided cryoneurolysis: preliminary experience and clinical outcomes. Journal of Ultrasound in Medicine2012;31(12):2025-34. [DOI: 10.7863/jum.2012.31.12.2025]">Friedman 2012</a>)) </p> </li> </ul> </p> </section> <section id="CD014687-sec-0024"> <h5 class="title">Surgical treatments</h5> <p> <ul id="CD014687-list-0006"> <li> <p>Neurectomy (surgery on the MN with excision of the nerve)</p> </li> <li> <p>Surgical neurolysis (surgery on the MN without excision of the nerve)</p> </li> <li> <p>Osteotomy (surgery on the metatarsal adjacent to the MN)</p> </li> </ul> </p> </section> </section> <section id="CD014687-sec-0025"> <h4 class="title">Types of outcome measures</h4> <p>We defined time points for measuring primary and secondary outcomes as short term (less than three months from baseline), intermediate term (three months to less than 12 months from baseline), and long term (12 months or longer from baseline). If more than one measurement occurred within a time interval, we used the measurement closest to three months (short term), six months (intermediate term) and 12 months (long term). When trials used different methods to evaluate the same outcome (such as pain assessed by means of different questionnaires), we selected a commonly used outcome measure (such as pain reported on a 0 to 100 visual analogue scale (VAS)). Where available, we extracted end‐point scores for our primary analysis. </p> <p>The outcomes listed below are those of interest to the review. We included studies that measured one or more of these outcomes, even if no outcome data were available or reported. </p> <section id="CD014687-sec-0026"> <h5 class="title">Primary outcomes</h5> <section id="CD014687-sec-0027"> <h6 class="title">Pain</h6> <p>We included VASs, numerical rating scales or pain scales (or subscales) of participant‐reported outcome measures for use with foot or ankle diseases (<a href="./references#CD014687-bbs2-0058" title="JiaY , HuangH , GagnierJJ . A systematic review of measurement properties of patient-reported outcome measures for use in patients with foot or ankle diseases. Quality of Life Research2017;26(8):1969-2010. [DOI: 10.1007/s11136-017-1542-4]">Jia 2017</a>). Where possible, we combined results from all similar continuous pain scales as mean differences (MD) and results from dissimilar scales as standardised mean differences (SMD). In this review, we consistently presented scales so that a lower numerical rating corresponded to less pain. When included studies presented scales where a higher numerical rating corresponded to less pain, we transformed the data by reflecting the recorded pain score around the midpoint of the scale. For example, a VAS 0 to 100 scale has a midpoint of 50, so a score of 70, when a higher score corresponds to less pain is equivalent to a score of 30, when a lower score corresponds to less pain. </p> <p>There are no published data investigating the minimal clinically important differences (MCID) for MN. Published randomised controlled trials (RCTs) have used a 15‐point change, as in <a href="./references#CD014687-bbs2-0003" title="HauMYT , ThomsonL , AujlaR , MadhadevanD , BhatiaM . Medium-term results of corticosteroid injections for Morton’s neuroma. Foot &amp; Ankle International2021;42(4):464-8. [DOI: 10.1177/1071100720966332]MahadevanD , AttwalM , BhattR , BhatiaM . Corticosteroid injection for Morton's neuroma with or without ultrasound guidance: a randomised controlled trial. Bone &amp; Joint Journal2016;98-B(4):498-503. [DOI: 10.1302/0301-620X.98B4.36880]">Mahadevan 2016</a>, and a 30‐point change, as in <a href="./references#CD014687-bbs2-0066" title="Lizano-DíezX , Ginés-CespedosaA , Alentorn-GeliE , Pérez-PrietoD , González-LucenaG , GambaC , et al. Corticosteroid injection for the treatment of Morton's neuroma: a prospective, double-blinded, randomized, placebo-controlled trial. Foot and Ankle International2017;38(9):944-51. [DOI: 10.1177/107110071770956]">Lizano‐Diez 2017</a>, on a 0 to 100 pain VAS. A study investigating acute pain found that a difference of approximately 13 points (95% confidence interval (CI) 10 to 17) represented the minimum change that was clinically significant (<a href="./references#CD014687-bbs2-0046" title="GallagherEJ , LiebmanM , BijurPE . Prospective validation of clinically important changes in pain severity measured on a visual analog scale. Annals of Emergency Medicine2001;38(6):633-8. [DOI: 10.1067/mem.2001.118863]">Gallagher 2001</a>). Based on these studies, we will use a 15‐point change on a 0 to 100 pain VAS as the MCID. </p> </section> </section> <section id="CD014687-sec-0028"> <h5 class="title">Secondary outcomes</h5> <p><b>Function:</b> measured by self‐report using questionnaire scales (e.g. Foot Function Index disability or activity subscales) or objective measures of functional capacity (e.g. six‐minute walk test) </p> <p><b>Health‐related quality of life (HRQoL) or satisfaction:</b> measured by self‐report questionnaire (e.g. Johnson scale) (<a href="./references#CD014687-bbs2-0059" title="JohnsonJE , JohnsonKA , UnniKK . Persistent pain after excision of an interdigital neuroma. Results of reoperation. The Journal of Bone and Joint Surgery1988;70(5):651-7.">Johnson 1988</a>) </p> <p><b>Adverse events</b> </p> <p> <ul id="CD014687-list-0007"> <li> <p>Increase in pain: measured by self‐report</p> </li> <li> <p>Unable to wear preferred footwear due to symptoms</p> </li> <li> <p>Any other emergent or intervention‐related event, e.g. infection, hypoaesthesia (absent or reduced sensitivity to skin stimulation), callosities (hard, thickened skin) over plantar scars, or complex regional pain syndrome (<a href="./references#CD014687-bbs2-0072" title="McQuayHJ , MooreRA , EcclestonC , MorleyS , WilliamsAC . Systematic review of outpatient services for chronic pain control. Health Technology Assessment1997;1(6):1-135. [PMID: 9483161]">McQuay 1997</a>) </p> </li> </ul> </p> </section> </section> </section> <section id="CD014687-sec-0029"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD014687-sec-0030"> <h4 class="title">Electronic searches</h4> <p>On 13 June 2021 and 11 July 2022, the Cochrane Neuromuscular Information Specialist searched the following sources. </p> <p> <ul id="CD014687-list-0008"> <li> <p>Cochrane Neuromuscular Specialised Register (to 11 July 2022; <a href="./appendices#CD014687-sec-0122">Appendix 1</a>) </p> </li> <li> <p>Cochrane Central Register of Controlled Trials (CENTRAL, Issue 7 2022; <a href="./appendices#CD014687-sec-0123">Appendix 2</a>) </p> </li> <li> <p>MEDLINE Ovid (1946 to 8 July 2022; <a href="./appendices#CD014687-sec-0124">Appendix 3</a>) </p> </li> <li> <p>Embase Ovid (1974 to 2022 Week 27; <a href="./appendices#CD014687-sec-0125">Appendix 4</a>) </p> </li> <li> <p>Cumulative Index to Nursing and Allied Health Literature (CINAHL) Plus EBSCOhost (1937 to 11 July 2022; <a href="./appendices#CD014687-sec-0126">Appendix 5</a>) </p> </li> <li> <p>US National Institutes for Health Clinical Trials Registry, ClinicalTrials.gov (<a href="http://www.ClinicalTrials.gov" target="_blank">www.ClinicalTrials.gov</a>; until 11 July 2022; <a href="./appendices#CD014687-sec-0127">Appendix 6</a>) </p> </li> <li> <p>World Health Organization (WHO) International Clinical Trials Registry Portal (ICTRP: <a href="https://apps.who.int/trialsearch/" target="_blank">apps.who.int/trialsearch</a> to 11 July 2022; <a href="./appendices#CD014687-sec-0128">Appendix 7</a>) </p> </li> </ul> </p> <p>We searched all databases from their inception to the present, and we did not impose any restrictions for language, date, document type or publication status. </p> </section> <section id="CD014687-sec-0031"> <h4 class="title">Searching other resources</h4> <p>We searched reference lists of all included primary studies and review articles for additional references. </p> </section> </section> <section id="CD014687-sec-0032"> <h3 class="title" id="CD014687-sec-0032">Data collection and analysis</h3> <section id="CD014687-sec-0033"> <h4 class="title">Selection of studies</h4> <p>We exported search results into <a href="./references#CD014687-bbs2-0037" title="Covidence. Version accessed 12 April 2020. Melbourne, Australia: Veritas Health Innovation, 2022. Available at covidence.org.">Covidence</a>, where duplicates were removed. Two review authors (BM and MH) independently screened titles and abstracts of all the potential studies identified and coded them as 'retrieve' (eligible or potentially eligible or unclear) or 'do not retrieve' (clearly ineligible). We retrieved the full‐text study reports and abstracts when studies were only published as an abstract, and two review authors (BM and MH) independently screened the full text to identify studies for inclusion, and identified and recorded reasons for exclusion of the ineligible studies. We resolved any disagreement through discussion or, if required, consulted a third person (CT). We identified and excluded duplicates and collated multiple reports of the same study so that each study, rather than each report, is the unit of interest in the review. We recorded the selection process in sufficient detail to complete a PRISMA flow diagram (<a href="#CD014687-fig-0001">Figure 1</a>) and <a href="./references#CD014687-sec-0137" title="">Characteristics of included studies</a> table. </p> <div class="figure" id="CD014687-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Flow diagram of study selection." data-id="CD014687-fig-0001" src="/cdsr/doi/10.1002/14651858.CD014687.pub2/media/CDSR/CD014687/image_n/nCD014687-FIG-01.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Flow diagram of study selection.</p> </div> </div> </div> </section> <section id="CD014687-sec-0034"> <h4 class="title">Data extraction and management</h4> <p>We used a data extraction form to record study characteristics and outcome data, which we piloted on one study in the review. Two review authors (BM and RW) independently extracted study characteristics from the studies we included. We resolved disagreements by consensus or by involving a third person (CT). We extracted the following study characteristics: </p> <p> <ul id="CD014687-list-0009"> <li> <p>study design and setting;</p> </li> <li> <p>characteristics of participants (e.g. disease severity and age);</p> </li> <li> <p>eligibility criteria;</p> </li> <li> <p>intervention details;</p> </li> <li> <p>outcomes assessed;</p> </li> <li> <p>source(s) of study funding; and</p> </li> <li> <p>any conflicts of interest amongst investigators.</p> </li> </ul> </p> <p>Where participants had more than one neuroma (clustering), we recorded the number of feet and the number of neuromas. </p> <p>Two review authors (BM and RW) independently extracted outcome data from the included studies. We noted in the <a href="./references#CD014687-sec-0137" title="">Characteristics of included studies</a> table those trials that did not report outcome data in a usable way. We resolved disagreements by consensus or by involving a third person (CT). One review author (BM) transferred data into <a href="./references#CD014687-bbs2-0085" title="Review Manager Web (RevMan Web). Version 5.4.0. The Cochrane Collaboration, 2022 (accessed 06 July 2023). Available at revman.cochrane.org.">RevMan Web 2022</a>. A second review author (RW) checked the outcome data entries and spot‐checked study characteristics for accuracy against the trial reports. </p> <p>We converted categorical data to dichotomous data as follows.</p> <p> <ul id="CD014687-list-0010"> <li> <p>When there was an odd number of categories, we combined the response options favouring the intervention above the central category as one category and the remaining responses as the second category. For example, <a href="./references#CD014687-bbs2-0030" title="BucknallV , RutherfordD , MacDonaldD , ShalabyH , McKinleyJ , BreuschSJ . Outcomes following excision of Morton's interdigital neuroma: a prospective study. Bone and Joint Journal2016;98-B(10):1376-81. [DOI: 10.1302/0301-620X.98B10.37610]">Bucknall 2016</a> used the statement ‘The surgery has met my expectations’ with the categorical responses 'strongly agree, agree, no opinion, disagree, or strongly disagree'. We would dichotomise this with 'strongly agree' and 'agree' in one category and the remaining responses in the other category. </p> </li> <li> <p>When there was an even number of categories, we combined half the total response options favouring the intervention as one category and the remaining responses as the other category. For example, <a href="./references#CD014687-bbs2-0019" title="AkermarkC , CroneH , SaartokT , ZuberZ . Plantar versus dorsal incision in the treatment of primary intermetatarsal Morton's neuroma. Foot and Ankle International2008;29(2):136-41. [DOI: 10.3113/FAI.2008.0136]">Akermark 2008</a> includes a question regarding scar tenderness, with the categorical responses 'none, slight, moderate, severe'. We would dichotomise this with 'none' and 'slight' in one category and 'moderate' and 'severe' in the other category. </p> </li> </ul> </p> <p>When reports required translation, we extracted data from the translation provided. Where possible, a review author checked numerical data in the translation against the study report. When data were incomplete or required further clarification, we contacted the study authors. </p> <p>We used <a href="./references#CD014687-bbs2-0037" title="Covidence. Version accessed 12 April 2020. Melbourne, Australia: Veritas Health Innovation, 2022. Available at covidence.org.">Covidence</a> software to collect the data extracted from the included studies. We used Engauge Digitizer to extract data from included study figures when data were not reported (<a href="./references#CD014687-bbs2-0065" title="LiT , HigginsJP , DeeksJJ , editor(s). Chapter 5: Collecting data. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022). Cochrane, 2022. Available from training.cochrane.org/handbook (accessed 06 July 2023).">Li 2022</a>). </p> </section> <section id="CD014687-sec-0035"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors (BM and JM) independently assessed the risk of bias for each result listed in the summary of findings tables using the Cochrane risk of bias 2 (RoB 2) criteria outlined in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (the <i>Handbook</i>)(<a href="./references#CD014687-bbs2-0052" title="HigginsJP , SavovićJ , PageMJ , ElbersRG , SterneJA . Chapter 8: Assessing risk of bias in a randomized trial. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022). Cochrane, 2022. Available from training.cochrane.org/handbook (accessed 06 July 2023).">Higgins 2022a</a>). </p> <p>For trials with more than two intervention groups, we followed the additional guidance for assessing the risk of bias in Chapter 23 of the <i>Handbook</i> (<a href="./references#CD014687-bbs2-0053" title="HigginsJP , EldridgeS , LiT , editor(s). Chapter 23: Including variants on randomized trials. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA editor(s). Cochrane Handbook for Systematic Reviews of InterventionsVersion 6.3 (updated February 2022). Cochrane, 2022. Available from training.cochrane.org/handbook (accessed 06 July 2023).">Higgins 2022b</a>). We resolved any disagreements by discussion or by involving another author (CT). </p> <p>We assessed the risk of bias according to the following domains:</p> <p> <ul id="CD014687-list-0011"> <li> <p>bias arising from the randomisation process;</p> </li> <li> <p>bias due to deviations from intended interventions;</p> </li> <li> <p>bias due to missing outcome data;</p> </li> <li> <p>bias in measurement of the outcome;</p> </li> <li> <p>bias in selection of the reported result; and</p> </li> <li> <p>bias arising from the timing of identification and recruitment of participants (for cluster‐randomised trials only). </p> </li> </ul> </p> <p>We used the signalling questions to guide our judgements for each domain and determined an overall risk of bias for each result. We graded each potential source of bias as high, low, or some concerns and provided a justification for our judgement. We reported the source(s) of information for each decision using, for example, a quote from the study report. Where information on risk of bias related to unpublished data or correspondence with a trialist, we noted this. We summarised the risk of bias for each key outcome (across domains) for each study and addressed the risk of bias when synthesising results (see <a href="#CD014687-sec-0046">Data synthesis</a>) (<a href="./references#CD014687-bbs2-0052" title="HigginsJP , SavovićJ , PageMJ , ElbersRG , SterneJA . Chapter 8: Assessing risk of bias in a randomized trial. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022). Cochrane, 2022. Available from training.cochrane.org/handbook (accessed 06 July 2023).">Higgins 2022a</a>). </p> <p>When considering bias due to deviations from intended interventions, we addressed the question of assignment rather than adherence to intervention. </p> <p>We used the Microsoft Excel RoB 2 tool (<a href="./references#CD014687-bbs2-0086" title="RoB2 Development Group. Risk of bias tools. www.riskofbias.info/ (accessed 06 July 2023).">RoB2 2022</a>). </p> <p>The outcomes, measurement methods and time points we assessed for risk of bias were:</p> <p> <ul id="CD014687-list-0012"> <li> <p>pain, measured by self‐report at the intermediate‐term for non‐surgical and long‐term for surgical time points previously defined; </p> </li> <li> <p>function, measured by self‐report or objective assessment at the intermediate‐term for non‐surgical and long‐term for surgical time points previously defined; </p> </li> <li> <p>satisfaction or HRQoL, measured by self‐report at the intermediate‐term for non‐surgical and long‐term for surgical time points previously defined; and </p> </li> <li> <p>adverse events leading to medical intervention or discontinuation from study.</p> </li> </ul> </p> <section id="CD014687-sec-0036"> <h5 class="title">Cluster‐randomised and cross‐over trials</h5> <p>For cluster‐randomised and cross‐over trials, we followed the guidance from Cochrane Methods (<a href="./references#CD014687-bbs2-0035" title="Cochrane Methods. Risk of Bias 2 FAQs. Last updated 22 February 2022 . Available from methods.cochrane.org/risk-bias-2-faqs (accessed 06 July 2023).">Cochrane Methods 2022</a>). For cluster‐randomised trials, we used the Excel RoB 2 tool for cluster‐randomised trials (<a href="./references#CD014687-bbs2-0086" title="RoB2 Development Group. Risk of bias tools. www.riskofbias.info/ (accessed 06 July 2023).">RoB2 2022</a>). For cross‐over trials, we used the Excel RoB 2 tool for cross‐over trials (<a href="./references#CD014687-bbs2-0086" title="RoB2 Development Group. Risk of bias tools. www.riskofbias.info/ (accessed 06 July 2023).">RoB2 2022</a>). </p> </section> <section id="CD014687-sec-0037"> <h5 class="title">Conflicts of interest and risk of bias</h5> <p>We assessed whether there was a reason for ‘notable concern’ about conflicts of interest for each study. We included a table indicating our judgement for each study and provided a rationale for each assessment. We defined a notable concern as described in <a href="./references#CD014687-bbs2-0029" title="BoutronI , PageMJ , HigginsJP , AltmanDG , LundhA , HróbjartssonA . Chapter 7: Considering bias and conflicts of interest among the included studies. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022). Cochrane, 2022. Available from training.cochrane.org/handbook (accessed 06 July 2023).">Boutron 2022</a>, "important conflicts of interest expected to have a potential impact on study design, risk of bias in study results or risk of bias in a synthesis due to missing results". </p> </section> <section id="CD014687-sec-0038"> <h5 class="title">Assessment of bias in conducting the systematic review</h5> <p>We conducted the review according to its published protocol and reported any deviations from it in the '<a href="#CD014687-sec-0135">Differences between protocol and review</a>' section of the systematic review (<a href="./references#CD014687-bbs2-0098" title="MatthewsBG , ThomsonCE , McKinleyJC , HardingMP , WareRS . Treatments for Morton's neuroma. Cochrane Database of Systematic Reviews2021, Issue 7. Art. No: CD014687. [DOI: 10.1002/14651858.CD014687]">Matthews 2021</a>). </p> </section> </section> <section id="CD014687-sec-0039"> <h4 class="title">Measures of treatment effect</h4> <p>We analysed dichotomous data as risk ratios (RR) and continuous data as MD, or SMD for results across studies with outcomes that are conceptually the same but measured on different scales. We reported the corresponding 95% confidence intervals (CI). We entered data presented as a scale using a consistent direction of effect. </p> </section> <section id="CD014687-sec-0040"> <h4 class="title">Unit of analysis issues</h4> <section id="CD014687-sec-0041"> <h5 class="title">Cluster‐randomised trials</h5> <p>A cluster‐randomised trial may include participants with one neuroma in either foot or multiple neuromas in one foot. (In the extremely unlikely event that participants have one or more neuromas in one foot and multiple neuromas in the other foot, we would ask for additional statistical support from the Cochrane Methods Support Unit to guide our analysis and synthesis of these studies.) Studies included in meta‐analyses may have randomised at either the participant or neuroma level. Where cluster randomisation (i.e. randomisation at the participant level) occurred, we calculated effective sample sizes following the guidance in Section 23.1.4 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD014687-bbs2-0053" title="HigginsJP , EldridgeS , LiT , editor(s). Chapter 23: Including variants on randomized trials. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA editor(s). Cochrane Handbook for Systematic Reviews of InterventionsVersion 6.3 (updated February 2022). Cochrane, 2022. Available from training.cochrane.org/handbook (accessed 06 July 2023).">Higgins 2022b</a>). Different cluster‐randomisation scenarios include randomisation occurring at the participant level with individual outcome judgements recorded for multiple neuromas (e.g. all neuromas treated using the same intervention within a participant), or randomisation occurring at the neuroma level with individual outcome judgements recorded for multiple neuromas (i.e. within‐participant neuromas may be treated with different interventions). We calculated effective sample sizes where the number of MNs and number of participants were known. If the intracluster correlation coefficient was not reported, we conservatively assumed it to be 0.05. Where we included clustered studies in a meta‐analysis, we reported the effective sample size per MN, not per participant. </p> <p>We planned to conduct sensitivity analysis to investigate any change in effect size with the inclusion of cluster‐randomised studies. When a cluster‐randomised trial lacked the detail required to enable us to perform appropriate analysis of the data (e.g. there was not enough information to conduct approximate analyses of cluster‐randomised trials for a meta‐analysis by calculating an effective sample size or inflating the standard error), we planned to present these studies in a table in the results section and not include them in the meta‐analysis. </p> </section> <section id="CD014687-sec-0042"> <h5 class="title">Cross‐over trials</h5> <p>In cross‐over trials where randomisation occurs at the participant level (e.g. one neuroma in one foot), we would have assessed whether the first intervention would lead to a carry‐over effect that would cause a permanent or long‐term modification of the condition. If this occurred, we would only have used data from the first period, following the guidance in Section 23.2.4 of the <i>Handbook</i> (<a href="./references#CD014687-bbs2-0053" title="HigginsJP , EldridgeS , LiT , editor(s). Chapter 23: Including variants on randomized trials. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA editor(s). Cochrane Handbook for Systematic Reviews of InterventionsVersion 6.3 (updated February 2022). Cochrane, 2022. Available from training.cochrane.org/handbook (accessed 06 July 2023).">Higgins 2022b</a>). Where there was no carry‐over effect from the first period, we would follow the guidance in Section 23.2.5 of the <i>Handbook</i> (<a href="./references#CD014687-bbs2-0053" title="HigginsJP , EldridgeS , LiT , editor(s). Chapter 23: Including variants on randomized trials. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA editor(s). Cochrane Handbook for Systematic Reviews of InterventionsVersion 6.3 (updated February 2022). Cochrane, 2022. Available from training.cochrane.org/handbook (accessed 06 July 2023).">Higgins 2022b</a>). Where randomisation occurred at the neuroma level (e.g. one neuroma in either foot), and separate interventions and outcome judgements were made for each foot or neuroma, we would follow the guidance in Section 23.2.5 of the <i>Handbook</i> (<a href="./references#CD014687-bbs2-0053" title="HigginsJP , EldridgeS , LiT , editor(s). Chapter 23: Including variants on randomized trials. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA editor(s). Cochrane Handbook for Systematic Reviews of InterventionsVersion 6.3 (updated February 2022). Cochrane, 2022. Available from training.cochrane.org/handbook (accessed 06 July 2023).">Higgins 2022b</a>). Our analysis would have accounted for the pairing of feet or neuroma within individuals in the same way that pairing of intervention periods is recognised in the analysis of a cross‐over trial. We would have analysed the data as if it were achieved from the first period of a cross‐over trial, and followed the guidance in Section 23.2.4 of the <i>Handbook</i> (<a href="./references#CD014687-bbs2-0053" title="HigginsJP , EldridgeS , LiT , editor(s). Chapter 23: Including variants on randomized trials. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA editor(s). Cochrane Handbook for Systematic Reviews of InterventionsVersion 6.3 (updated February 2022). Cochrane, 2022. Available from training.cochrane.org/handbook (accessed 06 July 2023).">Higgins 2022b</a>). If a meta‐analysis included cross‐over trials, we would have followed the guidance in Sections 23.2.6 and 23.2.7 (<a href="./references#CD014687-bbs2-0053" title="HigginsJP , EldridgeS , LiT , editor(s). Chapter 23: Including variants on randomized trials. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA editor(s). Cochrane Handbook for Systematic Reviews of InterventionsVersion 6.3 (updated February 2022). Cochrane, 2022. Available from training.cochrane.org/handbook (accessed 06 July 2023).">Higgins 2022b</a>). </p> <p>Where a single study reported more than two intervention groups, we would have reported all intervention groups in the <a href="./references#CD014687-sec-0137" title="">Characteristics of included studies</a> tables, but would only have included detailed descriptions of intervention groups relevant to the review topic. We would have followed the guidance in Section 23.3.2 of the <i>Cochrane Handbookfor Systematic Reviews of Interventions</i> (<a href="./references#CD014687-bbs2-0053" title="HigginsJP , EldridgeS , LiT , editor(s). Chapter 23: Including variants on randomized trials. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA editor(s). Cochrane Handbook for Systematic Reviews of InterventionsVersion 6.3 (updated February 2022). Cochrane, 2022. Available from training.cochrane.org/handbook (accessed 06 July 2023).">Higgins 2022b</a>). We would only have included the relevant groups in a meta‐analysis. For studies with more than two relevant intervention groups (e.g. 'intervention A' versus 'intervention B' versus control), we would combine 'intervention A' and 'intervention B' for the analysis, if they had a similar therapeutic target or mechanism. Where 'intervention A' and 'intervention B' had a different therapeutic target or mechanism, we would divide results from the control group evenly for separate comparisons against the two interventions. For both strategies, we would follow the guidance in Section 23.3.4 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD014687-bbs2-0053" title="HigginsJP , EldridgeS , LiT , editor(s). Chapter 23: Including variants on randomized trials. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA editor(s). Cochrane Handbook for Systematic Reviews of InterventionsVersion 6.3 (updated February 2022). Cochrane, 2022. Available from training.cochrane.org/handbook (accessed 06 July 2023).">Higgins 2022b</a>). </p> </section> </section> <section id="CD014687-sec-0043"> <h4 class="title">Dealing with missing data</h4> <p>We contacted investigators or study sponsors in order to verify key study characteristics and obtain missing numerical outcome data when necessary (e.g. when a study was available as an abstract only). Where possible, we extracted data to allow an intention‐to‐treat (ITT) analysis including all randomised participants according to the groups to which they were originally assigned. For missing summary data, we calculated standard deviations from other statistics such as standard errors, CI or P values, using the calculator function within <a href="./references#CD014687-bbs2-0085" title="Review Manager Web (RevMan Web). Version 5.4.0. The Cochrane Collaboration, 2022 (accessed 06 July 2023). Available at revman.cochrane.org.">RevMan Web 2022</a>. Where median values are reported, means were calculated using a formula developed by Hozo and colleagues (<a href="./references#CD014687-bbs2-0056" title="Hozo Stela Pudar, Djulbegovic Benjamin, Hozo Iztok. Estimating the mean and variance from the median, range, and the size of a sample. BMC medical research methodology2005;5(13):1-10. [DOI: 10.1186/1471-2288-5-13]">Hozo 2005</a>). </p> </section> <section id="CD014687-sec-0044"> <h4 class="title">Assessment of heterogeneity</h4> <p>We used the I<sup>2</sup> statistic to measure heterogeneity amongst the trials in each analysis. If substantial unexplained heterogeneity had been identified in any of the analyses, we would have reported it and then explored possible causes for it by repeating the analyses after stratifying by study type.We used the rough guide to interpretation as outlined in Section 10.10.2 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i>, as follows: </p> <p> <ul id="CD014687-list-0013"> <li> <p>0% to 40%: might not be important;</p> </li> <li> <p>30% to 60%: may represent moderate heterogeneity;</p> </li> <li> <p>50% to 90%: may represent substantial heterogeneity;</p> </li> <li> <p>75% to 100%: considerable heterogeneity.</p> </li> </ul> </p> <p>We avoided the use of absolute cut‐off values, but interpreted I<sup>2</sup> in relation to the size and direction of effects and strength of evidence for heterogeneity (e.g. P value from the Chi<sup>2</sup> test, or CI for I<sup>2</sup>) (<a href="./references#CD014687-bbs2-0040" title="DeeksJJ , HigginsJP , AltmanDG , editor(s). Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch, VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022). Cochrane, 2022. Available from training.cochrane.org/handbook (accessed 06 July 2023).">Deeks 2022</a>). </p> </section> <section id="CD014687-sec-0045"> <h4 class="title">Assessment of reporting biases</h4> <p>If we had been able to pool more than 10 trials, we would have created and examined a funnel plot to explore possible publication bias. Where searches identified trial protocols, clinical trial registrations or abstracts indicating the existence of unpublished studies, we attempted to determine the status of any unpublished studies by contact with the investigators. </p> </section> <section id="CD014687-sec-0046"> <h4 class="title">Data synthesis</h4> <p>We grouped the data into similar interventions (e.g. similar therapeutic targets or mechanisms) and pooled trial data by outcome if they measured the same construct (e.g. pain) and had scales that could be combined for analysis (e.g. both use continuous scales). To clarify the term 'similar intervention', we would combine data concerning injection of corticosteroids as they come from the same class of drug and would have a similar therapeutic target. Conversely, we would not combine corticosteroid injection and Botox injection data since they do not have a similar therapeutic target. </p> <section id="CD014687-sec-0047"> <h5 class="title">Data synthesis methods</h5> <p>As a general rule, we used the frequentist random‐effects model in <a href="./references#CD014687-bbs2-0085" title="Review Manager Web (RevMan Web). Version 5.4.0. The Cochrane Collaboration, 2022 (accessed 06 July 2023). Available at revman.cochrane.org.">RevMan Web 2022</a>, as this is usually a more conservative approach. When the weightings given to individual studies included in a meta‐analysis were influenced by a few trials, we intended to perform a sensitivity analysis to determine whether their results were systematically different, since in these circumstances, use of a random‐effects meta‐analysis would exacerbate the effects of the bias. If the analyses were systematically different, we would have reported both analyses. Had studies been very homogeneous, with similar designs and populations, we would have used a fixed‐effect model. </p> </section> <section id="CD014687-sec-0048"> <h5 class="title">Incorporating bias in data synthesis</h5> <p>We incorporated risk of bias assessments in our analyses by presenting all studies and providing narrative descriptions of the risks of bias. </p> </section> <section id="CD014687-sec-0049"> <h5 class="title">Narrative synthesis</h5> <p>Where meta‐analysis was not possible, we provided a narrative synthesis of the available data following the guidance in Section 12.2.1 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD014687-bbs2-0071" title="McKenzieJE , BrennanSE . Chapter 12: Synthesizing and presenting findings using other methods. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022). Cochrane, 2022. Available from training.cochrane.org/handbook (accessed 06 July 2023).">McKenzie 2022</a>). </p> </section> </section> <section id="CD014687-sec-0050"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We did not perform any subgroup analyses.</p> </section> <section id="CD014687-sec-0051"> <h4 class="title">Sensitivity analysis</h4> <p>Had we included more studies, we would have performed a sensitivity analysis to investigate any change in effect size with the inclusion of cluster‐randomised studies or, where the weightings given to individual studies comprising a meta‐analysis are influenced by a few trials. We would also have performed the following sensitivity analyses. </p> <p> <ul id="CD014687-list-0014"> <li> <p>Repeat analyses excluding studies with outcomes graded with an overall high risk of bias. </p> </li> <li> <p>Repeat analyses excluding any unpublished studies.</p> </li> </ul> </p> <section id="CD014687-sec-0052"> <h5 class="title">Reaching conclusions</h5> <p>We based our conclusions only on the findings from the quantitative and narrative synthesis of the studies included in this review. We avoided making recommendations for practice; our implications for research suggest priorities for future research and outline the remaining uncertainties in the area. </p> </section> </section> <section id="CD014687-sec-0053"> <h4 class="title">Summary of findings and assessment of the certainty of the evidence</h4> <p>We created three summary of findings tables using <a href="./references#CD014687-bbs2-0051" title="GRADEpro GDT: GRADEpro Guideline Development Tool. Version accessed 15 May 2020. Hamilton (ON): McMaster University (developed by Evidence Prime), 2022. Available at gradepro.org.">GRADEpro GDT</a> software for the following comparisons: </p> <p> <ul id="CD014687-list-0015"> <li> <p>corticosteroid and local anaesthetic injection (CS+LA) versus local anaesthetic injection (LA); </p> </li> <li> <p>ultrasound‐guided corticosteroid and local anaesthetic injection (UG CS+LA) versus non‐ultrasound‐guided corticosteroid and anaesthetic injection (NUG CS+LA); </p> </li> <li> <p>plantar‐incision neurectomy (PN) versus dorsal‐incision neurectomy (PN).</p> </li> </ul> </p> <p>We presented the following outcomes in each table when data were available:</p> <p> <ul id="CD014687-list-0016"> <li> <p><b>pain:</b> between‐group difference in pain measured by self‐report using a standardised questionnaire (e.g. VAS pain scale) assessed in the intermediate term (three months to less than 12 months from baseline); </p> </li> <li> <p><b>function:</b> change in function measured by self‐report or objective measure of functional capacity using a standardised questionnaire (e.g. Foot Function Index disability or activity limitation subscales, or six‐minute walk test) assessed in the intermediate term (three months to less than 12 months from baseline); </p> </li> <li> <p><b>health‐related quality of life (HRQoL) or satisfaction:</b> level of satisfaction measured by self‐report using a standardised questionnaire (e.g. Johnson scale) assessed in the intermediate term (three months to less than 12 months from baseline); </p> </li> <li> <p><b>adverse events:</b> adverse events leading to medical intervention or discontinuation from the study. </p> </li> </ul> </p> <p>Two review authors (BM and MH) used the five GRADE considerations (risk of bias, inconsistency of effect, imprecision, indirectness and publication bias) to independently assess the certainty of the body of evidence (studies that contributed data for prespecified outcomes). We used methods and recommendations described in Chapter 14 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD014687-bbs2-0091" title="SchünemannHJ , HigginsJP , VistGE , GlasziouP , AklEA , SkoetzN , et al. Chapter 14: Completing 'Summary of findings' tables and grading the certainty of the evidence. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022). Cochrane, 2022. Available from training.cochrane.org/handbook (accessed 06 July 2023).">Schünemann 2019</a>). We resolved any disagreements by discussion or by involving another author (CT). We assessed the certainty of the evidence according to the GRADE criteria. We considered that RCTs provide high‐certainty evidence only if the five GRADE criteria above are not present to any serious degree. We downgraded the evidence once (to moderate certainty) if a GRADE consideration was serious, twice (to low certainty) if it was very serious, and three times if combined downgrading decisions contributed to three or more downgrades. We justified all decisions to downgrade or upgrade the quality of studies using footnotes, and made comments to aid readers' understanding of the review where necessary. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD014687-sec-0054" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD014687-sec-0054"></div> <section id="CD014687-sec-0055"> <h3 class="title">Description of studies</h3> <section id="CD014687-sec-0056"> <h4 class="title">Results of the search</h4> <p>Our database searches identified a total of 419 records; no records were identified from other sources. After 161 duplicates were removed, 258 potentially eligible records remained. We excluded a further 183 records during the title and abstract screening, which left 75 full‐text articles that we read. We discarded 48 of these articles after reading the full text, as closer inspection showed they were not relevant. A further 19 full‐text articles (relating to 12 studies) were excluded because they did not meet our population inclusion. This left eight full‐text articles that related to six studies that we included (<a href="#CD014687-fig-0001">Figure 1</a>). </p> </section> <section id="CD014687-sec-0057"> <h4 class="title">Included studies</h4> <p>This review identified eight full‐text articles that detailed six separate studies (<a href="./references#CD014687-bbs2-0001" title="AkermarkC , CroneH , SkoogA , WeidenhielmL . A prospective randomized controlled trial of plantar versus dorsal incisions for operative treatment of primary Morton's neuroma. Foot &amp; Ankle International2013;34(9):1198-204. [DOI: 10.1177/1071100713484300]">Akermark 2013</a>; <a href="./references#CD014687-bbs2-0002" title="Lizano-DíezX , Ginés-CespedosaA , Alentorn-GeliE , Pérez-PrietoD , González-LucenaG , GambaC , et al. Corticosteroid injection for the treatment of Morton's neuroma: a prospective, double-blinded, randomized, placebo-controlled trial. Foot &amp; Ankle International2017;38(9):944-51. [DOI: 10.1177/1071100717709569]">Lizano‐Diez 2017</a>; <a href="./references#CD014687-bbs2-0003" title="HauMYT , ThomsonL , AujlaR , MadhadevanD , BhatiaM . Medium-term results of corticosteroid injections for Morton’s neuroma. Foot &amp; Ankle International2021;42(4):464-8. [DOI: 10.1177/1071100720966332]MahadevanD , AttwalM , BhattR , BhatiaM . Corticosteroid injection for Morton's neuroma with or without ultrasound guidance: a randomised controlled trial. Bone &amp; Joint Journal2016;98-B(4):498-503. [DOI: 10.1302/0301-620X.98B4.36880]">Mahadevan 2016</a>; <a href="./references#CD014687-bbs2-0004" title="SantiagoFR , MuñozPT , Ramos-BossiniAJL , MartinezAM , OlletaNP . Long-term comparison between blind and ultrasound-guided corticoid injections in Morton neuroma. European Radiology2022;32:1-9. [DOI: 10.1007/s00330-022-08932-y]SantiagoFR , OlletaNP , MuñozPT , ÁlvarezLG , MartínezAM . Short term comparison between blind and ultrasound guided injection in Morton neuroma. European Radiology2019;29(2):620-7. [DOI: 10.1007/s00330-018-5670-1]">Santiago 2022</a>; <a href="./references#CD014687-bbs2-0005" title="SeokH , KimSH , LeeSY , ParkSW . Extracorporeal shockwave therapy in patients with Morton's neuroma a randomized, placebo-controlled trial. Journal of the American Podiatric Medical Association2016;106(2):93-9. [DOI: 10.7547/14-131]">Seok 2016</a>; <a href="./references#CD014687-bbs2-0006" title="ThomsonCE , BeggsI , MartinDJ , McMillanD , EdwardsRT , RussellD , et al. Methylprednisolone injections for the treatment of Morton neuroma: a patient-blinded randomized trial. Journal of Bone and Joint Surgery. American Volume2013;95(9):790-S1. [DOI: 10.2106/JBJS.I.01780]">Thomson 2013</a>) (<a href="#CD014687-fig-0001">Figure 1</a>). A long‐term follow‐up of <a href="./references#CD014687-bbs2-0004" title="SantiagoFR , MuñozPT , Ramos-BossiniAJL , MartinezAM , OlletaNP . Long-term comparison between blind and ultrasound-guided corticoid injections in Morton neuroma. European Radiology2022;32:1-9. [DOI: 10.1007/s00330-022-08932-y]SantiagoFR , OlletaNP , MuñozPT , ÁlvarezLG , MartínezAM . Short term comparison between blind and ultrasound guided injection in Morton neuroma. European Radiology2019;29(2):620-7. [DOI: 10.1007/s00330-018-5670-1]">Santiago 2022</a> was published in 2022, and one for <a href="./references#CD014687-bbs2-0003" title="HauMYT , ThomsonL , AujlaR , MadhadevanD , BhatiaM . Medium-term results of corticosteroid injections for Morton’s neuroma. Foot &amp; Ankle International2021;42(4):464-8. [DOI: 10.1177/1071100720966332]MahadevanD , AttwalM , BhattR , BhatiaM . Corticosteroid injection for Morton's neuroma with or without ultrasound guidance: a randomised controlled trial. Bone &amp; Joint Journal2016;98-B(4):498-503. [DOI: 10.1302/0301-620X.98B4.36880]">Mahadevan 2016</a> was published in 2021. The six included studies were all RCTs that used a parallel‐group design. Two studies were undertaken in Spain (<a href="./references#CD014687-bbs2-0002" title="Lizano-DíezX , Ginés-CespedosaA , Alentorn-GeliE , Pérez-PrietoD , González-LucenaG , GambaC , et al. Corticosteroid injection for the treatment of Morton's neuroma: a prospective, double-blinded, randomized, placebo-controlled trial. Foot &amp; Ankle International2017;38(9):944-51. [DOI: 10.1177/1071100717709569]">Lizano‐Diez 2017</a>; <a href="./references#CD014687-bbs2-0004" title="SantiagoFR , MuñozPT , Ramos-BossiniAJL , MartinezAM , OlletaNP . Long-term comparison between blind and ultrasound-guided corticoid injections in Morton neuroma. European Radiology2022;32:1-9. [DOI: 10.1007/s00330-022-08932-y]SantiagoFR , OlletaNP , MuñozPT , ÁlvarezLG , MartínezAM . Short term comparison between blind and ultrasound guided injection in Morton neuroma. European Radiology2019;29(2):620-7. [DOI: 10.1007/s00330-018-5670-1]">Santiago 2022</a>), two in the UK (<a href="./references#CD014687-bbs2-0003" title="HauMYT , ThomsonL , AujlaR , MadhadevanD , BhatiaM . Medium-term results of corticosteroid injections for Morton’s neuroma. Foot &amp; Ankle International2021;42(4):464-8. [DOI: 10.1177/1071100720966332]MahadevanD , AttwalM , BhattR , BhatiaM . Corticosteroid injection for Morton's neuroma with or without ultrasound guidance: a randomised controlled trial. Bone &amp; Joint Journal2016;98-B(4):498-503. [DOI: 10.1302/0301-620X.98B4.36880]">Mahadevan 2016</a>; <a href="./references#CD014687-bbs2-0006" title="ThomsonCE , BeggsI , MartinDJ , McMillanD , EdwardsRT , RussellD , et al. Methylprednisolone injections for the treatment of Morton neuroma: a patient-blinded randomized trial. Journal of Bone and Joint Surgery. American Volume2013;95(9):790-S1. [DOI: 10.2106/JBJS.I.01780]">Thomson 2013</a>), one in Sweden (<a href="./references#CD014687-bbs2-0001" title="AkermarkC , CroneH , SkoogA , WeidenhielmL . A prospective randomized controlled trial of plantar versus dorsal incisions for operative treatment of primary Morton's neuroma. Foot &amp; Ankle International2013;34(9):1198-204. [DOI: 10.1177/1071100713484300]">Akermark 2013</a>), and one in South Korea (<a href="./references#CD014687-bbs2-0005" title="SeokH , KimSH , LeeSY , ParkSW . Extracorporeal shockwave therapy in patients with Morton's neuroma a randomized, placebo-controlled trial. Journal of the American Podiatric Medical Association2016;106(2):93-9. [DOI: 10.7547/14-131]">Seok 2016</a>). </p> <p>We assembled detailed descriptions of the study interventions using the template for intervention description and replication (TIDieR) checklist (<a href="./references#CD014687-bbs2-0055" title="Hoffmann TammyC , Glasziou PaulP , Boutron Isabelle, Milne Ruairidh, Perera Rafael, Moher David, Altman DouglasG , Barbour Virginia, Macdonald Helen, Johnston Marie. Better reporting of interventions: template for intervention description and replication (TIDieR) checklist and guide. Brittish Medical Journal2014;348:1-12. [DOI: 10.1136/bmj.g1687]">Hoffmann 2014</a>), and these are reported in the <a href="./references#CD014687-sec-0137" title="">Characteristics of included studies</a> section. </p> <p>Full details of these trials can be viewed in the <a href="./references#CD014687-sec-0137" title="">Characteristics of included studies</a> section. </p> <section id="CD014687-sec-0058"> <h5 class="title">Participants</h5> <p>Participants in all studies had confirmed MN symptoms and a positive clinical test of webspace compression or Mulder's sign. MN was confirmed by ultrasound scan (<a href="./references#CD014687-bbs2-0003" title="HauMYT , ThomsonL , AujlaR , MadhadevanD , BhatiaM . Medium-term results of corticosteroid injections for Morton’s neuroma. Foot &amp; Ankle International2021;42(4):464-8. [DOI: 10.1177/1071100720966332]MahadevanD , AttwalM , BhattR , BhatiaM . Corticosteroid injection for Morton's neuroma with or without ultrasound guidance: a randomised controlled trial. Bone &amp; Joint Journal2016;98-B(4):498-503. [DOI: 10.1302/0301-620X.98B4.36880]">Mahadevan 2016</a>; <a href="./references#CD014687-bbs2-0004" title="SantiagoFR , MuñozPT , Ramos-BossiniAJL , MartinezAM , OlletaNP . Long-term comparison between blind and ultrasound-guided corticoid injections in Morton neuroma. European Radiology2022;32:1-9. [DOI: 10.1007/s00330-022-08932-y]SantiagoFR , OlletaNP , MuñozPT , ÁlvarezLG , MartínezAM . Short term comparison between blind and ultrasound guided injection in Morton neuroma. European Radiology2019;29(2):620-7. [DOI: 10.1007/s00330-018-5670-1]">Santiago 2022</a>; <a href="./references#CD014687-bbs2-0005" title="SeokH , KimSH , LeeSY , ParkSW . Extracorporeal shockwave therapy in patients with Morton's neuroma a randomized, placebo-controlled trial. Journal of the American Podiatric Medical Association2016;106(2):93-9. [DOI: 10.7547/14-131]">Seok 2016</a>; <a href="./references#CD014687-bbs2-0006" title="ThomsonCE , BeggsI , MartinDJ , McMillanD , EdwardsRT , RussellD , et al. Methylprednisolone injections for the treatment of Morton neuroma: a patient-blinded randomized trial. Journal of Bone and Joint Surgery. American Volume2013;95(9):790-S1. [DOI: 10.2106/JBJS.I.01780]">Thomson 2013</a>), or magnetic resonance imaging (<a href="./references#CD014687-bbs2-0001" title="AkermarkC , CroneH , SkoogA , WeidenhielmL . A prospective randomized controlled trial of plantar versus dorsal incisions for operative treatment of primary Morton's neuroma. Foot &amp; Ankle International2013;34(9):1198-204. [DOI: 10.1177/1071100713484300]">Akermark 2013</a>; <a href="./references#CD014687-bbs2-0002" title="Lizano-DíezX , Ginés-CespedosaA , Alentorn-GeliE , Pérez-PrietoD , González-LucenaG , GambaC , et al. Corticosteroid injection for the treatment of Morton's neuroma: a prospective, double-blinded, randomized, placebo-controlled trial. Foot &amp; Ankle International2017;38(9):944-51. [DOI: 10.1177/1071100717709569]">Lizano‐Diez 2017</a>). In <a href="./references#CD014687-bbs2-0003" title="HauMYT , ThomsonL , AujlaR , MadhadevanD , BhatiaM . Medium-term results of corticosteroid injections for Morton’s neuroma. Foot &amp; Ankle International2021;42(4):464-8. [DOI: 10.1177/1071100720966332]MahadevanD , AttwalM , BhattR , BhatiaM . Corticosteroid injection for Morton's neuroma with or without ultrasound guidance: a randomised controlled trial. Bone &amp; Joint Journal2016;98-B(4):498-503. [DOI: 10.1302/0301-620X.98B4.36880]">Mahadevan 2016</a> randomisation per foot resulted in clustered data. The design effect for the clustered data was 1.0125, which was calculated using the formula 1 + (m ‐ 1)ICC where m equals the mean cluster size and the ICC equals 0.05. The effective sample size was unchanged, indicating that the clustering had a negligible effect on the data analysis. </p> </section> <section id="CD014687-sec-0059"> <h5 class="title">Interventions</h5> <p>One study evaluated a noninvasive nonsurgical intervention consisting of shockwave therapy (SWT) versus sham SWT (<a href="./references#CD014687-bbs2-0005" title="SeokH , KimSH , LeeSY , ParkSW . Extracorporeal shockwave therapy in patients with Morton's neuroma a randomized, placebo-controlled trial. Journal of the American Podiatric Medical Association2016;106(2):93-9. [DOI: 10.7547/14-131]">Seok 2016</a>). Four studies evaluated invasive nonsurgical interventions with two trials evaluating corticosteroid and local anaesthetic injection (CS+LA) versus local anaesthetic injection (LA) (<a href="./references#CD014687-bbs2-0002" title="Lizano-DíezX , Ginés-CespedosaA , Alentorn-GeliE , Pérez-PrietoD , González-LucenaG , GambaC , et al. Corticosteroid injection for the treatment of Morton's neuroma: a prospective, double-blinded, randomized, placebo-controlled trial. Foot &amp; Ankle International2017;38(9):944-51. [DOI: 10.1177/1071100717709569]">Lizano‐Diez 2017</a>; <a href="./references#CD014687-bbs2-0006" title="ThomsonCE , BeggsI , MartinDJ , McMillanD , EdwardsRT , RussellD , et al. Methylprednisolone injections for the treatment of Morton neuroma: a patient-blinded randomized trial. Journal of Bone and Joint Surgery. American Volume2013;95(9):790-S1. [DOI: 10.2106/JBJS.I.01780]">Thomson 2013</a>), while two other studies evaluated ultrasound‐guided corticosteroid injection (UG CS+LA) versus non‐ultrasound‐guided corticosteroid injection (NUG CS+LA) (<a href="./references#CD014687-bbs2-0003" title="HauMYT , ThomsonL , AujlaR , MadhadevanD , BhatiaM . Medium-term results of corticosteroid injections for Morton’s neuroma. Foot &amp; Ankle International2021;42(4):464-8. [DOI: 10.1177/1071100720966332]MahadevanD , AttwalM , BhattR , BhatiaM . Corticosteroid injection for Morton's neuroma with or without ultrasound guidance: a randomised controlled trial. Bone &amp; Joint Journal2016;98-B(4):498-503. [DOI: 10.1302/0301-620X.98B4.36880]">Mahadevan 2016</a>; <a href="./references#CD014687-bbs2-0004" title="SantiagoFR , MuñozPT , Ramos-BossiniAJL , MartinezAM , OlletaNP . Long-term comparison between blind and ultrasound-guided corticoid injections in Morton neuroma. European Radiology2022;32:1-9. [DOI: 10.1007/s00330-022-08932-y]SantiagoFR , OlletaNP , MuñozPT , ÁlvarezLG , MartínezAM . Short term comparison between blind and ultrasound guided injection in Morton neuroma. European Radiology2019;29(2):620-7. [DOI: 10.1007/s00330-018-5670-1]">Santiago 2022</a>). One study evaluated a surgical intervention involving a plantar incision neurectomy (PN) versus a dorsal incision neurectomy (DN) (<a href="./references#CD014687-bbs2-0001" title="AkermarkC , CroneH , SkoogA , WeidenhielmL . A prospective randomized controlled trial of plantar versus dorsal incisions for operative treatment of primary Morton's neuroma. Foot &amp; Ankle International2013;34(9):1198-204. [DOI: 10.1177/1071100713484300]">Akermark 2013</a>). </p> </section> <section id="CD014687-sec-0060"> <h5 class="title">Outcomes</h5> <p>The study investigating SWT versus sham SWT assessed pain, function, satisfaction and adverse events at one week and four weeks after treatment (<a href="./references#CD014687-bbs2-0005" title="SeokH , KimSH , LeeSY , ParkSW . Extracorporeal shockwave therapy in patients with Morton's neuroma a randomized, placebo-controlled trial. Journal of the American Podiatric Medical Association2016;106(2):93-9. [DOI: 10.7547/14-131]">Seok 2016</a>). </p> <p>Two studies investigated CS+LA versus LA: <a href="./references#CD014687-bbs2-0002" title="Lizano-DíezX , Ginés-CespedosaA , Alentorn-GeliE , Pérez-PrietoD , González-LucenaG , GambaC , et al. Corticosteroid injection for the treatment of Morton's neuroma: a prospective, double-blinded, randomized, placebo-controlled trial. Foot &amp; Ankle International2017;38(9):944-51. [DOI: 10.1177/1071100717709569]">Lizano‐Diez 2017</a> assessed pain, function, satisfaction and adverse events at one week, two weeks, three months and six months, while the other, <a href="./references#CD014687-bbs2-0006" title="ThomsonCE , BeggsI , MartinDJ , McMillanD , EdwardsRT , RussellD , et al. Methylprednisolone injections for the treatment of Morton neuroma: a patient-blinded randomized trial. Journal of Bone and Joint Surgery. American Volume2013;95(9):790-S1. [DOI: 10.2106/JBJS.I.01780]">Thomson 2013</a>, assessed foot health, pain, function, HRQoL and adverse events at one month, three months and 12 months. </p> <p>Both the studies that investigated UG CS+LA versus NUG CS+LA assessed pain, function, satisfaction and adverse events: <a href="./references#CD014687-bbs2-0003" title="HauMYT , ThomsonL , AujlaR , MadhadevanD , BhatiaM . Medium-term results of corticosteroid injections for Morton’s neuroma. Foot &amp; Ankle International2021;42(4):464-8. [DOI: 10.1177/1071100720966332]MahadevanD , AttwalM , BhattR , BhatiaM . Corticosteroid injection for Morton's neuroma with or without ultrasound guidance: a randomised controlled trial. Bone &amp; Joint Journal2016;98-B(4):498-503. [DOI: 10.1302/0301-620X.98B4.36880]">Mahadevan 2016</a> made assessments at three months, six months and 12 months and <a href="./references#CD014687-bbs2-0004" title="SantiagoFR , MuñozPT , Ramos-BossiniAJL , MartinezAM , OlletaNP . Long-term comparison between blind and ultrasound-guided corticoid injections in Morton neuroma. European Radiology2022;32:1-9. [DOI: 10.1007/s00330-022-08932-y]SantiagoFR , OlletaNP , MuñozPT , ÁlvarezLG , MartínezAM . Short term comparison between blind and ultrasound guided injection in Morton neuroma. European Radiology2019;29(2):620-7. [DOI: 10.1007/s00330-018-5670-1]">Santiago 2022</a> at 15 days, 30 days, 45 days, two months, three months, six months, 12 months, 24 months and 36 months. </p> <p>The <a href="./references#CD014687-bbs2-0001" title="AkermarkC , CroneH , SkoogA , WeidenhielmL . A prospective randomized controlled trial of plantar versus dorsal incisions for operative treatment of primary Morton's neuroma. Foot &amp; Ankle International2013;34(9):1198-204. [DOI: 10.1177/1071100713484300]">Akermark 2013</a> study investigated PN versus DN and assessed pain, function, and satisfaction at three months, 12 months and a mean of 34 months (range 28 months to 42 months). </p> </section> <section id="CD014687-sec-0061"> <h5 class="title">Funding</h5> <p>Funding sources were reported by two studies (<a href="./references#CD014687-bbs2-0005" title="SeokH , KimSH , LeeSY , ParkSW . Extracorporeal shockwave therapy in patients with Morton's neuroma a randomized, placebo-controlled trial. Journal of the American Podiatric Medical Association2016;106(2):93-9. [DOI: 10.7547/14-131]">Seok 2016</a>; <a href="./references#CD014687-bbs2-0006" title="ThomsonCE , BeggsI , MartinDJ , McMillanD , EdwardsRT , RussellD , et al. Methylprednisolone injections for the treatment of Morton neuroma: a patient-blinded randomized trial. Journal of Bone and Joint Surgery. American Volume2013;95(9):790-S1. [DOI: 10.2106/JBJS.I.01780]">Thomson 2013</a>). <a href="./references#CD014687-bbs2-0005" title="SeokH , KimSH , LeeSY , ParkSW . Extracorporeal shockwave therapy in patients with Morton's neuroma a randomized, placebo-controlled trial. Journal of the American Podiatric Medical Association2016;106(2):93-9. [DOI: 10.7547/14-131]">Seok 2016</a> was supported by the Soonchunhyang University Research Fund, and <a href="./references#CD014687-bbs2-0006" title="ThomsonCE , BeggsI , MartinDJ , McMillanD , EdwardsRT , RussellD , et al. Methylprednisolone injections for the treatment of Morton neuroma: a patient-blinded randomized trial. Journal of Bone and Joint Surgery. American Volume2013;95(9):790-S1. [DOI: 10.2106/JBJS.I.01780]">Thomson 2013</a> was funded for research costs and an international conference presentation by the Chief Scientist Office of the Scottish Government, Health and Social Care Directorate. No funding source was reported for four studies (<a href="./references#CD014687-bbs2-0001" title="AkermarkC , CroneH , SkoogA , WeidenhielmL . A prospective randomized controlled trial of plantar versus dorsal incisions for operative treatment of primary Morton's neuroma. Foot &amp; Ankle International2013;34(9):1198-204. [DOI: 10.1177/1071100713484300]">Akermark 2013</a>; <a href="./references#CD014687-bbs2-0002" title="Lizano-DíezX , Ginés-CespedosaA , Alentorn-GeliE , Pérez-PrietoD , González-LucenaG , GambaC , et al. Corticosteroid injection for the treatment of Morton's neuroma: a prospective, double-blinded, randomized, placebo-controlled trial. Foot &amp; Ankle International2017;38(9):944-51. [DOI: 10.1177/1071100717709569]">Lizano‐Diez 2017</a>; <a href="./references#CD014687-bbs2-0003" title="HauMYT , ThomsonL , AujlaR , MadhadevanD , BhatiaM . Medium-term results of corticosteroid injections for Morton’s neuroma. Foot &amp; Ankle International2021;42(4):464-8. [DOI: 10.1177/1071100720966332]MahadevanD , AttwalM , BhattR , BhatiaM . Corticosteroid injection for Morton's neuroma with or without ultrasound guidance: a randomised controlled trial. Bone &amp; Joint Journal2016;98-B(4):498-503. [DOI: 10.1302/0301-620X.98B4.36880]">Mahadevan 2016</a>; <a href="./references#CD014687-bbs2-0004" title="SantiagoFR , MuñozPT , Ramos-BossiniAJL , MartinezAM , OlletaNP . Long-term comparison between blind and ultrasound-guided corticoid injections in Morton neuroma. European Radiology2022;32:1-9. [DOI: 10.1007/s00330-022-08932-y]SantiagoFR , OlletaNP , MuñozPT , ÁlvarezLG , MartínezAM . Short term comparison between blind and ultrasound guided injection in Morton neuroma. European Radiology2019;29(2):620-7. [DOI: 10.1007/s00330-018-5670-1]">Santiago 2022</a>). </p> </section> <section id="CD014687-sec-0062"> <h5 class="title">Contact with trial authors</h5> <p>We contacted the authors of all six studies for missing data or clarification of data. Attempts to contact the authors of <a href="./references#CD014687-bbs2-0001" title="AkermarkC , CroneH , SkoogA , WeidenhielmL . A prospective randomized controlled trial of plantar versus dorsal incisions for operative treatment of primary Morton's neuroma. Foot &amp; Ankle International2013;34(9):1198-204. [DOI: 10.1177/1071100713484300]">Akermark 2013</a>; <a href="./references#CD014687-bbs2-0002" title="Lizano-DíezX , Ginés-CespedosaA , Alentorn-GeliE , Pérez-PrietoD , González-LucenaG , GambaC , et al. Corticosteroid injection for the treatment of Morton's neuroma: a prospective, double-blinded, randomized, placebo-controlled trial. Foot &amp; Ankle International2017;38(9):944-51. [DOI: 10.1177/1071100717709569]">Lizano‐Diez 2017</a>; <a href="./references#CD014687-bbs2-0003" title="HauMYT , ThomsonL , AujlaR , MadhadevanD , BhatiaM . Medium-term results of corticosteroid injections for Morton’s neuroma. Foot &amp; Ankle International2021;42(4):464-8. [DOI: 10.1177/1071100720966332]MahadevanD , AttwalM , BhattR , BhatiaM . Corticosteroid injection for Morton's neuroma with or without ultrasound guidance: a randomised controlled trial. Bone &amp; Joint Journal2016;98-B(4):498-503. [DOI: 10.1302/0301-620X.98B4.36880]">Mahadevan 2016</a> and <a href="./references#CD014687-bbs2-0005" title="SeokH , KimSH , LeeSY , ParkSW . Extracorporeal shockwave therapy in patients with Morton's neuroma a randomized, placebo-controlled trial. Journal of the American Podiatric Medical Association2016;106(2):93-9. [DOI: 10.7547/14-131]">Seok 2016</a> were unsuccessful. We received responses from the authors of <a href="./references#CD014687-bbs2-0004" title="SantiagoFR , MuñozPT , Ramos-BossiniAJL , MartinezAM , OlletaNP . Long-term comparison between blind and ultrasound-guided corticoid injections in Morton neuroma. European Radiology2022;32:1-9. [DOI: 10.1007/s00330-022-08932-y]SantiagoFR , OlletaNP , MuñozPT , ÁlvarezLG , MartínezAM . Short term comparison between blind and ultrasound guided injection in Morton neuroma. European Radiology2019;29(2):620-7. [DOI: 10.1007/s00330-018-5670-1]">Santiago 2022</a> clarifying the inclusion criteria and <a href="./references#CD014687-bbs2-0006" title="ThomsonCE , BeggsI , MartinDJ , McMillanD , EdwardsRT , RussellD , et al. Methylprednisolone injections for the treatment of Morton neuroma: a patient-blinded randomized trial. Journal of Bone and Joint Surgery. American Volume2013;95(9):790-S1. [DOI: 10.2106/JBJS.I.01780]">Thomson 2013</a> clarifying the scale for the European Quality of Life pain/discomfort dimension (EQ‐5D). </p> </section> </section> <section id="CD014687-sec-0063"> <h4 class="title">Excluded studies</h4> <p>We assessed 75 full‐text studies for eligibility and discarded 48 full‐text articles after reading the full text, as closer inspection showed they were not relevant. Twelve studies (19 full‐text articles) were excluded as they provided insufficient information about the inclusion criteria of the populations studied (<a href="#CD014687-fig-0001">Figure 1</a>) (<a href="./references#CD014687-bbs2-0007" title="CampbellCM , DiamondE , SchmidtWK , KellyM , AllenR , HoughtonW , et al. A randomized, double-blind, placebo-controlled trial of injected capsaicin for pain in Morton's neuroma. Pain2016;157(6):1297-1304. [DOI: 10.1097/j.pain.0000000000000544]NCT00130962. ALGRX 4975 in the treatment of patients with Morton's neuroma [A randomized, double-blind, placebo-controlled trial of ALGRX 4975 in subjects with painful intermetatarsal neuroma]. ClinicalTrials.gov/show/NCT00130962 (first received 17 August 2005). ">Campbell 2016</a>; <a href="./references#CD014687-bbs2-0008" title="ColgroveRC , HuangEY , BarthAH , GreeneMA . Interdigital neuroma: intermuscular neuroma transposition compared with resection. Foot &amp; Ankle International2000;21(3):206-11. [DOI: 10.1177/107110070002100304]">Colgrove 2000</a>; <a href="./references#CD014687-bbs2-0009" title="NCT03511677. Insole on Morton's neuroma [Effectiveness of insole on Morton's neuroma]. ClinicalTrials.gov/show/NCT03511677 (first received 30 April 2018). OliveiraH , JonesA , JenningsF , VassalliM , RosenfeldA , NatourJ . Effectiveness of customized insoles in patients with Morton's neuroma: a randomized, controlled, double-blind clinical trial. Annals of the Rheumatic Diseases2019;78(Supplement 2):252. [DOI: 10.1136/annrheumdis-2019-eular.1147]deOliveiraHA , NatourJ , VassalliM , RosenfeldA , JenningsF , JonesA . Effectiveness of customized insoles in patients with Morton's neuroma: a randomized, controlled, double-blind clinical trial. Clinical Rehabilitation2019;33(12):1898-1907. [DOI: 10.1177/0269215519873949]">de Oliveira 2019</a>; <a href="./references#CD014687-bbs2-0010" title="DiezEM , MasSM , PiJF , AramburoF . Comparative results of two different techniques in the treatment of the Morton's neuroma. Foot1999;9(3):134-7. [DOI: 10.1054/foot.1999.0543]">Diez 1999</a>; <a href="./references#CD014687-bbs2-0011" title="FridmanR , CainJD , WeilL . Extracorporeal shockwave therapy for interdigital neuroma: a randomized, placebo-controlled, double-blind trial. Journal of the American Podiatric Medical Association2009;99(3):191-3. [DOI: 10.7547/0980191]LandorfKB . Extracorporeal shockwave therapy for interdigital neuroma: a randomized, placebo-controlled, double-blind trial. Journal of the American Podiatric Medical Association2009;99(5):472‐3. [DOI: 10.7547/0990472a]PayneCB . Extracorporeal shockwave therapy for interdigital neuroma: a randomized, placebo-controlled, double-blind trial. Journal of the American Podiatric Medical Association2009;99(5):472. [DOI: 10.7547/0990472]TurlikM . Extracorporeal shockwave therapy for interdigital neuroma: a randomized, placebo-controlled, double-blind trial. Journal of the American Podiatric Medical Association2009;99(5):473. [DOI: 10.7547/0990473]">Fridman 2009</a>; <a href="./references#CD014687-bbs2-0012" title="GovenderN , KretzmannH , PriceJL , BrantinghamJW , GlobeG . A single-blinded randomized placebo-controlled clinical trial of manipulation and mobilization in the treatment of Morton's neuroma. Journal of the American Chiropractic Association2007;44(3):8-18. ">Govender 2007</a>; <a href="./references#CD014687-bbs2-0013" title="HansonP , CampbellJ , StevensR , GottliebI , KellyM , AllenR . CNTX-4975 (trans-capsaicin) injection provides clinically meaningful pain reduction in subjects with painful intermetatarsal neuroma (Morton's neuroma): an open-label, ascending-dose study. Arthritis and Rheumatology2017;69(S10):Abstract 2225. [DOI: 10.1002/art.40321]NCT02550756. Study to evaluate the safety and tolerability of CNTX-4975 in subjects with painful intermetatarsal neuroma (Morton's neuroma) [An open label, ascending dose study to evaluate the safety and tolerability of CNTX-4975 in subjects with painful intermetatarsal neuroma (Morton's neuroma)]. ClinicalTrials.gov/show/NCT02550756 (first received 15 September 2015). ">Hanson 2017</a>; <a href="./references#CD014687-bbs2-0014" title="KilmartinTE , WallaceWA . Effect of pronation and supination orthosis on Morton's neuroma and lower extremity function. Foot &amp; Ankle International1994;15(5):256-62. [DOI: 10.1177/107110079401500505]">Kilmartin 1994</a>; <a href="./references#CD014687-bbs2-0015" title="NashiM , VenkatachalamAK , MudduBN . Surgery of Morton's neuroma: dorsal or plantar approach?Journal of the Royal College of Surgeons of Edinburgh1997;42(1):36-7. [PMID: PMID: 9046143]">Nashi 1997</a>; <a href="./references#CD014687-bbs2-0016" title="QuinnSG , RajaF , RajaD . A study to measure the efficacy of injectable betamethasone (betnesol) for the treatment of Morton's neuroma. British Journal of Podiatry1999;2(4):130-1. ">Quinn 1999</a>; <a href="./references#CD014687-bbs2-0017" title="SaygiB , YildirimY , SaygiEK , KaraH , EsemenliT . Morton neuroma: comparative results of two conservative methods. Foot &amp; Ankle International2005;26(7):556-9. [DOI: 10.1177/107110070502600711]">Saygi 2005</a>; <a href="./references#CD014687-bbs2-0018" title="TanL , ChenK , QuanJ , ChenQ , ZhangY . Clinical efficacy of ultrasound-guided interventional therapy for Morton neuroma. Chinese Journal of Medical Imaging Technology2019;35(5):750-3. [DOI: 10.13929/j.1003-3289.201808069]">Tan 2019</a>). In order to be included, we required potential participants in the studies to have a relevant history, physical examination and a confirmatory test. We attempted to contact trial authors when there was insufficient information regarding their inclusion criteria; we received three replies that confirmed the exclusion of three studies (<a href="./references#CD014687-bbs2-0049" title="Govender Neetu, Kretzmann Heidi, Price JenniferL , Brantingham JamesW , Globe Gary. A Single-Blinded Randomized Placebo-Controlled Clinical Trial of Manipulation and Mobilization in the Treatment of Morton's Neuroma.. Journal of the American Chiropractic Association2007;44(3):8-18.">Govender 2007</a>; <a href="./references#CD014687-bbs2-0060" title="Kilmartin Timothy Edward, Wallace W Angus. Effect of pronation and supination orthosis on Morton's neuroma and lower extremity function. Foot &amp; ankle international1994;15(5):256-262.">Kilmartin 1994</a>; <a href="./references#CD014687-bbs2-0077" title="NashiM , VenkatachalamAK , MudduBN . Surgery of Morton's neuroma: dorsal or plantar approach?Journal of the Royal College of Surgeons of Edinburgh1997;42(1):36-7. [3400156] [PMID: 9046143]">Nashi 1997</a>). Further details of excluded studies can be found in the <a href="./references#CD014687-sec-0138" title="">Characteristics of excluded studies</a> section. </p> </section> </section> <section id="CD014687-sec-0064"> <h3 class="title">Risk of bias in included studies</h3> <p>Risk of bias assessments for each outcome and time point, including all domain judgements and support for judgements, are located in <a href="./references#CD014687-sec-0139" title="">Risk of bias (tables)</a>. (To access further detailed risk of bias assessment data, please use the following link: <a href="https://osf.io/tnc8u/" target="_blank">osf.io/tnc8u/</a>) </p> <p>One study, <a href="./references#CD014687-bbs2-0003" title="HauMYT , ThomsonL , AujlaR , MadhadevanD , BhatiaM . Medium-term results of corticosteroid injections for Morton’s neuroma. Foot &amp; Ankle International2021;42(4):464-8. [DOI: 10.1177/1071100720966332]MahadevanD , AttwalM , BhattR , BhatiaM . Corticosteroid injection for Morton's neuroma with or without ultrasound guidance: a randomised controlled trial. Bone &amp; Joint Journal2016;98-B(4):498-503. [DOI: 10.1302/0301-620X.98B4.36880]">Mahadevan 2016</a>, included clustered data; we assessed this using the risk of bias Microsoft Excel tool for clustered data (<a href="./references#CD014687-bbs2-0086" title="RoB2 Development Group. Risk of bias tools. www.riskofbias.info/ (accessed 06 July 2023).">RoB2 2022</a>). We reported the additional Domain 1b for this study (timing of identification or recruitment of participants) under Domain 1 in <a href="./references#CD014687-sec-0139" title="">Risk of bias (tables)</a>. </p> <p>We judged two studies, <a href="./references#CD014687-bbs2-0002" title="Lizano-DíezX , Ginés-CespedosaA , Alentorn-GeliE , Pérez-PrietoD , González-LucenaG , GambaC , et al. Corticosteroid injection for the treatment of Morton's neuroma: a prospective, double-blinded, randomized, placebo-controlled trial. Foot &amp; Ankle International2017;38(9):944-51. [DOI: 10.1177/1071100717709569]">Lizano‐Diez 2017</a> and <a href="./references#CD014687-bbs2-0005" title="SeokH , KimSH , LeeSY , ParkSW . Extracorporeal shockwave therapy in patients with Morton's neuroma a randomized, placebo-controlled trial. Journal of the American Podiatric Medical Association2016;106(2):93-9. [DOI: 10.7547/14-131]">Seok 2016</a>, to be at a high risk of bias due to the number of participants lost to follow‐up. No trials were judged to be at low risk of bias for pain, function, satisfaction or HRQoL. We judged <a href="./references#CD014687-bbs2-0006" title="ThomsonCE , BeggsI , MartinDJ , McMillanD , EdwardsRT , RussellD , et al. Methylprednisolone injections for the treatment of Morton neuroma: a patient-blinded randomized trial. Journal of Bone and Joint Surgery. American Volume2013;95(9):790-S1. [DOI: 10.2106/JBJS.I.01780]">Thomson 2013</a> to be at low risk of bias for serious adverse events. Satisfaction outcomes all used unvalidated Likert scales, so we judged them to have some concerns. We judged the overall risk of bias for the remaining outcomes as having some concerns, due to the absence of a preregistered protocol. </p> </section> <section id="CD014687-sec-0065"> <h3 class="title" id="CD014687-sec-0065">Effects of interventions</h3> <p>See: <a href="./full#CD014687-tbl-0001"><b>Summary of findings 1</b> Summary of findings: corticosteroid and local anaesthetic injection (CS+LA) versus local anaesthetic injection (LA) for people with Morton's neuroma</a>; <a href="./full#CD014687-tbl-0002"><b>Summary of findings 2</b> Summary of findings: ultrasound‐guided injection of corticosteroid and local anaesthetic (UG CS+LA) versus non‐ultrasound‐guided injection of corticosteroid and local anaesthetic (NUG CS+LA) for people with Morton's neuroma</a>; <a href="./full#CD014687-tbl-0003"><b>Summary of findings 3</b> Summary of findings: plantar‐incision neurectomy (PN) versus dorsal‐incision neurectomy (DN) for people with Morton's neuroma</a> </p> <p>See: <a href="./full#CD014687-tbl-0001">summary of findings Table 1</a>; <a href="./full#CD014687-tbl-0002">summary of findings Table 2</a>; <a href="./full#CD014687-tbl-0003">summary of findings Table 3</a> </p> <section id="CD014687-sec-0066"> <h4 class="title">Nonsurgical treatments</h4> <section id="CD014687-sec-0067"> <h5 class="title">Shockwave therapy (SWT) versus sham SWT</h5> <p>This comparison was studied in <a href="./references#CD014687-bbs2-0005" title="SeokH , KimSH , LeeSY , ParkSW . Extracorporeal shockwave therapy in patients with Morton's neuroma a randomized, placebo-controlled trial. Journal of the American Podiatric Medical Association2016;106(2):93-9. [DOI: 10.7547/14-131]">Seok 2016</a>. </p> <section id="CD014687-sec-0068"> <h6 class="title"><i>Primary outcome</i> </h6> <section id="CD014687-sec-0069"> <p><b>Pain</b></p> <p>The primary outcome of pain was measured using a VAS (0 to 100 mm; a lower score indicated less pain). When short‐term, between‐group differences were analysed, SWT resulted in little to no difference in pain compared to sham SWT (MD ‐7.10 mm, 95% CI ‐20.10 to 5.90; P = 0.28; 1 study, 26 participants; <a href="./references#CD014687-fig-0002" title="">Analysis 1.1</a>). </p> <p>The study duration was four weeks, and therefore did not report intermediate‐ or long‐term outcome data for pain. </p> </section> </section> <section id="CD014687-sec-0070"> <h6 class="title"><i>Secondary outcomes</i> </h6> <section id="CD014687-sec-0071"> <p><b>Function</b></p> <p>Function was measured with the American Orthopaedic Foot and Ankle Society Lesser Toe Metatarsophalangeal‐lnterphalangeal Scale (AOFAS; 0 to 100 points; a higher score indicates improved function). When short‐term (4‐week), between‐group differences were analysed, SWT resulted in little to no difference compared to sham SWT (MD 3.30 points, 95% CI ‐8.38 to 14.98; P = 0.58; 1 study, 26 participants; <a href="./references#CD014687-fig-0003" title="">Analysis 1.2</a>). </p> </section> <section id="CD014687-sec-0072"> <p><b>HRQoL</b></p> <p>This study did not measure HRQoL.</p> </section> <section id="CD014687-sec-0073"> <p><b>Satisfaction</b></p> <p>Satisfaction was measured using the Johnson scale (4‐item Likert scale ranging from 'completely satisfied' to 'dissatisfied'). When the outcome data were dichotomised into satisfied and dissatisfied, the evidence suggested that SWT resulted in little to no difference in satisfaction compared to sham SWT (risk ratio (RR) 3.43, 95% CI 0.89 to 13.15; P = 0.07; 1 study, 26 participants; <a href="./references#CD014687-fig-0004" title="">Analysis 1.3</a>). </p> </section> <section id="CD014687-sec-0074"> <p><b>Adverse events</b></p> <p>Adverse events were recorded during the trial, but none were reported by participants (<a href="./references#CD014687-fig-0005" title="">Analysis 2.1</a>). </p> </section> </section> </section> <section id="CD014687-sec-0075"> <h5 class="title">Corticosteroid and local anaesthetic injection (CS+LA) versus local anaesthetic injection (LA) </h5> <p>Studied in <a href="./references#CD014687-bbs2-0002" title="Lizano-DíezX , Ginés-CespedosaA , Alentorn-GeliE , Pérez-PrietoD , González-LucenaG , GambaC , et al. Corticosteroid injection for the treatment of Morton's neuroma: a prospective, double-blinded, randomized, placebo-controlled trial. Foot &amp; Ankle International2017;38(9):944-51. [DOI: 10.1177/1071100717709569]">Lizano‐Diez 2017</a>; <a href="./references#CD014687-bbs2-0006" title="ThomsonCE , BeggsI , MartinDJ , McMillanD , EdwardsRT , RussellD , et al. Methylprednisolone injections for the treatment of Morton neuroma: a patient-blinded randomized trial. Journal of Bone and Joint Surgery. American Volume2013;95(9):790-S1. [DOI: 10.2106/JBJS.I.01780]">Thomson 2013</a>; see <a href="./full#CD014687-tbl-0001">summary of findings Table 1</a> </p> <section id="CD014687-sec-0076"> <h6 class="title"><i>Primary outcome</i> </h6> <section id="CD014687-sec-0077"> <p><b>Pain</b></p> <p>In <a href="./references#CD014687-bbs2-0002" title="Lizano-DíezX , Ginés-CespedosaA , Alentorn-GeliE , Pérez-PrietoD , González-LucenaG , GambaC , et al. Corticosteroid injection for the treatment of Morton's neuroma: a prospective, double-blinded, randomized, placebo-controlled trial. Foot &amp; Ankle International2017;38(9):944-51. [DOI: 10.1177/1071100717709569]">Lizano‐Diez 2017</a>, pain was measured with a VAS (0 to 100 mm; a lower score indicated less pain), while in <a href="./references#CD014687-bbs2-0006" title="ThomsonCE , BeggsI , MartinDJ , McMillanD , EdwardsRT , RussellD , et al. Methylprednisolone injections for the treatment of Morton neuroma: a patient-blinded randomized trial. Journal of Bone and Joint Surgery. American Volume2013;95(9):790-S1. [DOI: 10.2106/JBJS.I.01780]">Thomson 2013</a>, pain was a secondary outcome measured using a different VAS (0 to 100 mm; a higher score indicated less pain). At the short‐term time point (i.e. two weeks for <a href="./references#CD014687-bbs2-0002" title="Lizano-DíezX , Ginés-CespedosaA , Alentorn-GeliE , Pérez-PrietoD , González-LucenaG , GambaC , et al. Corticosteroid injection for the treatment of Morton's neuroma: a prospective, double-blinded, randomized, placebo-controlled trial. Foot &amp; Ankle International2017;38(9):944-51. [DOI: 10.1177/1071100717709569]">Lizano‐Diez 2017</a>, and one month for <a href="./references#CD014687-bbs2-0006" title="ThomsonCE , BeggsI , MartinDJ , McMillanD , EdwardsRT , RussellD , et al. Methylprednisolone injections for the treatment of Morton neuroma: a patient-blinded randomized trial. Journal of Bone and Joint Surgery. American Volume2013;95(9):790-S1. [DOI: 10.2106/JBJS.I.01780]">Thomson 2013</a>), and also at the intermediate‐term time point (i.e. six months for <a href="./references#CD014687-bbs2-0002" title="Lizano-DíezX , Ginés-CespedosaA , Alentorn-GeliE , Pérez-PrietoD , González-LucenaG , GambaC , et al. Corticosteroid injection for the treatment of Morton's neuroma: a prospective, double-blinded, randomized, placebo-controlled trial. Foot &amp; Ankle International2017;38(9):944-51. [DOI: 10.1177/1071100717709569]">Lizano‐Diez 2017</a>, and three months for <a href="./references#CD014687-bbs2-0006" title="ThomsonCE , BeggsI , MartinDJ , McMillanD , EdwardsRT , RussellD , et al. Methylprednisolone injections for the treatment of Morton neuroma: a patient-blinded randomized trial. Journal of Bone and Joint Surgery. American Volume2013;95(9):790-S1. [DOI: 10.2106/JBJS.I.01780]">Thomson 2013</a>), the evidence suggested that CS+LA resulted in little to no difference in pain. The MD for short‐term pain was ‐3.67 mm (95% CI ‐11.76 to 4.41; P = 0.37, I<sup>2</sup> = 0%; 2 studies, 157 participants; <a href="./references#CD014687-fig-0006" title="">Analysis 3.1</a>), and for intermediate‐term pain ‐6.31 mm (95% CI ‐14.23 to 1.61; P = 0.12, I<sup>2</sup> = 0%; 2 studies, 157 participants; low‐certainty evidence; <a href="./references#CD014687-fig-0007" title="">Analysis 3.2</a>). </p> <p>At the long‐term time‐point only <a href="./references#CD014687-bbs2-0006" title="ThomsonCE , BeggsI , MartinDJ , McMillanD , EdwardsRT , RussellD , et al. Methylprednisolone injections for the treatment of Morton neuroma: a patient-blinded randomized trial. Journal of Bone and Joint Surgery. American Volume2013;95(9):790-S1. [DOI: 10.2106/JBJS.I.01780]">Thomson 2013</a> reported outcomes. This trial unblinded participants after the three‐month data collection point, but not the personnel who analysed the data, and reported long‐term data at 12 months from baseline. The measurements showed that CS+LA probably resulted in little to no difference in pain (MD 1.40 mm, 95% CI ‐9.59 to 12.39; P = 0.80; 1 study, 118 participants; <a href="./references#CD014687-fig-0008" title="">Analysis 3.3</a>). </p> </section> </section> <section id="CD014687-sec-0078"> <h6 class="title"><i>Secondary outcomes</i> </h6> <section id="CD014687-sec-0079"> <p><b>Function</b></p> <p>In <a href="./references#CD014687-bbs2-0002" title="Lizano-DíezX , Ginés-CespedosaA , Alentorn-GeliE , Pérez-PrietoD , González-LucenaG , GambaC , et al. Corticosteroid injection for the treatment of Morton's neuroma: a prospective, double-blinded, randomized, placebo-controlled trial. Foot &amp; Ankle International2017;38(9):944-51. [DOI: 10.1177/1071100717709569]">Lizano‐Diez 2017</a> function was measured with the AOFAS (0 to 100 points; a higher score indicates improved function). We transformed the AOFAS score, so a lower score indicated improved function. <a href="./references#CD014687-bbs2-0006" title="ThomsonCE , BeggsI , MartinDJ , McMillanD , EdwardsRT , RussellD , et al. Methylprednisolone injections for the treatment of Morton neuroma: a patient-blinded randomized trial. Journal of Bone and Joint Surgery. American Volume2013;95(9):790-S1. [DOI: 10.2106/JBJS.I.01780]">Thomson 2013</a> separated the Manchester Foot Pain and Disability Schedule (MFPDS) into pain‐related, walking, and work or activity domains. Each domain was scored on a 0 to 100‐point scale with a lower score indicating improved function. We combined the three MFPDS domains into a single score. </p> <p>We analysed the AOFAS and MFPDS questionnaires for the short‐term time point (two weeks to one month) using SMD. The evidence suggests that CS+LA results in an improvement in function (SMD ‐0.50, 95% CI ‐0.82 to ‐0.18; P = 0.002, I<sup>2</sup> = 0%; 2 studies, 157 participants; <a href="./references#CD014687-fig-0009" title="">Analysis 4.1</a>). Converting the SMD back to the AOFAS gave an estimated MD of ‐6.75 points (95% CI ‐10.94 to ‐2.43) and an estimated MD of ‐12.30 points for the MFPDS (95% CI ‐20.17 to ‐4.43); these are moderate effect sizes, but we are unaware of a MCID for the AOFAS or MFPDS. </p> <p>We analysed the AOFAS and MFPDS questionnaires for the intermediate‐term time point (three to six months) using SMD. These results showed that CS+LA may result in little to no difference in function compared to LA alone (SMD ‐0.30, 95% CI ‐0.61 to 0.02; P = 0.06, I<sup>2</sup> = 0%; 2 studies, 157 participants; low‐certainty evidence; <a href="./references#CD014687-fig-0010" title="">Analysis 4.2</a>). Converting the SMD back to the AOFAS gave an estimated MD of ‐3.33 points (95% CI ‐6.77 to 0.22) and an estimated MD of ‐7.71 points (95% CI ‐15.68 to 0.51) for the MFPDS, which includes the possibility of no effect. </p> <p>The long‐term time point included data from one trial that reported the MFPDS at 12 months (<a href="./references#CD014687-bbs2-0006" title="ThomsonCE , BeggsI , MartinDJ , McMillanD , EdwardsRT , RussellD , et al. Methylprednisolone injections for the treatment of Morton neuroma: a patient-blinded randomized trial. Journal of Bone and Joint Surgery. American Volume2013;95(9):790-S1. [DOI: 10.2106/JBJS.I.01780]">Thomson 2013</a>). These results showed that CS+LA may result in little to no difference in function compared to LA (MD 5.30, 95% CI ‐4.25 to 14.85; P = 0.28; 1 study, 118 participants; <a href="./references#CD014687-fig-0011" title="">Analysis 4.3</a>). </p> </section> <section id="CD014687-sec-0080"> <p><b>Health‐related quality of life (HRQoL)</b></p> <p>In <a href="./references#CD014687-bbs2-0006" title="ThomsonCE , BeggsI , MartinDJ , McMillanD , EdwardsRT , RussellD , et al. Methylprednisolone injections for the treatment of Morton neuroma: a patient-blinded randomized trial. Journal of Bone and Joint Surgery. American Volume2013;95(9):790-S1. [DOI: 10.2106/JBJS.I.01780]">Thomson 2013</a> HRQoL was measured using the EQ‐5D (0 = death, 1 = perfect health). The study reported an EQ‐5D range of ‐0.59 to 1, but correspondence with the author confirmed the lower range value to be a manuscript error. </p> <p>For the short‐term time point (one month), CS+LA resulted in little to no difference in HRQoL (MD 0.03, 95% CI ‐0.07 to 0.13; P = 0.56; 1 study, 122 participants; <a href="./references#CD014687-fig-0012" title="">Analysis 5.1</a>). At the intermediate time point (six months), CS+LA probably resulted in little to no difference in HRQoL compared to LA (MD 0.07, 95% CI ‐0.03 to 0.17; P = 0.19; 1 study, 122 participants; moderate‐certainty evidence; <a href="./references#CD014687-fig-0013" title="">Analysis 5.2</a>). For the long‐term time point (12 months), CS+LA probably resulted in little to no difference in HRQoL (MD ‐0.03, 95% CI ‐0.14 to 0.08; P = 0.60; 1 study, 125 participants; <a href="./references#CD014687-fig-0014" title="">Analysis 5.3</a>). </p> </section> <section id="CD014687-sec-0081"> <p><b>Satisfaction</b></p> <p>In <a href="./references#CD014687-bbs2-0002" title="Lizano-DíezX , Ginés-CespedosaA , Alentorn-GeliE , Pérez-PrietoD , González-LucenaG , GambaC , et al. Corticosteroid injection for the treatment of Morton's neuroma: a prospective, double-blinded, randomized, placebo-controlled trial. Foot &amp; Ankle International2017;38(9):944-51. [DOI: 10.1177/1071100717709569]">Lizano‐Diez 2017</a> satisfaction was measured using the modified Johnson scale (4‐item Likert scale ranging from 'completely satisfied' to 'I wish I had never had the infiltration'). We dichotomised the data into 'satisfied' and 'dissatisfied'. </p> <p>The intermediate‐term time point (six months) showed that CS+LA may not increase satisfaction (RR 1.08, 95% CI 0.63 to 1.85; P = 0.78; 1 study, 35 participants; low‐certainty evidence; <a href="./references#CD014687-fig-0015" title="">Analysis 6.1</a>). A short‐term time point was not reported, and the study concluded before the long‐term time point. </p> </section> <section id="CD014687-sec-0082"> <p><b>Adverse events</b></p> <p>The evidence is very uncertain about the effect of CS+LA on adverse events when compared with LA (RR 9.84, 95% CI 1.28 to 75.56; P = 0.03, I<sup>2</sup> = 0%; 2 studies, 157 participants; very low‐certainty evidence; <a href="./references#CD014687-fig-0016" title="">Analysis 7.1</a>). Adverse events were reported by <a href="./references#CD014687-bbs2-0006" title="ThomsonCE , BeggsI , MartinDJ , McMillanD , EdwardsRT , RussellD , et al. Methylprednisolone injections for the treatment of Morton neuroma: a patient-blinded randomized trial. Journal of Bone and Joint Surgery. American Volume2013;95(9):790-S1. [DOI: 10.2106/JBJS.I.01780]">Thomson 2013</a> at three months and by <a href="./references#CD014687-bbs2-0002" title="Lizano-DíezX , Ginés-CespedosaA , Alentorn-GeliE , Pérez-PrietoD , González-LucenaG , GambaC , et al. Corticosteroid injection for the treatment of Morton's neuroma: a prospective, double-blinded, randomized, placebo-controlled trial. Foot &amp; Ankle International2017;38(9):944-51. [DOI: 10.1177/1071100717709569]">Lizano‐Diez 2017</a> at six months. They are expressed as the number of events divided by the participant sample size of the combined CS+LA group (n/N). Some participants who received CS+LA developed mild skin atrophy (3/76), hypopigmentation of the dorsal skin over the injection site (3/76), atrophy of the plantar fat pad (2/76), and several reported increased pain in the foot lasting for one or two days following the injection (<a href="./references#CD014687-bbs2-0002" title="Lizano-DíezX , Ginés-CespedosaA , Alentorn-GeliE , Pérez-PrietoD , González-LucenaG , GambaC , et al. Corticosteroid injection for the treatment of Morton's neuroma: a prospective, double-blinded, randomized, placebo-controlled trial. Foot &amp; Ankle International2017;38(9):944-51. [DOI: 10.1177/1071100717709569]">Lizano‐Diez 2017</a>; <a href="./references#CD014687-bbs2-0006" title="ThomsonCE , BeggsI , MartinDJ , McMillanD , EdwardsRT , RussellD , et al. Methylprednisolone injections for the treatment of Morton neuroma: a patient-blinded randomized trial. Journal of Bone and Joint Surgery. American Volume2013;95(9):790-S1. [DOI: 10.2106/JBJS.I.01780]">Thomson 2013</a>). No adverse events were reported for the LA groups. </p> </section> </section> </section> <section id="CD014687-sec-0083"> <h5 class="title">Ultrasound‐guided corticosteroid injection and local anaesthetic (UG CS+LA) versus non‐ultrasound‐guided corticosteroid and local anaesthetic injection (NUG CS+LA) </h5> <p>This comparison was investigated in two studies (<a href="./references#CD014687-bbs2-0003" title="HauMYT , ThomsonL , AujlaR , MadhadevanD , BhatiaM . Medium-term results of corticosteroid injections for Morton’s neuroma. Foot &amp; Ankle International2021;42(4):464-8. [DOI: 10.1177/1071100720966332]MahadevanD , AttwalM , BhattR , BhatiaM . Corticosteroid injection for Morton's neuroma with or without ultrasound guidance: a randomised controlled trial. Bone &amp; Joint Journal2016;98-B(4):498-503. [DOI: 10.1302/0301-620X.98B4.36880]">Mahadevan 2016</a>; <a href="./references#CD014687-bbs2-0004" title="SantiagoFR , MuñozPT , Ramos-BossiniAJL , MartinezAM , OlletaNP . Long-term comparison between blind and ultrasound-guided corticoid injections in Morton neuroma. European Radiology2022;32:1-9. [DOI: 10.1007/s00330-022-08932-y]SantiagoFR , OlletaNP , MuñozPT , ÁlvarezLG , MartínezAM . Short term comparison between blind and ultrasound guided injection in Morton neuroma. European Radiology2019;29(2):620-7. [DOI: 10.1007/s00330-018-5670-1]">Santiago 2022</a>); see <a href="./full#CD014687-tbl-0002">summary of findings Table 2</a>. </p> <section id="CD014687-sec-0084"> <h6 class="title"><i>Primary outcome</i> </h6> <section id="CD014687-sec-0085"> <p><b>Pain</b></p> <p><a href="./references#CD014687-bbs2-0003" title="HauMYT , ThomsonL , AujlaR , MadhadevanD , BhatiaM . Medium-term results of corticosteroid injections for Morton’s neuroma. Foot &amp; Ankle International2021;42(4):464-8. [DOI: 10.1177/1071100720966332]MahadevanD , AttwalM , BhattR , BhatiaM . Corticosteroid injection for Morton's neuroma with or without ultrasound guidance: a randomised controlled trial. Bone &amp; Joint Journal2016;98-B(4):498-503. [DOI: 10.1302/0301-620X.98B4.36880]">Mahadevan 2016</a> measured pain with a VAS (0 to 100 mm; a lower score indicated less pain), while in <a href="./references#CD014687-bbs2-0004" title="SantiagoFR , MuñozPT , Ramos-BossiniAJL , MartinezAM , OlletaNP . Long-term comparison between blind and ultrasound-guided corticoid injections in Morton neuroma. European Radiology2022;32:1-9. [DOI: 10.1007/s00330-022-08932-y]SantiagoFR , OlletaNP , MuñozPT , ÁlvarezLG , MartínezAM . Short term comparison between blind and ultrasound guided injection in Morton neuroma. European Radiology2019;29(2):620-7. [DOI: 10.1007/s00330-018-5670-1]">Santiago 2022</a> pain was measured using a VAS (0 to 10 points; a lower score indicated less pain), which we transformed into a 0 to 100 mm scale. </p> <p>At the short‐term time point (two months), it is likely that UG CS+LA results in a large reduction in pain compared to NUG CS+LA (MD ‐29.00, 95% CI ‐41.63 to ‐16.37; P = &lt; 0.001; 1 study, 72 feet; <a href="./references#CD014687-fig-0017" title="">Analysis 8.1</a>) (<a href="./references#CD014687-bbs2-0004" title="SantiagoFR , MuñozPT , Ramos-BossiniAJL , MartinezAM , OlletaNP . Long-term comparison between blind and ultrasound-guided corticoid injections in Morton neuroma. European Radiology2022;32:1-9. [DOI: 10.1007/s00330-022-08932-y]SantiagoFR , OlletaNP , MuñozPT , ÁlvarezLG , MartínezAM . Short term comparison between blind and ultrasound guided injection in Morton neuroma. European Radiology2019;29(2):620-7. [DOI: 10.1007/s00330-018-5670-1]">Santiago 2022</a>). No short‐term time point was reported in <a href="./references#CD014687-bbs2-0003" title="HauMYT , ThomsonL , AujlaR , MadhadevanD , BhatiaM . Medium-term results of corticosteroid injections for Morton’s neuroma. Foot &amp; Ankle International2021;42(4):464-8. [DOI: 10.1177/1071100720966332]MahadevanD , AttwalM , BhattR , BhatiaM . Corticosteroid injection for Morton's neuroma with or without ultrasound guidance: a randomised controlled trial. Bone &amp; Joint Journal2016;98-B(4):498-503. [DOI: 10.1302/0301-620X.98B4.36880]">Mahadevan 2016</a>. </p> <p>For the intermediate‐term time point (six months), UG CS+LA probably reduces pain compared to NUG CS+LA (MD ‐15.01, 95% CI ‐27.88 to ‐2.14; P = 0.02, I<sup>2</sup> = 0%; 2 studies, 116 feet; moderate‐certainty evidence; <a href="./references#CD014687-fig-0018" title="">Analysis 8.2</a>). </p> <p>At the long‐term time point (12 months), the evidence suggests that UG CS+LA probably reduces pain compared to NUG CS+LA (MD ‐15.46, 95% CI ‐26.02 to ‐4.90; P = 0.004, I<sup>2</sup> = 0%; 2 studies, 116 feet; <a href="./references#CD014687-fig-0019" title="">Analysis 8.3</a>). </p> </section> </section> <section id="CD014687-sec-0086"> <h6 class="title"><i>Secondary outcomes</i> </h6> <section id="CD014687-sec-0087"> <p><b>Function</b></p> <p>In <a href="./references#CD014687-bbs2-0003" title="HauMYT , ThomsonL , AujlaR , MadhadevanD , BhatiaM . Medium-term results of corticosteroid injections for Morton’s neuroma. Foot &amp; Ankle International2021;42(4):464-8. [DOI: 10.1177/1071100720966332]MahadevanD , AttwalM , BhattR , BhatiaM . Corticosteroid injection for Morton's neuroma with or without ultrasound guidance: a randomised controlled trial. Bone &amp; Joint Journal2016;98-B(4):498-503. [DOI: 10.1302/0301-620X.98B4.36880]">Mahadevan 2016</a> function was measured with the Manchester‐Oxford Foot Questionnaire (MOXFQ; 0 to 100 points, a lower score indicated improved function) while <a href="./references#CD014687-bbs2-0004" title="SantiagoFR , MuñozPT , Ramos-BossiniAJL , MartinezAM , OlletaNP . Long-term comparison between blind and ultrasound-guided corticoid injections in Morton neuroma. European Radiology2022;32:1-9. [DOI: 10.1007/s00330-022-08932-y]SantiagoFR , OlletaNP , MuñozPT , ÁlvarezLG , MartínezAM . Short term comparison between blind and ultrasound guided injection in Morton neuroma. European Radiology2019;29(2):620-7. [DOI: 10.1007/s00330-018-5670-1]">Santiago 2022</a> used the Manchester Foot Pain and Disability Schedule (MFPDS; 17 to 51 points, a lower score indicated improved function). </p> <p>At the short‐term time point (two months), UG CS+LA probably results in an improvement in function when compared with NUG CS+LA, but we are unaware of a MCID for the MFPDS (MD ‐6.80, 95% CI ‐11.25 to ‐2.35; P = 0.003; 1 study, 72 feet; <a href="./references#CD014687-fig-0020" title="">Analysis 9.1</a>). </p> <p>The intermediate‐term time point (six months) was analysed via the MOXFQ and MFPDS questionnaires (<a href="./references#CD014687-bbs2-0003" title="HauMYT , ThomsonL , AujlaR , MadhadevanD , BhatiaM . Medium-term results of corticosteroid injections for Morton’s neuroma. Foot &amp; Ankle International2021;42(4):464-8. [DOI: 10.1177/1071100720966332]MahadevanD , AttwalM , BhattR , BhatiaM . Corticosteroid injection for Morton's neuroma with or without ultrasound guidance: a randomised controlled trial. Bone &amp; Joint Journal2016;98-B(4):498-503. [DOI: 10.1302/0301-620X.98B4.36880]">Mahadevan 2016</a>; <a href="./references#CD014687-bbs2-0004" title="SantiagoFR , MuñozPT , Ramos-BossiniAJL , MartinezAM , OlletaNP . Long-term comparison between blind and ultrasound-guided corticoid injections in Morton neuroma. European Radiology2022;32:1-9. [DOI: 10.1007/s00330-022-08932-y]SantiagoFR , OlletaNP , MuñozPT , ÁlvarezLG , MartínezAM . Short term comparison between blind and ultrasound guided injection in Morton neuroma. European Radiology2019;29(2):620-7. [DOI: 10.1007/s00330-018-5670-1]">Santiago 2022</a>, respectively), using an SMD. The evidence suggests that UG CS+LA probably increases function compared to NUG CS+LA (SMD ‐0.47, 95% CI ‐0.84 to ‐0.10; P = 0.01, I<sup>2</sup> = 0%; 2 studies, 116 feet; moderate‐certainty evidence; <a href="./references#CD014687-fig-0021" title="">Analysis 9.2</a>). Converting the SMD back to the MOXFQ gives an estimated MD of ‐21.95 points (95% CI ‐39.23 to ‐4.67) and the MFPDS gives an estimated MD of ‐5.12 points (95% CI ‐9.16 to ‐1.90). The effect sizes for both are small to moderate, but we are unaware of a MCID for the MOXFQ or MFPDS that would set this result in context. </p> <p>The long‐term time point (12 months) were analysed via the MOXFQ and MFPDS questionnaires (<a href="./references#CD014687-bbs2-0003" title="HauMYT , ThomsonL , AujlaR , MadhadevanD , BhatiaM . Medium-term results of corticosteroid injections for Morton’s neuroma. Foot &amp; Ankle International2021;42(4):464-8. [DOI: 10.1177/1071100720966332]MahadevanD , AttwalM , BhattR , BhatiaM . Corticosteroid injection for Morton's neuroma with or without ultrasound guidance: a randomised controlled trial. Bone &amp; Joint Journal2016;98-B(4):498-503. [DOI: 10.1302/0301-620X.98B4.36880]">Mahadevan 2016</a>; <a href="./references#CD014687-bbs2-0004" title="SantiagoFR , MuñozPT , Ramos-BossiniAJL , MartinezAM , OlletaNP . Long-term comparison between blind and ultrasound-guided corticoid injections in Morton neuroma. European Radiology2022;32:1-9. [DOI: 10.1007/s00330-022-08932-y]SantiagoFR , OlletaNP , MuñozPT , ÁlvarezLG , MartínezAM . Short term comparison between blind and ultrasound guided injection in Morton neuroma. European Radiology2019;29(2):620-7. [DOI: 10.1007/s00330-018-5670-1]">Santiago 2022</a>, respectively); we analysed them using a SMD. UG CS+LA may result in an improvement in function when compared with NUG CS+LA (SMD ‐0.52, 95% CI ‐0.94 to ‐0.10; P = 0.02, I<sup>2</sup> = 20%; 2 studies, 116 feet; <a href="./references#CD014687-fig-0022" title="">Analysis 9.3</a>). Converting the SMD back to the MOXFQ gives an estimated MD of ‐27.72 points (95% CI ‐50.10 to ‐5.33), which is a moderate effect size. The MFPDS gives an estimated MD of ‐4.78 points (95% CI ‐8.65 to ‐0.92), which is a small to moderate effect size. </p> </section> <section id="CD014687-sec-0088"> <p><b>HRQoL</b></p> <p>The EQ‐5D was a listed outcome in the registered protocol for <a href="./references#CD014687-bbs2-0004" title="SantiagoFR , MuñozPT , Ramos-BossiniAJL , MartinezAM , OlletaNP . Long-term comparison between blind and ultrasound-guided corticoid injections in Morton neuroma. European Radiology2022;32:1-9. [DOI: 10.1007/s00330-022-08932-y]SantiagoFR , OlletaNP , MuñozPT , ÁlvarezLG , MartínezAM . Short term comparison between blind and ultrasound guided injection in Morton neuroma. European Radiology2019;29(2):620-7. [DOI: 10.1007/s00330-018-5670-1]">Santiago 2022</a>, but no results were reported and no reason was provided for the difference between protocol and study. HRQoL was not reported by <a href="./references#CD014687-bbs2-0003" title="HauMYT , ThomsonL , AujlaR , MadhadevanD , BhatiaM . Medium-term results of corticosteroid injections for Morton’s neuroma. Foot &amp; Ankle International2021;42(4):464-8. [DOI: 10.1177/1071100720966332]MahadevanD , AttwalM , BhattR , BhatiaM . Corticosteroid injection for Morton's neuroma with or without ultrasound guidance: a randomised controlled trial. Bone &amp; Joint Journal2016;98-B(4):498-503. [DOI: 10.1302/0301-620X.98B4.36880]">Mahadevan 2016</a>. </p> </section> <section id="CD014687-sec-0089"> <p><b>Satisfaction</b></p> <p><a href="./references#CD014687-bbs2-0003" title="HauMYT , ThomsonL , AujlaR , MadhadevanD , BhatiaM . Medium-term results of corticosteroid injections for Morton’s neuroma. Foot &amp; Ankle International2021;42(4):464-8. [DOI: 10.1177/1071100720966332]MahadevanD , AttwalM , BhattR , BhatiaM . Corticosteroid injection for Morton's neuroma with or without ultrasound guidance: a randomised controlled trial. Bone &amp; Joint Journal2016;98-B(4):498-503. [DOI: 10.1302/0301-620X.98B4.36880]">Mahadevan 2016</a> measured satisfaction using the Johnson Scale, while <a href="./references#CD014687-bbs2-0004" title="SantiagoFR , MuñozPT , Ramos-BossiniAJL , MartinezAM , OlletaNP . Long-term comparison between blind and ultrasound-guided corticoid injections in Morton neuroma. European Radiology2022;32:1-9. [DOI: 10.1007/s00330-022-08932-y]SantiagoFR , OlletaNP , MuñozPT , ÁlvarezLG , MartínezAM . Short term comparison between blind and ultrasound guided injection in Morton neuroma. European Radiology2019;29(2):620-7. [DOI: 10.1007/s00330-018-5670-1]">Santiago 2022</a> used a similar four‐statement Likert scale. </p> <p>For the short‐term time point (two months), UG CS+LA probably results in a large increase in satisfaction compared to NUG CS+LA (RR 2.02, 95% CI 1.28 to 3.17; P = 0.002; 1 study, 72 feet; <a href="./references#CD014687-fig-0023" title="">Analysis 10.1</a>) (<a href="./references#CD014687-bbs2-0004" title="SantiagoFR , MuñozPT , Ramos-BossiniAJL , MartinezAM , OlletaNP . Long-term comparison between blind and ultrasound-guided corticoid injections in Morton neuroma. European Radiology2022;32:1-9. [DOI: 10.1007/s00330-022-08932-y]SantiagoFR , OlletaNP , MuñozPT , ÁlvarezLG , MartínezAM . Short term comparison between blind and ultrasound guided injection in Morton neuroma. European Radiology2019;29(2):620-7. [DOI: 10.1007/s00330-018-5670-1]">Santiago 2022</a>). </p> <p>At the intermediate‐term time point (six months), UG CS+LA may increase satisfaction compared to NUG CS+LA (RR 1.71, 95% CI 1.19 to 2.44; P = 0.003, I<sup>2</sup> = 15%; 2 studies, 114 feet; low‐certainty evidence; <a href="./references#CD014687-fig-0024" title="">Analysis 10.2</a>) (<a href="./references#CD014687-bbs2-0003" title="HauMYT , ThomsonL , AujlaR , MadhadevanD , BhatiaM . Medium-term results of corticosteroid injections for Morton’s neuroma. Foot &amp; Ankle International2021;42(4):464-8. [DOI: 10.1177/1071100720966332]MahadevanD , AttwalM , BhattR , BhatiaM . Corticosteroid injection for Morton's neuroma with or without ultrasound guidance: a randomised controlled trial. Bone &amp; Joint Journal2016;98-B(4):498-503. [DOI: 10.1302/0301-620X.98B4.36880]">Mahadevan 2016</a>; <a href="./references#CD014687-bbs2-0004" title="SantiagoFR , MuñozPT , Ramos-BossiniAJL , MartinezAM , OlletaNP . Long-term comparison between blind and ultrasound-guided corticoid injections in Morton neuroma. European Radiology2022;32:1-9. [DOI: 10.1007/s00330-022-08932-y]SantiagoFR , OlletaNP , MuñozPT , ÁlvarezLG , MartínezAM . Short term comparison between blind and ultrasound guided injection in Morton neuroma. European Radiology2019;29(2):620-7. [DOI: 10.1007/s00330-018-5670-1]">Santiago 2022</a>). </p> <p>For the long‐term time point (12 months), UG CS+LA may result in a large increase in satisfaction compared to NUG CS+LA (RR 1.82, 95% CI 1.17 to 2.83; P = 0.008; 1 study, 68 feet; <a href="./references#CD014687-fig-0025" title="">Analysis 10.3</a>) (<a href="./references#CD014687-bbs2-0004" title="SantiagoFR , MuñozPT , Ramos-BossiniAJL , MartinezAM , OlletaNP . Long-term comparison between blind and ultrasound-guided corticoid injections in Morton neuroma. European Radiology2022;32:1-9. [DOI: 10.1007/s00330-022-08932-y]SantiagoFR , OlletaNP , MuñozPT , ÁlvarezLG , MartínezAM . Short term comparison between blind and ultrasound guided injection in Morton neuroma. European Radiology2019;29(2):620-7. [DOI: 10.1007/s00330-018-5670-1]">Santiago 2022</a>). </p> </section> <section id="CD014687-sec-0090"> <p><b>Adverse events</b></p> <p>UG CS+LA may result in little to no difference in adverse events when compared with NUG CS+LA (RR 0.42, 95% CI 0.12 to 1.39; P = 0.15, I<sup>2</sup> = 0%; 2 studies, 116 feet; low‐certainty evidence; <a href="./references#CD014687-fig-0026" title="">Analysis 11.1</a>). Both trials reported adverse events at 12 months expressed as the number of events and the sample size of feet (not participants) (n/N) separately for the UG CS+LA and NUG CS+LA injection groups (<a href="./references#CD014687-bbs2-0003" title="HauMYT , ThomsonL , AujlaR , MadhadevanD , BhatiaM . Medium-term results of corticosteroid injections for Morton’s neuroma. Foot &amp; Ankle International2021;42(4):464-8. [DOI: 10.1177/1071100720966332]MahadevanD , AttwalM , BhattR , BhatiaM . Corticosteroid injection for Morton's neuroma with or without ultrasound guidance: a randomised controlled trial. Bone &amp; Joint Journal2016;98-B(4):498-503. [DOI: 10.1302/0301-620X.98B4.36880]">Mahadevan 2016</a>; <a href="./references#CD014687-bbs2-0004" title="SantiagoFR , MuñozPT , Ramos-BossiniAJL , MartinezAM , OlletaNP . Long-term comparison between blind and ultrasound-guided corticoid injections in Morton neuroma. European Radiology2022;32:1-9. [DOI: 10.1007/s00330-022-08932-y]SantiagoFR , OlletaNP , MuñozPT , ÁlvarezLG , MartínezAM . Short term comparison between blind and ultrasound guided injection in Morton neuroma. European Radiology2019;29(2):620-7. [DOI: 10.1007/s00330-018-5670-1]">Santiago 2022</a>). Depigmentation or fat atrophy, or both, at the injection site was the only adverse event reported and occurred in the combined UG CS+LA injection group (3/61) and the combined NUG CS+LA injection group (7/55). </p> </section> </section> </section> </section> <section id="CD014687-sec-0091"> <h4 class="title">Surgical treatments</h4> <section id="CD014687-sec-0092"> <h5 class="title">Plantar incision neurectomy (PN) versus dorsal incision neurectomy (DN)</h5> <p>These interventions were compared in <a href="./references#CD014687-bbs2-0001" title="AkermarkC , CroneH , SkoogA , WeidenhielmL . A prospective randomized controlled trial of plantar versus dorsal incisions for operative treatment of primary Morton's neuroma. Foot &amp; Ankle International2013;34(9):1198-204. [DOI: 10.1177/1071100713484300]">Akermark 2013</a>; see <a href="./full#CD014687-tbl-0003">summary of findings Table 3</a>. </p> <section id="CD014687-sec-0093"> <h6 class="title"><i>Primary outcomes</i> </h6> <section id="CD014687-sec-0094"> <p><b>Pain</b></p> <p>Baseline and time‐point data were not reported; results were presented as percentages and P values (<a href="./references#CD014687-bbs2-0001" title="AkermarkC , CroneH , SkoogA , WeidenhielmL . A prospective randomized controlled trial of plantar versus dorsal incisions for operative treatment of primary Morton's neuroma. Foot &amp; Ankle International2013;34(9):1198-204. [DOI: 10.1177/1071100713484300]">Akermark 2013</a>). Our attempts to contact the trial authors for baseline and time‐point data were unsuccessful. We were unable to extract meaningful data from the published results for pain. </p> </section> </section> <section id="CD014687-sec-0095"> <h6 class="title"><i>Secondary outcomes</i> </h6> <section id="CD014687-sec-0096"> <p><b>Function</b></p> <p>Function was assessed with a four‐point Likert scale, but baseline and time‐point data were not reported; results were presented as percentage improvements and P values (<a href="./references#CD014687-bbs2-0001" title="AkermarkC , CroneH , SkoogA , WeidenhielmL . A prospective randomized controlled trial of plantar versus dorsal incisions for operative treatment of primary Morton's neuroma. Foot &amp; Ankle International2013;34(9):1198-204. [DOI: 10.1177/1071100713484300]">Akermark 2013</a>). We were unable to extract meaningful data from the published results for function. </p> </section> <section id="CD014687-sec-0097"> <p><b>HRQoL</b></p> <p>HRQoL was not measured in this study.</p> </section> <section id="CD014687-sec-0098"> <p><b>Satisfaction</b></p> <p><a href="./references#CD014687-bbs2-0001" title="AkermarkC , CroneH , SkoogA , WeidenhielmL . A prospective randomized controlled trial of plantar versus dorsal incisions for operative treatment of primary Morton's neuroma. Foot &amp; Ankle International2013;34(9):1198-204. [DOI: 10.1177/1071100713484300]">Akermark 2013</a> measured satisfaction using a four‐item Likert scale. The study reported that the participants' overall satisfaction was similar between the plantar and dorsal incision groups at the 3‐month, 12‐month and 28‐ to 42‐month follow‐up (final satisfaction follow‐up: plantar 87%, dorsal 83%, P = 0.164). </p> <p>At the long‐term time point, (mean 34 months, range 28 to 42 months), PN may result in little to no difference in satisfaction compared to DN (RR 1.06, 95% CI 0.87 to 1.28; P = 0.58; 1 study, 73 participants; low‐certainty evidence; <a href="./references#CD014687-fig-0027" title="">Analysis 12.1</a>). </p> </section> <section id="CD014687-sec-0099"> <p><b>Adverse events</b></p> <p>PN may result in little to no difference in adverse events compared with DN (RR 0.95, 95% CI 0.32 to 2.85; P = 0.93; 1 study, 75 participants; low‐certainty evidence; <a href="./references#CD014687-fig-0028" title="">Analysis 13.1</a>). </p> <p>Adverse events were expressed as the number of events divided by the participant sample size in each intervention group (n/N). There were five adverse events in the PN group, which included three small hypertrophic scar formations (3/35), a larger hypertrophic scar (1/35) and a foreign body reaction (1/35), with all five resulting in an additional surgical intervention. The DN group had six adverse events, which included a missed nerve (artery resected) (1/40), wound infection (1/40), postoperative dehiscence (closed wound splits open) (1/40), postoperative deep vein thrombosis (1/40) and reoperation with a plantar incision due to intolerable, persistent pain (2/40). Histological examination from the reoperation with plantar incision found an amputation neuroma (a secondary neuroma that may form after a neurectomy) and fibrous granulation tissue (scar tissue) from the excised tissue. These histological findings are likely causes of the intolerable, persistent pain. </p> </section> </section> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD014687-sec-0100" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD014687-sec-0100"></div> <section id="CD014687-sec-0101"> <h3 class="title" id="CD014687-sec-0101">Summary of main results</h3> <p>Our comprehensive literature review identified six randomised controlled trials (RCTs) that investigated four Morton's neuroma (MN) treatments, three of which were nonsurgical. These RCTs included 373 participants with a confirmed MN diagnosis of symptoms. </p> <p>While pain probably reduces with an ultrasound‐guided corticosteroid and local anaesthetic injection (UG CS+LA), compared to a non‐ultrasound‐guided corticosteroid and anaesthetic injection (NUG CS+LA), there was little difference for shockwave therapy (SWT) compared with sham SWT, or corticosteroid and local anaesthetic injection (CS+LA) compared with local anaesthetic injection (LA). Pain could not be compared for plantar incision neurectomy (PN) with dorsal incision neurectomy (DN). </p> <p>Two RCTs compared CS+LA versus LA injections and assessed pain, function, HRQoL and satisfaction (<a href="./references#CD014687-bbs2-0002" title="Lizano-DíezX , Ginés-CespedosaA , Alentorn-GeliE , Pérez-PrietoD , González-LucenaG , GambaC , et al. Corticosteroid injection for the treatment of Morton's neuroma: a prospective, double-blinded, randomized, placebo-controlled trial. Foot &amp; Ankle International2017;38(9):944-51. [DOI: 10.1177/1071100717709569]">Lizano‐Diez 2017</a>; <a href="./references#CD014687-bbs2-0006" title="ThomsonCE , BeggsI , MartinDJ , McMillanD , EdwardsRT , RussellD , et al. Methylprednisolone injections for the treatment of Morton neuroma: a patient-blinded randomized trial. Journal of Bone and Joint Surgery. American Volume2013;95(9):790-S1. [DOI: 10.2106/JBJS.I.01780]">Thomson 2013</a>). The analyses suggest CS+LA makes little to no difference for pain in the short (less than 3 months), intermediate (3 months to less than 12 months) or long term (longer than 12 months) with low‐certainty evidence for the intermediate term. Functional improvement with CS+LA was greatest in the short term, with a moderate effect size, but the clinical meaningfulness of the effect is uncertain. CS+LA probably results in little to no difference in HRQoL, with moderate‐certainty evidence for the intermediate term. Satisfaction assessments showed that CS+LA may not increase satisfaction when compared to LA (<a href="./references#CD014687-bbs2-0002" title="Lizano-DíezX , Ginés-CespedosaA , Alentorn-GeliE , Pérez-PrietoD , González-LucenaG , GambaC , et al. Corticosteroid injection for the treatment of Morton's neuroma: a prospective, double-blinded, randomized, placebo-controlled trial. Foot &amp; Ankle International2017;38(9):944-51. [DOI: 10.1177/1071100717709569]">Lizano‐Diez 2017</a>). The evidence was very uncertain about adverse events, which included skin and fat pad atrophy and skin hypopigmentation with CS+LA; no adverse events were reported for LA. </p> <p>Two RCTs compared UG CS+LA to NUG CS+LA and assessed pain, function, and satisfaction, but not HRQoL (<a href="./references#CD014687-bbs2-0003" title="HauMYT , ThomsonL , AujlaR , MadhadevanD , BhatiaM . Medium-term results of corticosteroid injections for Morton’s neuroma. Foot &amp; Ankle International2021;42(4):464-8. [DOI: 10.1177/1071100720966332]MahadevanD , AttwalM , BhattR , BhatiaM . Corticosteroid injection for Morton's neuroma with or without ultrasound guidance: a randomised controlled trial. Bone &amp; Joint Journal2016;98-B(4):498-503. [DOI: 10.1302/0301-620X.98B4.36880]">Mahadevan 2016</a>; <a href="./references#CD014687-bbs2-0004" title="SantiagoFR , MuñozPT , Ramos-BossiniAJL , MartinezAM , OlletaNP . Long-term comparison between blind and ultrasound-guided corticoid injections in Morton neuroma. European Radiology2022;32:1-9. [DOI: 10.1007/s00330-022-08932-y]SantiagoFR , OlletaNP , MuñozPT , ÁlvarezLG , MartínezAM . Short term comparison between blind and ultrasound guided injection in Morton neuroma. European Radiology2019;29(2):620-7. [DOI: 10.1007/s00330-018-5670-1]">Santiago 2022</a>). The <a href="./references#CD014687-bbs2-0003" title="HauMYT , ThomsonL , AujlaR , MadhadevanD , BhatiaM . Medium-term results of corticosteroid injections for Morton’s neuroma. Foot &amp; Ankle International2021;42(4):464-8. [DOI: 10.1177/1071100720966332]MahadevanD , AttwalM , BhattR , BhatiaM . Corticosteroid injection for Morton's neuroma with or without ultrasound guidance: a randomised controlled trial. Bone &amp; Joint Journal2016;98-B(4):498-503. [DOI: 10.1302/0301-620X.98B4.36880]">Mahadevan 2016</a> study randomised participants with bilateral neuromas per foot. The analyses showed that UG CS+LA probably results in a large reduction in pain in the short term, but the pain reduction is less at intermediate‐ and long‐term time points. Function improved with a small to moderate effect with UG CS+LA compared to NUG CS+LA across all three time points, with moderate‐certainty evidence for the intermediate term, but we are unaware of a minimum clinical important difference (MCID) for the Manchester Foot Pain and Disability Schedule (MFPDS) or the Manchester‐Oxford Foot Questionnaire (MOXFQ). Satisfaction was greater for UG CS+LA in the short and long term than in the intermediate term (low‐certainty evidence) when compared with NUG CS+LA. There was little to no difference in adverse events between the interventions. Adverse events for these corticosteroid injections were similar to those in the CS+LA versus LA studies and included fat pad atrophy and skin hypopigmentation (<a href="./references#CD014687-bbs2-0003" title="HauMYT , ThomsonL , AujlaR , MadhadevanD , BhatiaM . Medium-term results of corticosteroid injections for Morton’s neuroma. Foot &amp; Ankle International2021;42(4):464-8. [DOI: 10.1177/1071100720966332]MahadevanD , AttwalM , BhattR , BhatiaM . Corticosteroid injection for Morton's neuroma with or without ultrasound guidance: a randomised controlled trial. Bone &amp; Joint Journal2016;98-B(4):498-503. [DOI: 10.1302/0301-620X.98B4.36880]">Mahadevan 2016</a>; <a href="./references#CD014687-bbs2-0004" title="SantiagoFR , MuñozPT , Ramos-BossiniAJL , MartinezAM , OlletaNP . Long-term comparison between blind and ultrasound-guided corticoid injections in Morton neuroma. European Radiology2022;32:1-9. [DOI: 10.1007/s00330-022-08932-y]SantiagoFR , OlletaNP , MuñozPT , ÁlvarezLG , MartínezAM . Short term comparison between blind and ultrasound guided injection in Morton neuroma. European Radiology2019;29(2):620-7. [DOI: 10.1007/s00330-018-5670-1]">Santiago 2022</a>). </p> <p>The surgical RCT compared PN with DN (<a href="./references#CD014687-bbs2-0001" title="AkermarkC , CroneH , SkoogA , WeidenhielmL . A prospective randomized controlled trial of plantar versus dorsal incisions for operative treatment of primary Morton's neuroma. Foot &amp; Ankle International2013;34(9):1198-204. [DOI: 10.1177/1071100713484300]">Akermark 2013</a>). Although pain and function were reported, we were unable to extract meaningful data from the published results. HRQoL was not measured. PN may result in little to no difference in satisfaction compared to DN. The difference in adverse events between the groups was minimal (low‐certainty evidence), and included painful scarring and a foreign body reaction in the PN group, and wound infection, incision reopening, deep vein thrombosis and reoperation with a PN in the DN group. </p> </section> <section id="CD014687-sec-0102"> <h3 class="title" id="CD014687-sec-0102">Overall completeness and applicability of evidence</h3> <p>A small number of RCTs has reported a limited range of nonsurgical and surgical interventions for MN. Only one of the six studies we included in this review reached a sufficiently large sample size (90 participants) to provide optimal information to assess the outcome of pain (<a href="./references#CD014687-bbs2-0006" title="ThomsonCE , BeggsI , MartinDJ , McMillanD , EdwardsRT , RussellD , et al. Methylprednisolone injections for the treatment of Morton neuroma: a patient-blinded randomized trial. Journal of Bone and Joint Surgery. American Volume2013;95(9):790-S1. [DOI: 10.2106/JBJS.I.01780]">Thomson 2013</a>). The inclusion criteria used in our review provided a high level of confidence that the participants enroled in each included study were diagnosed with MN, but this inclusion criterion also resulted in us excluding nine RCTs from the review. </p> <p>The published nonrandomised clinical trials and case series report a broader range of nonsurgical and surgical interventions for MN than the published RCTs do (<a href="./references#CD014687-bbs2-0070" title="MatthewsBG , HurnSE , HardingMP , HenryRA , WareRS . The effectiveness of nonsurgical interventions for common plantar digital compressive neuropathy (Morton's neuroma): a systematic review and meta-analysis. Journal of Foot and Ankle Research2019;12(12):1-21. [DOI: 10.1186/s13047-019-0320-7]">Matthews 2019</a>). Our review included two nonsurgical intervention types; SWT versus sham SWT and CS+LA versus LA, with corticosteroid and local anaesthetic injections also assessed when administered with and without ultrasound guidance. While interventions concerning footwear modifications, foot orthoses, foot mobilisation, chemical neurolysis (alcohol sclerosing injections) and temperature neurolysis (radiofrequency nerve ablations) have been examined in studies, they were not included in this review either because they were not assessed within a RCT, or because the relevant RCT did not meet our inclusion criteria. The only surgical intervention we included was plantar versus dorsal neurectomy. We either did not identify RCTs investigating surgical neurolysis and osteotomy procedures, or they did not meet our inclusion criteria. The included trials have only met the review objectives partially, when one considers the broader range of interventions available for MN, or comparisons between nonsurgical and surgical interventions. </p> <p>Pain was the most consistently reported outcome, and was generally measured using a visual analogue scale (VAS) from 0 to 100 mm. We estimated the minimal clinically important difference (MCID) for pain to be 15 mm, but there is a need to investigate an objective MCID value. </p> <p>Function was measured using a range of questionnaires including the American Orthopaedic Foot and Ankle Society Lesser Toe Metatarsophalangeal‐lnterphalangeal Scale (AOFAS) – which is not perceived as being particularly reliable (<a href="./references#CD014687-bbs2-0021" title="American Orthopaedic Foot &amp; Ankle Society. Position Statements &amp; Clinical Guidelines: Patient Reported Outcomes Measures. www.aofas.org/research-policy/position-statements-clinical-guidelines (accessed 06 July 2023).">AOFAS 2022</a>); the Manchester Foot Pain and Disability Schedule (MFPDS), which was used differently in two studies (<a href="./references#CD014687-bbs2-0004" title="SantiagoFR , MuñozPT , Ramos-BossiniAJL , MartinezAM , OlletaNP . Long-term comparison between blind and ultrasound-guided corticoid injections in Morton neuroma. European Radiology2022;32:1-9. [DOI: 10.1007/s00330-022-08932-y]SantiagoFR , OlletaNP , MuñozPT , ÁlvarezLG , MartínezAM . Short term comparison between blind and ultrasound guided injection in Morton neuroma. European Radiology2019;29(2):620-7. [DOI: 10.1007/s00330-018-5670-1]">Santiago 2022</a>; <a href="./references#CD014687-bbs2-0006" title="ThomsonCE , BeggsI , MartinDJ , McMillanD , EdwardsRT , RussellD , et al. Methylprednisolone injections for the treatment of Morton neuroma: a patient-blinded randomized trial. Journal of Bone and Joint Surgery. American Volume2013;95(9):790-S1. [DOI: 10.2106/JBJS.I.01780]">Thomson 2013</a>); and the Manchester‐Oxford Foot Questionnaire (MOXFQ). </p> <p>HRQoL was measured in one study using the EuroQol 5 Dimension Instrument (EQ‐5D) (<a href="./references#CD014687-bbs2-0006" title="ThomsonCE , BeggsI , MartinDJ , McMillanD , EdwardsRT , RussellD , et al. Methylprednisolone injections for the treatment of Morton neuroma: a patient-blinded randomized trial. Journal of Bone and Joint Surgery. American Volume2013;95(9):790-S1. [DOI: 10.2106/JBJS.I.01780]">Thomson 2013</a>). </p> <p>Satisfaction was measured by five studies using unvalidated four‐ to five‐item Likert scales. </p> <p>The choice of function and satisfaction outcome measures with poor validation, or modification without revalidation, reduces the certainty of the evidence reported by these measures. </p> </section> <section id="CD014687-sec-0103"> <h3 class="title" id="CD014687-sec-0103">Quality of the evidence</h3> <p>Using the GRADE approach (<a href="./references#CD014687-bbs2-0091" title="SchünemannHJ , HigginsJP , VistGE , GlasziouP , AklEA , SkoetzN , et al. Chapter 14: Completing 'Summary of findings' tables and grading the certainty of the evidence. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022). Cochrane, 2022. Available from training.cochrane.org/handbook (accessed 06 July 2023).">Schünemann 2019</a>), we assessed that the certainty of the evidence ranged from very low to moderate across all outcomes with most having evidence of low certainty. We rated the overall risk of bias as 'some concerns' for most outcomes across all studies. We did not downgrade the certainty of the evidence where the overall risk of bias was rated as 'some concerns'. The outcomes from <a href="./references#CD014687-bbs2-0002" title="Lizano-DíezX , Ginés-CespedosaA , Alentorn-GeliE , Pérez-PrietoD , González-LucenaG , GambaC , et al. Corticosteroid injection for the treatment of Morton's neuroma: a prospective, double-blinded, randomized, placebo-controlled trial. Foot &amp; Ankle International2017;38(9):944-51. [DOI: 10.1177/1071100717709569]">Lizano‐Diez 2017</a> were rated as being at high risk of bias due to missing outcome data, and we downgraded the certainty of evidence by one level. </p> <p>Where a comparison included only one study, we assessed that there was no inconsistency and, when data from two studies were combined in meta‐analysis, we found that the effect estimates from each study were not inconsistent when assessed using Chi<sup>2</sup>, I<sup>2</sup> or P values. Five included studies reported adverse events, but due to suboptimal information sizes, and a wide confidence interval (CI) (<a href="./references#CD014687-bbs2-0002" title="Lizano-DíezX , Ginés-CespedosaA , Alentorn-GeliE , Pérez-PrietoD , González-LucenaG , GambaC , et al. Corticosteroid injection for the treatment of Morton's neuroma: a prospective, double-blinded, randomized, placebo-controlled trial. Foot &amp; Ankle International2017;38(9):944-51. [DOI: 10.1177/1071100717709569]">Lizano‐Diez 2017</a>; <a href="./references#CD014687-bbs2-0006" title="ThomsonCE , BeggsI , MartinDJ , McMillanD , EdwardsRT , RussellD , et al. Methylprednisolone injections for the treatment of Morton neuroma: a patient-blinded randomized trial. Journal of Bone and Joint Surgery. American Volume2013;95(9):790-S1. [DOI: 10.2106/JBJS.I.01780]">Thomson 2013</a>), or the possibility of no effect (<a href="./references#CD014687-bbs2-0003" title="HauMYT , ThomsonL , AujlaR , MadhadevanD , BhatiaM . Medium-term results of corticosteroid injections for Morton’s neuroma. Foot &amp; Ankle International2021;42(4):464-8. [DOI: 10.1177/1071100720966332]MahadevanD , AttwalM , BhattR , BhatiaM . Corticosteroid injection for Morton's neuroma with or without ultrasound guidance: a randomised controlled trial. Bone &amp; Joint Journal2016;98-B(4):498-503. [DOI: 10.1302/0301-620X.98B4.36880]">Mahadevan 2016</a>; <a href="./references#CD014687-bbs2-0004" title="SantiagoFR , MuñozPT , Ramos-BossiniAJL , MartinezAM , OlletaNP . Long-term comparison between blind and ultrasound-guided corticoid injections in Morton neuroma. European Radiology2022;32:1-9. [DOI: 10.1007/s00330-022-08932-y]SantiagoFR , OlletaNP , MuñozPT , ÁlvarezLG , MartínezAM . Short term comparison between blind and ultrasound guided injection in Morton neuroma. European Radiology2019;29(2):620-7. [DOI: 10.1007/s00330-018-5670-1]">Santiago 2022</a>), or including no effect (<a href="./references#CD014687-bbs2-0001" title="AkermarkC , CroneH , SkoogA , WeidenhielmL . A prospective randomized controlled trial of plantar versus dorsal incisions for operative treatment of primary Morton's neuroma. Foot &amp; Ankle International2013;34(9):1198-204. [DOI: 10.1177/1071100713484300]">Akermark 2013</a>), we downgraded the evidence twice for imprecision. </p> <p>We specified a population, intervention, comparison, outcome (PICO) for the review (<a href="#CD014687-sec-0016">Criteria for considering studies for this review</a>). We did not downgrade for PICO indirectness, but noted that four studies across two comparisons used a varying number of injections ‐ CS+LA and LA, and UG CS+LA and NUG CS+LA ‐ over different time periods (<a href="./references#CD014687-bbs2-0002" title="Lizano-DíezX , Ginés-CespedosaA , Alentorn-GeliE , Pérez-PrietoD , González-LucenaG , GambaC , et al. Corticosteroid injection for the treatment of Morton's neuroma: a prospective, double-blinded, randomized, placebo-controlled trial. Foot &amp; Ankle International2017;38(9):944-51. [DOI: 10.1177/1071100717709569]">Lizano‐Diez 2017</a>; <a href="./references#CD014687-bbs2-0003" title="HauMYT , ThomsonL , AujlaR , MadhadevanD , BhatiaM . Medium-term results of corticosteroid injections for Morton’s neuroma. Foot &amp; Ankle International2021;42(4):464-8. [DOI: 10.1177/1071100720966332]MahadevanD , AttwalM , BhattR , BhatiaM . Corticosteroid injection for Morton's neuroma with or without ultrasound guidance: a randomised controlled trial. Bone &amp; Joint Journal2016;98-B(4):498-503. [DOI: 10.1302/0301-620X.98B4.36880]">Mahadevan 2016</a>; <a href="./references#CD014687-bbs2-0004" title="SantiagoFR , MuñozPT , Ramos-BossiniAJL , MartinezAM , OlletaNP . Long-term comparison between blind and ultrasound-guided corticoid injections in Morton neuroma. European Radiology2022;32:1-9. [DOI: 10.1007/s00330-022-08932-y]SantiagoFR , OlletaNP , MuñozPT , ÁlvarezLG , MartínezAM . Short term comparison between blind and ultrasound guided injection in Morton neuroma. European Radiology2019;29(2):620-7. [DOI: 10.1007/s00330-018-5670-1]">Santiago 2022</a>; <a href="./references#CD014687-bbs2-0006" title="ThomsonCE , BeggsI , MartinDJ , McMillanD , EdwardsRT , RussellD , et al. Methylprednisolone injections for the treatment of Morton neuroma: a patient-blinded randomized trial. Journal of Bone and Joint Surgery. American Volume2013;95(9):790-S1. [DOI: 10.2106/JBJS.I.01780]">Thomson 2013</a>). </p> <p>Optimal information size (OIS), which is the minimum sample size required to allow a conclusion about an intervention's effectiveness to be reached, was calculated for all outcomes using <a href="https://www.psychologie.hhu.de/arbeitsgruppen/allgemeine-psychologie-und-arbeitspsychologie/gpower" target="_blank">GPower</a> and has been reported in the footnotes of the summary of findings tables. Where participant numbers for an outcome were less than the calculated OIS, we downgraded for imprecision by one level or, where the difference was large, such as for nonsurgical serious adverse events, we downgraded by two levels. When confidence intervals crossed two effect sizes, or were wider than 20% of a scale (e.g. 0 to 100 scale, CI wider than 20), or when risk ratios included appreciable benefit or harm (RR &lt; 0.75 or RR &gt; 1.25), we downgraded one level for imprecision. </p> <p>Given the small number of studies included in the four comparisons, we did not undertake a formal assessment of reporting bias using a funnel plot. </p> </section> <section id="CD014687-sec-0104"> <h3 class="title" id="CD014687-sec-0104">Potential biases in the review process</h3> <p>The review authors adhered to the predefined objectives and eligibility criteria published in the review protocol (<a href="./references#CD014687-bbs2-0098" title="MatthewsBG , ThomsonCE , McKinleyJC , HardingMP , WareRS . Treatments for Morton's neuroma. Cochrane Database of Systematic Reviews2021, Issue 7. Art. No: CD014687. [DOI: 10.1002/14651858.CD014687]">Matthews 2021</a>). There was no restriction on publication date or language of publication of eligible studies, and we had one full‐text study report translated into English. We found no additional studies through searching the reference lists of relevant systematic reviews and included studies we identified. It is possible that we did not identify all MN studies; some may have published in unidentified journals or databases, or not been accepted for publication because of negative outcomes or methodological issues. We found no published results for a number of registered clinical trial protocols for studies. These studies may be ongoing or may have ended prior to study completion. We contacted the corresponding authors of these studies requesting clarification of their status and their inclusion criteria for MN; if we received no response, we excluded the registered protocol for the trial. </p> <p>A number of full‐text studies partially matched our inclusion criteria of MN symptoms (<a href="#CD014687-sec-0016">Criteria for considering studies for this review</a>). We attempted to contact corresponding trial authors for those trials that described partial inclusion criteria. If we received no reply, we excluded the studies for not fully meeting our criteria. We assessed conference abstracts using the same process. The exclusion of these full‐text studies and conference abstracts may be a source of bias in our review. </p> <p>More than one term is used in the literature to describe MN (<a href="./references#CD014687-bbs2-0061" title="LarsonEE , BarrettSL , BattistonB , Maloney CT Jr, DellonAL . Accurate nomenclature for forefoot nerve entrapment: a historical perspective. Journal of the American Podiatric Medical Association2005;95(3):298-306. [DOI: 10.7547/0950298]">Larson 2005</a>). While our search strategy used multiple MN terms, there may be terms that are used in languages other than English of which we are not aware. The US National Library of Medicine began indexing the term 'Morton neuroma' in 2017, which means that that medical subject heading (MeSH) cannot be used in MEDLINE searches that predate 2017. These search‐related issues may also be a source of bias. </p> <p>Where included studies were missing data, or reported data that we could not extract and convert to means and standard deviations (for continuous data) or event rates (for dichotomous data) to use in analysis, we attempted to contact the corresponding trial authors. We either received no reply or, when we did, the original trial data were no longer available. The missing data may introduce bias if the magnitude of effect differs systematically between data that are, and are not, reported. </p> <p>Five studies used a Likert scale to measure satisfaction. Two used the Johnson scale, which is an unvalidated four‐item Likert scale with non‐symmetrical wording across the scale (completely satisfied, satisfied with minor reservations, satisfied with major reservations, dissatisfied) (<a href="./references#CD014687-bbs2-0003" title="HauMYT , ThomsonL , AujlaR , MadhadevanD , BhatiaM . Medium-term results of corticosteroid injections for Morton’s neuroma. Foot &amp; Ankle International2021;42(4):464-8. [DOI: 10.1177/1071100720966332]MahadevanD , AttwalM , BhattR , BhatiaM . Corticosteroid injection for Morton's neuroma with or without ultrasound guidance: a randomised controlled trial. Bone &amp; Joint Journal2016;98-B(4):498-503. [DOI: 10.1302/0301-620X.98B4.36880]">Mahadevan 2016</a>; <a href="./references#CD014687-bbs2-0005" title="SeokH , KimSH , LeeSY , ParkSW . Extracorporeal shockwave therapy in patients with Morton's neuroma a randomized, placebo-controlled trial. Journal of the American Podiatric Medical Association2016;106(2):93-9. [DOI: 10.7547/14-131]">Seok 2016</a>). Two used unvalidated four‐item Likert scales with more symmetrical wording (very satisfied, satisfied, disappointed, extremely disappointed) (<a href="./references#CD014687-bbs2-0004" title="SantiagoFR , MuñozPT , Ramos-BossiniAJL , MartinezAM , OlletaNP . Long-term comparison between blind and ultrasound-guided corticoid injections in Morton neuroma. European Radiology2022;32:1-9. [DOI: 10.1007/s00330-022-08932-y]SantiagoFR , OlletaNP , MuñozPT , ÁlvarezLG , MartínezAM . Short term comparison between blind and ultrasound guided injection in Morton neuroma. European Radiology2019;29(2):620-7. [DOI: 10.1007/s00330-018-5670-1]">Santiago 2022</a>) and (excellent, good, fair, poor) (<a href="./references#CD014687-bbs2-0001" title="AkermarkC , CroneH , SkoogA , WeidenhielmL . A prospective randomized controlled trial of plantar versus dorsal incisions for operative treatment of primary Morton's neuroma. Foot &amp; Ankle International2013;34(9):1198-204. [DOI: 10.1177/1071100713484300]">Akermark 2013</a>). These scales were rated as 'some concerns' in the risk of bias, but there was discussion between review authors about rating these scales from 'high' (unvalidated) to 'low' (likely to represent participant satisfaction) in the risk of bias. </p> </section> <section id="CD014687-sec-0105"> <h3 class="title" id="CD014687-sec-0105">Agreements and disagreements with other studies or reviews</h3> <p>Our inclusion criteria specified that included studies must report on symptoms associated with MN and also use a clinical test and confirm the presence of a neuroma with an USS or MRI for participant inclusion (<a href="./references#CD014687-bbs2-0038" title="DandoC , CherryL , JonesL , BowenC . The clinical diagnosis of symptomatic forefoot neuroma in the general population: a Delphi consensus study. Journal of Foot and Ankle Research2017;10(1):59. [DOI: 10.1186/s13047-017-0241-2]">Dando 2017</a>). Our review used a more comprehensive inclusion criterion for participants than the 2004 Cochrane review, which included studies where there was 'pain associated with Morton's neuroma' (<a href="./references#CD014687-bbs2-0100" title="ThomsonCE , GibsonJN , MartinD . Interventions for the treatment of Morton's neuroma. Cochrane Database of Systematic Reviews2004, Issue 3. Art. No: CD003118. [DOI: 10.1002/14651858.CD003118.pub2]">Thomson 2004</a>). The change in this inclusion criterion resulted in three studies that had been included in the 2004 review being excluded from this 2024 review. The 2004 review concluded, "there was insufficient quantity and quality of trials within the evidence base to reach firm conclusions about the effectiveness of surgical and non‐surgical interventions for Morton's neuroma" which is the same conclusion reached in our review after an additional 20 years of MN research. Since 2004, nine systematic reviews have been published that include a wide range of MN interventions (<a href="./references#CD014687-bbs2-0027" title="BondiL , TarantinoU , BondiR , FollieroA . Treatment of Morton's neuroma: the evidence. Journal of Orthopaedics and Traumatology2005;6(4):199-202. [DOI: 10.1007/s10195-005-0110-9]">Bondi 2005</a>; <a href="./references#CD014687-bbs2-0032" title="ChoiJY , LeeHI , HongWH , SuhJS , HurJW . Corticosteroid injection for Morton's interdigital neuroma: a systematic review. Clinics in Orthopedic Surgery2021;21(3):206-11. [DOI: 10.1177/107110070002100304]">Choi 2021</a>; <a href="./references#CD014687-bbs2-0044" title="EdwardsSR , FlemingS , LandorfKB . Efficacy of a single corticosteroid injection for Morton's neuroma in adults: a systematic review. Journal of the American Podiatric Medical Association2021;111(4):1-12. [DOI: 10.7547/20-151]">Edwards 2021</a>; <a href="./references#CD014687-bbs2-0067" title="LorenzonP , RettoreC , ScalviA . Infiltrative therapy of Morton's neuroma: a systematic review of different treatment options. Acta Biomedica2022;92(Suppl 3):e2021556. [DOI: 10.23750/abm.v92iS3.12545]">Lorenzon 2022</a>; <a href="./references#CD014687-bbs2-0068" title="LuVM , PufferRC , EversonMC , GilderHE , BurksSS , SpinnerRJ . Treating Morton's neuroma by injection, neurolysis, or neurectomy: a systematic review and meta-analysis of pain and satisfaction outcomes. Acta Neurochirurgica2021;163(2):531-43. [DOI: 10.1007/s00701-020-04241-9]">Lu 2021</a>; <a href="./references#CD014687-bbs2-0070" title="MatthewsBG , HurnSE , HardingMP , HenryRA , WareRS . The effectiveness of nonsurgical interventions for common plantar digital compressive neuropathy (Morton's neuroma): a systematic review and meta-analysis. Journal of Foot and Ankle Research2019;12(12):1-21. [DOI: 10.1186/s13047-019-0320-7]">Matthews 2019</a>; <a href="./references#CD014687-bbs2-0088" title="SamailaE , ColoG , RavaA , NegriS , ValentiniR , FelliL , et al. Effectiveness of corticosteroid injections in Civinini-Morton's syndrome: a systematic review. Foot and Ankle Surgery2021;27(4):357-65. [DOI: 10.1016/j.fas.2020.05.001]">Samaila 2021</a>; <a href="./references#CD014687-bbs2-0094" title="ThomsonL , AujlaRS , DivallP , BhatiaM . Non-surgical treatments for Morton'sneuroma: a systematic review. Foot and Ankle Surgery2020;26(7):736-43. [DOI: 10.1016/j.fas.2019.09.009]">Thomson 2020</a>; <a href="./references#CD014687-bbs2-0095" title="ValisenaS , PetriGJ , FerreroA . Treatment of Morton's neuroma: a systematic review. Foot and Ankle Surgery2018;24(4):271-81. [DOI: 10.1016/j.fas.2017.03.010]">Valisena 2018</a>). Five of these nine reviews presented results that combined RCTs with observational studies, making comparisons with our review findings impractical (<a href="./references#CD014687-bbs2-0032" title="ChoiJY , LeeHI , HongWH , SuhJS , HurJW . Corticosteroid injection for Morton's interdigital neuroma: a systematic review. Clinics in Orthopedic Surgery2021;21(3):206-11. [DOI: 10.1177/107110070002100304]">Choi 2021</a>; <a href="./references#CD014687-bbs2-0067" title="LorenzonP , RettoreC , ScalviA . Infiltrative therapy of Morton's neuroma: a systematic review of different treatment options. Acta Biomedica2022;92(Suppl 3):e2021556. [DOI: 10.23750/abm.v92iS3.12545]">Lorenzon 2022</a>; <a href="./references#CD014687-bbs2-0068" title="LuVM , PufferRC , EversonMC , GilderHE , BurksSS , SpinnerRJ . Treating Morton's neuroma by injection, neurolysis, or neurectomy: a systematic review and meta-analysis of pain and satisfaction outcomes. Acta Neurochirurgica2021;163(2):531-43. [DOI: 10.1007/s00701-020-04241-9]">Lu 2021</a>; <a href="./references#CD014687-bbs2-0088" title="SamailaE , ColoG , RavaA , NegriS , ValentiniR , FelliL , et al. Effectiveness of corticosteroid injections in Civinini-Morton's syndrome: a systematic review. Foot and Ankle Surgery2021;27(4):357-65. [DOI: 10.1016/j.fas.2020.05.001]">Samaila 2021</a>; <a href="./references#CD014687-bbs2-0095" title="ValisenaS , PetriGJ , FerreroA . Treatment of Morton's neuroma: a systematic review. Foot and Ankle Surgery2018;24(4):271-81. [DOI: 10.1016/j.fas.2017.03.010]">Valisena 2018</a>). </p> <section id="CD014687-sec-0106"> <h4 class="title"><i>Shockwave therapy (SWT) versus sham SWT</i> </h4> <p>The <a href="./references#CD014687-bbs2-0070" title="MatthewsBG , HurnSE , HardingMP , HenryRA , WareRS . The effectiveness of nonsurgical interventions for common plantar digital compressive neuropathy (Morton's neuroma): a systematic review and meta-analysis. Journal of Foot and Ankle Research2019;12(12):1-21. [DOI: 10.1186/s13047-019-0320-7]">Matthews 2019</a> review included the <a href="./references#CD014687-bbs2-0005" title="SeokH , KimSH , LeeSY , ParkSW . Extracorporeal shockwave therapy in patients with Morton's neuroma a randomized, placebo-controlled trial. Journal of the American Podiatric Medical Association2016;106(2):93-9. [DOI: 10.7547/14-131]">Seok 2016</a> study and reported no effect for pain or satisfaction. The <a href="./references#CD014687-bbs2-0094" title="ThomsonL , AujlaRS , DivallP , BhatiaM . Non-surgical treatments for Morton'sneuroma: a systematic review. Foot and Ankle Surgery2020;26(7):736-43. [DOI: 10.1016/j.fas.2019.09.009]">Thomson 2020</a> review included <a href="./references#CD014687-bbs2-0005" title="SeokH , KimSH , LeeSY , ParkSW . Extracorporeal shockwave therapy in patients with Morton's neuroma a randomized, placebo-controlled trial. Journal of the American Podiatric Medical Association2016;106(2):93-9. [DOI: 10.7547/14-131]">Seok 2016</a> and another study, <a href="./references#CD014687-bbs2-0011" title="FridmanR , CainJD , WeilL . Extracorporeal shockwave therapy for interdigital neuroma: a randomized, placebo-controlled, double-blind trial. Journal of the American Podiatric Medical Association2009;99(3):191-3. [DOI: 10.7547/0980191]LandorfKB . Extracorporeal shockwave therapy for interdigital neuroma: a randomized, placebo-controlled, double-blind trial. Journal of the American Podiatric Medical Association2009;99(5):472‐3. [DOI: 10.7547/0990472a]PayneCB . Extracorporeal shockwave therapy for interdigital neuroma: a randomized, placebo-controlled, double-blind trial. Journal of the American Podiatric Medical Association2009;99(5):472. [DOI: 10.7547/0990472]TurlikM . Extracorporeal shockwave therapy for interdigital neuroma: a randomized, placebo-controlled, double-blind trial. Journal of the American Podiatric Medical Association2009;99(5):473. [DOI: 10.7547/0990473]">Fridman 2009</a>, which we excluded due to it having an ineligible population. <a href="./references#CD014687-bbs2-0094" title="ThomsonL , AujlaRS , DivallP , BhatiaM . Non-surgical treatments for Morton'sneuroma: a systematic review. Foot and Ankle Surgery2020;26(7):736-43. [DOI: 10.1016/j.fas.2019.09.009]">Thomson 2020</a> reported no effect for function at four weeks. These results are consistent with our review. </p> </section> <section id="CD014687-sec-0107"> <h4 class="title"><i>Corticosteroid and local anaesthetic injection (CS+LA) versus local anaesthetic injection (LA)</i> </h4> <p>Only one review reported a between‐group meta‐analysis for pain (<a href="./references#CD014687-bbs2-0070" title="MatthewsBG , HurnSE , HardingMP , HenryRA , WareRS . The effectiveness of nonsurgical interventions for common plantar digital compressive neuropathy (Morton's neuroma): a systematic review and meta-analysis. Journal of Foot and Ankle Research2019;12(12):1-21. [DOI: 10.1186/s13047-019-0320-7]">Matthews 2019</a>). The analysis favoured CS+LA when compared with LA and concluded that there was some short‐ to intermediate‐term evidence of pain reduction with corticosteroid injection (<a href="./references#CD014687-bbs2-0070" title="MatthewsBG , HurnSE , HardingMP , HenryRA , WareRS . The effectiveness of nonsurgical interventions for common plantar digital compressive neuropathy (Morton's neuroma): a systematic review and meta-analysis. Journal of Foot and Ankle Research2019;12(12):1-21. [DOI: 10.1186/s13047-019-0320-7]">Matthews 2019</a>). Our meta‐analysis of the same RCTs, <a href="./references#CD014687-bbs2-0002" title="Lizano-DíezX , Ginés-CespedosaA , Alentorn-GeliE , Pérez-PrietoD , González-LucenaG , GambaC , et al. Corticosteroid injection for the treatment of Morton's neuroma: a prospective, double-blinded, randomized, placebo-controlled trial. Foot &amp; Ankle International2017;38(9):944-51. [DOI: 10.1177/1071100717709569]">Lizano‐Diez 2017</a> and <a href="./references#CD014687-bbs2-0006" title="ThomsonCE , BeggsI , MartinDJ , McMillanD , EdwardsRT , RussellD , et al. Methylprednisolone injections for the treatment of Morton neuroma: a patient-blinded randomized trial. Journal of Bone and Joint Surgery. American Volume2013;95(9):790-S1. [DOI: 10.2106/JBJS.I.01780]">Thomson 2013</a>, reported the same direction of effect favouring CS+LA. <a href="./references#CD014687-bbs2-0070" title="MatthewsBG , HurnSE , HardingMP , HenryRA , WareRS . The effectiveness of nonsurgical interventions for common plantar digital compressive neuropathy (Morton's neuroma): a systematic review and meta-analysis. Journal of Foot and Ankle Research2019;12(12):1-21. [DOI: 10.1186/s13047-019-0320-7]">Matthews 2019</a> reported satisfaction values, but analysed these within‐group, and combined RCTs with observational studies, thus making comparison with our review findings impractical. </p> <p>The <a href="./references#CD014687-bbs2-0094" title="ThomsonL , AujlaRS , DivallP , BhatiaM . Non-surgical treatments for Morton'sneuroma: a systematic review. Foot and Ankle Surgery2020;26(7):736-43. [DOI: 10.1016/j.fas.2019.09.009]">Thomson 2020</a> review reported no effect for pain, function or HRQoL. While <a href="./references#CD014687-bbs2-0044" title="EdwardsSR , FlemingS , LandorfKB . Efficacy of a single corticosteroid injection for Morton's neuroma in adults: a systematic review. Journal of the American Podiatric Medical Association2021;111(4):1-12. [DOI: 10.7547/20-151]">Edwards 2021</a> reported there were no between‐group differences in pain or function at three or six months post‐intervention. The results from <a href="./references#CD014687-bbs2-0044" title="EdwardsSR , FlemingS , LandorfKB . Efficacy of a single corticosteroid injection for Morton's neuroma in adults: a systematic review. Journal of the American Podiatric Medical Association2021;111(4):1-12. [DOI: 10.7547/20-151]">Edwards 2021</a> and <a href="./references#CD014687-bbs2-0094" title="ThomsonL , AujlaRS , DivallP , BhatiaM . Non-surgical treatments for Morton'sneuroma: a systematic review. Foot and Ankle Surgery2020;26(7):736-43. [DOI: 10.1016/j.fas.2019.09.009]">Thomson 2020</a> are consistent with our review. </p> </section> <section id="CD014687-sec-0108"> <h4 class="title"><i>Ultrasound‐guided corticosteroid injection (UG CS+LA) versus non‐ultrasound‐guided corticosteroid injection (NUG CS+LA)</i> </h4> <p>In the <a href="./references#CD014687-bbs2-0094" title="ThomsonL , AujlaRS , DivallP , BhatiaM . Non-surgical treatments for Morton'sneuroma: a systematic review. Foot and Ankle Surgery2020;26(7):736-43. [DOI: 10.1016/j.fas.2019.09.009]">Thomson 2020</a> review, pain outcomes were reported after combining RCTs with observational studies, making comparisons with our review findings impractical. </p> <p>The <a href="./references#CD014687-bbs2-0032" title="ChoiJY , LeeHI , HongWH , SuhJS , HurJW . Corticosteroid injection for Morton's interdigital neuroma: a systematic review. Clinics in Orthopedic Surgery2021;21(3):206-11. [DOI: 10.1177/107110070002100304]">Choi 2021</a> review reported that a meta‐analysis of the studies by <a href="./references#CD014687-bbs2-0003" title="HauMYT , ThomsonL , AujlaR , MadhadevanD , BhatiaM . Medium-term results of corticosteroid injections for Morton’s neuroma. Foot &amp; Ankle International2021;42(4):464-8. [DOI: 10.1177/1071100720966332]MahadevanD , AttwalM , BhattR , BhatiaM . Corticosteroid injection for Morton's neuroma with or without ultrasound guidance: a randomised controlled trial. Bone &amp; Joint Journal2016;98-B(4):498-503. [DOI: 10.1302/0301-620X.98B4.36880]">Mahadevan 2016</a> and <a href="./references#CD014687-bbs2-0089" title="SantiagoFR , PradosON , TomásMP , Guzmán ÁL, MartínezMA . Short term comparison between blind and ultrasound guided injection in morton neuroma. European Radiology2019;29:620-7. [DOI: 10.1007/s00330-018-5670-1]">Santiago 2019</a> (short‐term results only) was impossible because "the characteristics of the selected studies were totally heterogeneous with regard to the injected agent, outcome parameters, outcome measurement, timing, number of injections, and follow‐up period". The long‐term results of <a href="./references#CD014687-bbs2-0004" title="SantiagoFR , MuñozPT , Ramos-BossiniAJL , MartinezAM , OlletaNP . Long-term comparison between blind and ultrasound-guided corticoid injections in Morton neuroma. European Radiology2022;32:1-9. [DOI: 10.1007/s00330-022-08932-y]SantiagoFR , OlletaNP , MuñozPT , ÁlvarezLG , MartínezAM . Short term comparison between blind and ultrasound guided injection in Morton neuroma. European Radiology2019;29(2):620-7. [DOI: 10.1007/s00330-018-5670-1]">Santiago 2022</a> were published after publication of the <a href="./references#CD014687-bbs2-0032" title="ChoiJY , LeeHI , HongWH , SuhJS , HurJW . Corticosteroid injection for Morton's interdigital neuroma: a systematic review. Clinics in Orthopedic Surgery2021;21(3):206-11. [DOI: 10.1177/107110070002100304]">Choi 2021</a> review. </p> <p>The <a href="./references#CD014687-bbs2-0044" title="EdwardsSR , FlemingS , LandorfKB . Efficacy of a single corticosteroid injection for Morton's neuroma in adults: a systematic review. Journal of the American Podiatric Medical Association2021;111(4):1-12. [DOI: 10.7547/20-151]">Edwards 2021</a> review reported no difference between groups in the short, intermediate, or long term for pain based on the <a href="./references#CD014687-bbs2-0003" title="HauMYT , ThomsonL , AujlaR , MadhadevanD , BhatiaM . Medium-term results of corticosteroid injections for Morton’s neuroma. Foot &amp; Ankle International2021;42(4):464-8. [DOI: 10.1177/1071100720966332]MahadevanD , AttwalM , BhattR , BhatiaM . Corticosteroid injection for Morton's neuroma with or without ultrasound guidance: a randomised controlled trial. Bone &amp; Joint Journal2016;98-B(4):498-503. [DOI: 10.1302/0301-620X.98B4.36880]">Mahadevan 2016</a> study, while our review found that UG CS+LA probably reduces pain when compared with NUG CS+LA for all time points based on meta‐analyses of the <a href="./references#CD014687-bbs2-0003" title="HauMYT , ThomsonL , AujlaR , MadhadevanD , BhatiaM . Medium-term results of corticosteroid injections for Morton’s neuroma. Foot &amp; Ankle International2021;42(4):464-8. [DOI: 10.1177/1071100720966332]MahadevanD , AttwalM , BhattR , BhatiaM . Corticosteroid injection for Morton's neuroma with or without ultrasound guidance: a randomised controlled trial. Bone &amp; Joint Journal2016;98-B(4):498-503. [DOI: 10.1302/0301-620X.98B4.36880]">Mahadevan 2016</a> and <a href="./references#CD014687-bbs2-0004" title="SantiagoFR , MuñozPT , Ramos-BossiniAJL , MartinezAM , OlletaNP . Long-term comparison between blind and ultrasound-guided corticoid injections in Morton neuroma. European Radiology2022;32:1-9. [DOI: 10.1007/s00330-022-08932-y]SantiagoFR , OlletaNP , MuñozPT , ÁlvarezLG , MartínezAM . Short term comparison between blind and ultrasound guided injection in Morton neuroma. European Radiology2019;29(2):620-7. [DOI: 10.1007/s00330-018-5670-1]">Santiago 2022</a> studies. </p> </section> <section id="CD014687-sec-0109"> <h4 class="title"><i>Plantar neurectomy (PN) versus dorsal neurectomy (DN)</i> </h4> <p>Two reviews, <a href="./references#CD014687-bbs2-0068" title="LuVM , PufferRC , EversonMC , GilderHE , BurksSS , SpinnerRJ . Treating Morton's neuroma by injection, neurolysis, or neurectomy: a systematic review and meta-analysis of pain and satisfaction outcomes. Acta Neurochirurgica2021;163(2):531-43. [DOI: 10.1007/s00701-020-04241-9]">Lu 2021</a> and <a href="./references#CD014687-bbs2-0095" title="ValisenaS , PetriGJ , FerreroA . Treatment of Morton's neuroma: a systematic review. Foot and Ankle Surgery2018;24(4):271-81. [DOI: 10.1016/j.fas.2017.03.010]">Valisena 2018</a>, assessed <a href="./references#CD014687-bbs2-0001" title="AkermarkC , CroneH , SkoogA , WeidenhielmL . A prospective randomized controlled trial of plantar versus dorsal incisions for operative treatment of primary Morton's neuroma. Foot &amp; Ankle International2013;34(9):1198-204. [DOI: 10.1177/1071100713484300]">Akermark 2013</a> but both combined RCTs with observational studies, making comparisons with our review findings impractical. </p> </section> <section id="CD014687-sec-0110"> <h4 class="title"><i>Adverse events</i> </h4> <p>All nine systematic reviews reported similar types and rates of adverse events compared to our review. </p> </section> <section id="CD014687-sec-0111"> <h4 class="title"><i>Other interventions</i> </h4> <p>Seven systematic reviews included RCTs that we excluded from our review on the basis of inclusion criteria. The reported interventions included: </p> <p> <ul id="CD014687-list-0017"> <li> <p>felt wedging to pronate or supinate the foot (<a href="./references#CD014687-bbs2-0027" title="BondiL , TarantinoU , BondiR , FollieroA . Treatment of Morton's neuroma: the evidence. Journal of Orthopaedics and Traumatology2005;6(4):199-202. [DOI: 10.1007/s10195-005-0110-9]">Bondi 2005</a>; <a href="./references#CD014687-bbs2-0070" title="MatthewsBG , HurnSE , HardingMP , HenryRA , WareRS . The effectiveness of nonsurgical interventions for common plantar digital compressive neuropathy (Morton's neuroma): a systematic review and meta-analysis. Journal of Foot and Ankle Research2019;12(12):1-21. [DOI: 10.1186/s13047-019-0320-7]">Matthews 2019</a>; <a href="./references#CD014687-bbs2-0094" title="ThomsonL , AujlaRS , DivallP , BhatiaM . Non-surgical treatments for Morton'sneuroma: a systematic review. Foot and Ankle Surgery2020;26(7):736-43. [DOI: 10.1016/j.fas.2019.09.009]">Thomson 2020</a>); </p> </li> <li> <p>foot mobilisation (<a href="./references#CD014687-bbs2-0070" title="MatthewsBG , HurnSE , HardingMP , HenryRA , WareRS . The effectiveness of nonsurgical interventions for common plantar digital compressive neuropathy (Morton's neuroma): a systematic review and meta-analysis. Journal of Foot and Ankle Research2019;12(12):1-21. [DOI: 10.1186/s13047-019-0320-7]">Matthews 2019</a>); </p> </li> <li> <p>footwear modifications (<a href="./references#CD014687-bbs2-0027" title="BondiL , TarantinoU , BondiR , FollieroA . Treatment of Morton's neuroma: the evidence. Journal of Orthopaedics and Traumatology2005;6(4):199-202. [DOI: 10.1007/s10195-005-0110-9]">Bondi 2005</a>; <a href="./references#CD014687-bbs2-0032" title="ChoiJY , LeeHI , HongWH , SuhJS , HurJW . Corticosteroid injection for Morton's interdigital neuroma: a systematic review. Clinics in Orthopedic Surgery2021;21(3):206-11. [DOI: 10.1177/107110070002100304]">Choi 2021</a>; <a href="./references#CD014687-bbs2-0044" title="EdwardsSR , FlemingS , LandorfKB . Efficacy of a single corticosteroid injection for Morton's neuroma in adults: a systematic review. Journal of the American Podiatric Medical Association2021;111(4):1-12. [DOI: 10.7547/20-151]">Edwards 2021</a>; <a href="./references#CD014687-bbs2-0070" title="MatthewsBG , HurnSE , HardingMP , HenryRA , WareRS . The effectiveness of nonsurgical interventions for common plantar digital compressive neuropathy (Morton's neuroma): a systematic review and meta-analysis. Journal of Foot and Ankle Research2019;12(12):1-21. [DOI: 10.1186/s13047-019-0320-7]">Matthews 2019</a>; <a href="./references#CD014687-bbs2-0088" title="SamailaE , ColoG , RavaA , NegriS , ValentiniR , FelliL , et al. Effectiveness of corticosteroid injections in Civinini-Morton's syndrome: a systematic review. Foot and Ankle Surgery2021;27(4):357-65. [DOI: 10.1016/j.fas.2020.05.001]">Samaila 2021</a>); </p> </li> <li> <p>surgical neurolysis (<a href="./references#CD014687-bbs2-0027" title="BondiL , TarantinoU , BondiR , FollieroA . Treatment of Morton's neuroma: the evidence. Journal of Orthopaedics and Traumatology2005;6(4):199-202. [DOI: 10.1007/s10195-005-0110-9]">Bondi 2005</a>); </p> </li> <li> <p>capsaicin (<a href="./references#CD014687-bbs2-0067" title="LorenzonP , RettoreC , ScalviA . Infiltrative therapy of Morton's neuroma: a systematic review of different treatment options. Acta Biomedica2022;92(Suppl 3):e2021556. [DOI: 10.23750/abm.v92iS3.12545]">Lorenzon 2022</a>; <a href="./references#CD014687-bbs2-0094" title="ThomsonL , AujlaRS , DivallP , BhatiaM . Non-surgical treatments for Morton'sneuroma: a systematic review. Foot and Ankle Surgery2020;26(7):736-43. [DOI: 10.1016/j.fas.2019.09.009]">Thomson 2020</a>). </p> </li> </ul> </p> <p>Our comprehensive search found no RCTs for a range of MN interventions previously reported as observational studies in other systematic reviews. The reported interventions included: </p> <p> <ul id="CD014687-list-0018"> <li> <p>nonsurgical noninvasive interventions: neodymium:yttrium‐aluminum garnet (Nd:YAG) laser (<a href="./references#CD014687-bbs2-0094" title="ThomsonL , AujlaRS , DivallP , BhatiaM . Non-surgical treatments for Morton'sneuroma: a systematic review. Foot and Ankle Surgery2020;26(7):736-43. [DOI: 10.1016/j.fas.2019.09.009]">Thomson 2020</a>); </p> </li> <li> <p>nonsurgical invasive interventions:</p> <ul id="CD014687-list-0019"> <li> <p>alcohol sclerosing injections (chemical neurolysis) (<a href="./references#CD014687-bbs2-0073" title="MorganP , MonaghanW , RichardsS . A systematic review of ultrasound-guided and non-ultrasound-guided therapeutic injections to treat Morton's neuroma. Journal of the American Podiatric Medical Association2014;104(4):337-48. [DOI: 10.7547/0003-0538-104.4.337]">Morgan 2014</a>; <a href="./references#CD014687-bbs2-0090" title="SantosD , MorrisonG , CodaA . Sclerosing alcohol injections for the management of intermetatarsal neuromas: a systematic review. Foot2018;35:36-47. [DOI: 10.1016/j.foot.2017.12.003]">Santos 2018</a>; <a href="./references#CD014687-bbs2-0067" title="LorenzonP , RettoreC , ScalviA . Infiltrative therapy of Morton's neuroma: a systematic review of different treatment options. Acta Biomedica2022;92(Suppl 3):e2021556. [DOI: 10.23750/abm.v92iS3.12545]">Lorenzon 2022</a>; <a href="./references#CD014687-bbs2-0068" title="LuVM , PufferRC , EversonMC , GilderHE , BurksSS , SpinnerRJ . Treating Morton's neuroma by injection, neurolysis, or neurectomy: a systematic review and meta-analysis of pain and satisfaction outcomes. Acta Neurochirurgica2021;163(2):531-43. [DOI: 10.1007/s00701-020-04241-9]">Lu 2021</a>; <a href="./references#CD014687-bbs2-0070" title="MatthewsBG , HurnSE , HardingMP , HenryRA , WareRS . The effectiveness of nonsurgical interventions for common plantar digital compressive neuropathy (Morton's neuroma): a systematic review and meta-analysis. Journal of Foot and Ankle Research2019;12(12):1-21. [DOI: 10.1186/s13047-019-0320-7]">Matthews 2019</a>; <a href="./references#CD014687-bbs2-0094" title="ThomsonL , AujlaRS , DivallP , BhatiaM . Non-surgical treatments for Morton'sneuroma: a systematic review. Foot and Ankle Surgery2020;26(7):736-43. [DOI: 10.1016/j.fas.2019.09.009]">Thomson 2020</a>; <a href="./references#CD014687-bbs2-0095" title="ValisenaS , PetriGJ , FerreroA . Treatment of Morton's neuroma: a systematic review. Foot and Ankle Surgery2018;24(4):271-81. [DOI: 10.1016/j.fas.2017.03.010]">Valisena 2018</a>); </p> </li> <li> <p>Botox injections (<a href="./references#CD014687-bbs2-0067" title="LorenzonP , RettoreC , ScalviA . Infiltrative therapy of Morton's neuroma: a systematic review of different treatment options. Acta Biomedica2022;92(Suppl 3):e2021556. [DOI: 10.23750/abm.v92iS3.12545]">Lorenzon 2022</a>; <a href="./references#CD014687-bbs2-0070" title="MatthewsBG , HurnSE , HardingMP , HenryRA , WareRS . The effectiveness of nonsurgical interventions for common plantar digital compressive neuropathy (Morton's neuroma): a systematic review and meta-analysis. Journal of Foot and Ankle Research2019;12(12):1-21. [DOI: 10.1186/s13047-019-0320-7]">Matthews 2019</a>; <a href="./references#CD014687-bbs2-0094" title="ThomsonL , AujlaRS , DivallP , BhatiaM . Non-surgical treatments for Morton'sneuroma: a systematic review. Foot and Ankle Surgery2020;26(7):736-43. [DOI: 10.1016/j.fas.2019.09.009]">Thomson 2020</a>); </p> </li> <li> <p>cryoneurolysis (temperature neurolysis (<a href="./references#CD014687-bbs2-0070" title="MatthewsBG , HurnSE , HardingMP , HenryRA , WareRS . The effectiveness of nonsurgical interventions for common plantar digital compressive neuropathy (Morton's neuroma): a systematic review and meta-analysis. Journal of Foot and Ankle Research2019;12(12):1-21. [DOI: 10.1186/s13047-019-0320-7]">Matthews 2019</a>; <a href="./references#CD014687-bbs2-0094" title="ThomsonL , AujlaRS , DivallP , BhatiaM . Non-surgical treatments for Morton'sneuroma: a systematic review. Foot and Ankle Surgery2020;26(7):736-43. [DOI: 10.1016/j.fas.2019.09.009]">Thomson 2020</a>); </p> </li> <li> <p>radiofrequency ablation (temperature neurolysis) (<a href="./references#CD014687-bbs2-0095" title="ValisenaS , PetriGJ , FerreroA . Treatment of Morton's neuroma: a systematic review. Foot and Ankle Surgery2018;24(4):271-81. [DOI: 10.1016/j.fas.2017.03.010]">Valisena 2018</a>; <a href="./references#CD014687-bbs2-0067" title="LorenzonP , RettoreC , ScalviA . Infiltrative therapy of Morton's neuroma: a systematic review of different treatment options. Acta Biomedica2022;92(Suppl 3):e2021556. [DOI: 10.23750/abm.v92iS3.12545]">Lorenzon 2022</a>; <a href="./references#CD014687-bbs2-0070" title="MatthewsBG , HurnSE , HardingMP , HenryRA , WareRS . The effectiveness of nonsurgical interventions for common plantar digital compressive neuropathy (Morton's neuroma): a systematic review and meta-analysis. Journal of Foot and Ankle Research2019;12(12):1-21. [DOI: 10.1186/s13047-019-0320-7]">Matthews 2019</a>; <a href="./references#CD014687-bbs2-0094" title="ThomsonL , AujlaRS , DivallP , BhatiaM . Non-surgical treatments for Morton'sneuroma: a systematic review. Foot and Ankle Surgery2020;26(7):736-43. [DOI: 10.1016/j.fas.2019.09.009]">Thomson 2020</a>); </p> </li> <li> <p>hyaluronic acid injection (<a href="./references#CD014687-bbs2-0067" title="LorenzonP , RettoreC , ScalviA . Infiltrative therapy of Morton's neuroma: a systematic review of different treatment options. Acta Biomedica2022;92(Suppl 3):e2021556. [DOI: 10.23750/abm.v92iS3.12545]">Lorenzon 2022</a>; <a href="./references#CD014687-bbs2-0068" title="LuVM , PufferRC , EversonMC , GilderHE , BurksSS , SpinnerRJ . Treating Morton's neuroma by injection, neurolysis, or neurectomy: a systematic review and meta-analysis of pain and satisfaction outcomes. Acta Neurochirurgica2021;163(2):531-43. [DOI: 10.1007/s00701-020-04241-9]">Lu 2021</a>). </p> </li> </ul> </li> <li> <p>surgical interventions:</p> <ul id="CD014687-list-0020"> <li> <p>mini‐invasive surgery with percutaneous metatarsal osteotomies and ligament release (<a href="./references#CD014687-bbs2-0095" title="ValisenaS , PetriGJ , FerreroA . Treatment of Morton's neuroma: a systematic review. Foot and Ankle Surgery2018;24(4):271-81. [DOI: 10.1016/j.fas.2017.03.010]">Valisena 2018</a>); </p> </li> <li> <p>metatarsal shortening osteotomy and deep transverse metatarsal ligament release (<a href="./references#CD014687-bbs2-0095" title="ValisenaS , PetriGJ , FerreroA . Treatment of Morton's neuroma: a systematic review. Foot and Ankle Surgery2018;24(4):271-81. [DOI: 10.1016/j.fas.2017.03.010]">Valisena 2018</a>); </p> </li> <li> <p>surgical neurolysis (<a href="./references#CD014687-bbs2-0068" title="LuVM , PufferRC , EversonMC , GilderHE , BurksSS , SpinnerRJ . Treating Morton's neuroma by injection, neurolysis, or neurectomy: a systematic review and meta-analysis of pain and satisfaction outcomes. Acta Neurochirurgica2021;163(2):531-43. [DOI: 10.1007/s00701-020-04241-9]">Lu 2021</a>; <a href="./references#CD014687-bbs2-0095" title="ValisenaS , PetriGJ , FerreroA . Treatment of Morton's neuroma: a systematic review. Foot and Ankle Surgery2018;24(4):271-81. [DOI: 10.1016/j.fas.2017.03.010]">Valisena 2018</a>). </p> </li> </ul> </li> </ul> </p> </section> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD014687-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014687.pub2/media/CDSR/CD014687/urn:x-wiley:14651858:media:CD014687:CD014687-FIG-01" target="_blank"><b></b></a></p> </div><img alt="Flow diagram of study selection." data-id="CD014687-fig-0001" src="/cdsr/doi/10.1002/14651858.CD014687.pub2/media/CDSR/CD014687/image_n/nCD014687-FIG-01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014687.pub2/media/CDSR/CD014687/image_t/tCD014687-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Flow diagram of study selection.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014687.pub2/full#CD014687-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014687.pub2/media/CDSR/CD014687/image_n/nCD014687-FIG-01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014687-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014687.pub2/media/CDSR/CD014687/urn:x-wiley:14651858:media:CD014687:CD014687-CMP-001.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Shockwave therapy (SWT) versus sham SWT: short term (up to 1 month), Outcome 1: Pain: VAS (0‐100) (final values): short term (up to 1 month)" data-id="CD014687-fig-0002" src="/cdsr/doi/10.1002/14651858.CD014687.pub2/media/CDSR/CD014687/image_n/nCD014687-CMP-001.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014687.pub2/media/CDSR/CD014687/image_t/tCD014687-CMP-001.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1: Shockwave therapy (SWT) versus sham SWT: short term (up to 1 month), Outcome 1: Pain: VAS (0‐100) (final values): short term (up to 1 month) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014687.pub2/references#CD014687-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014687.pub2/media/CDSR/CD014687/image_n/nCD014687-CMP-001.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014687-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014687.pub2/media/CDSR/CD014687/urn:x-wiley:14651858:media:CD014687:CD014687-CMP-001.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Shockwave therapy (SWT) versus sham SWT: short term (up to 1 month), Outcome 2: Function: AOFAS (0‐100) (final values): short term (up to 1 month)" data-id="CD014687-fig-0003" src="/cdsr/doi/10.1002/14651858.CD014687.pub2/media/CDSR/CD014687/image_n/nCD014687-CMP-001.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014687.pub2/media/CDSR/CD014687/image_t/tCD014687-CMP-001.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1: Shockwave therapy (SWT) versus sham SWT: short term (up to 1 month), Outcome 2: Function: AOFAS (0‐100) (final values): short term (up to 1 month) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014687.pub2/references#CD014687-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014687.pub2/media/CDSR/CD014687/image_n/nCD014687-CMP-001.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014687-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014687.pub2/media/CDSR/CD014687/urn:x-wiley:14651858:media:CD014687:CD014687-CMP-001.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Shockwave therapy (SWT) versus sham SWT: short term (up to 1 month), Outcome 3: Satisfaction (short term)" data-id="CD014687-fig-0004" src="/cdsr/doi/10.1002/14651858.CD014687.pub2/media/CDSR/CD014687/image_n/nCD014687-CMP-001.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014687.pub2/media/CDSR/CD014687/image_t/tCD014687-CMP-001.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1: Shockwave therapy (SWT) versus sham SWT: short term (up to 1 month), Outcome 3: Satisfaction (short term) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014687.pub2/references#CD014687-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014687.pub2/media/CDSR/CD014687/image_n/nCD014687-CMP-001.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014687-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014687.pub2/media/CDSR/CD014687/urn:x-wiley:14651858:media:CD014687:CD014687-CMP-002.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Shockwave therapy (SWT) versus sham SWT: adverse events, Outcome 1: Adverse events: short term" data-id="CD014687-fig-0005" src="/cdsr/doi/10.1002/14651858.CD014687.pub2/media/CDSR/CD014687/image_n/nCD014687-CMP-002.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014687.pub2/media/CDSR/CD014687/image_t/tCD014687-CMP-002.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2: Shockwave therapy (SWT) versus sham SWT: adverse events, Outcome 1: Adverse events: short term </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014687.pub2/references#CD014687-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014687.pub2/media/CDSR/CD014687/image_n/nCD014687-CMP-002.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014687-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014687.pub2/media/CDSR/CD014687/urn:x-wiley:14651858:media:CD014687:CD014687-CMP-003.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Corticosteroid and local anaesthetic injection (CS+LA) versus local anaesthetic injection (LA): pain, Outcome 1: Pain: VAS (0‐100) meta‐analysis (change from baseline and final values) short‐term results" data-id="CD014687-fig-0006" src="/cdsr/doi/10.1002/14651858.CD014687.pub2/media/CDSR/CD014687/image_n/nCD014687-CMP-003.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014687.pub2/media/CDSR/CD014687/image_t/tCD014687-CMP-003.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3: Corticosteroid and local anaesthetic injection (CS+LA) versus local anaesthetic injection (LA): pain, Outcome 1: Pain: VAS (0‐100) meta‐analysis (change from baseline and final values) short‐term results </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014687.pub2/references#CD014687-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014687.pub2/media/CDSR/CD014687/image_n/nCD014687-CMP-003.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014687-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014687.pub2/media/CDSR/CD014687/urn:x-wiley:14651858:media:CD014687:CD014687-CMP-003.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Corticosteroid and local anaesthetic injection (CS+LA) versus local anaesthetic injection (LA): pain, Outcome 2: Pain: VAS (0‐100) meta‐analysis (change from baseline and final values) intermediate‐term results" data-id="CD014687-fig-0007" src="/cdsr/doi/10.1002/14651858.CD014687.pub2/media/CDSR/CD014687/image_n/nCD014687-CMP-003.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014687.pub2/media/CDSR/CD014687/image_t/tCD014687-CMP-003.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3: Corticosteroid and local anaesthetic injection (CS+LA) versus local anaesthetic injection (LA): pain, Outcome 2: Pain: VAS (0‐100) meta‐analysis (change from baseline and final values) intermediate‐term results </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014687.pub2/references#CD014687-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014687.pub2/media/CDSR/CD014687/image_n/nCD014687-CMP-003.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014687-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014687.pub2/media/CDSR/CD014687/urn:x-wiley:14651858:media:CD014687:CD014687-CMP-003.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Corticosteroid and local anaesthetic injection (CS+LA) versus local anaesthetic injection (LA): pain, Outcome 3: Pain: VAS (0‐100) (final values) long‐term results" data-id="CD014687-fig-0008" src="/cdsr/doi/10.1002/14651858.CD014687.pub2/media/CDSR/CD014687/image_n/nCD014687-CMP-003.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014687.pub2/media/CDSR/CD014687/image_t/tCD014687-CMP-003.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3: Corticosteroid and local anaesthetic injection (CS+LA) versus local anaesthetic injection (LA): pain, Outcome 3: Pain: VAS (0‐100) (final values) long‐term results </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014687.pub2/references#CD014687-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014687.pub2/media/CDSR/CD014687/image_n/nCD014687-CMP-003.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014687-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014687.pub2/media/CDSR/CD014687/urn:x-wiley:14651858:media:CD014687:CD014687-CMP-004.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Corticosteroid and local anaesthetic injection (CS+LA) versus local anaesthetic injection (LA): function, Outcome 1: Function: AOFAS (0‐100) and MFPDS (0‐100) meta‐analysis (final values) short term" data-id="CD014687-fig-0009" src="/cdsr/doi/10.1002/14651858.CD014687.pub2/media/CDSR/CD014687/image_n/nCD014687-CMP-004.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014687.pub2/media/CDSR/CD014687/image_t/tCD014687-CMP-004.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4: Corticosteroid and local anaesthetic injection (CS+LA) versus local anaesthetic injection (LA): function, Outcome 1: Function: AOFAS (0‐100) and MFPDS (0‐100) meta‐analysis (final values) short term </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014687.pub2/references#CD014687-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014687.pub2/media/CDSR/CD014687/image_n/nCD014687-CMP-004.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014687-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014687.pub2/media/CDSR/CD014687/urn:x-wiley:14651858:media:CD014687:CD014687-CMP-004.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Corticosteroid and local anaesthetic injection (CS+LA) versus local anaesthetic injection (LA): function, Outcome 2: Function: AOFAS (0‐100) and MFPDS (0‐100) meta‐analysis (final values) intermediate term" data-id="CD014687-fig-0010" src="/cdsr/doi/10.1002/14651858.CD014687.pub2/media/CDSR/CD014687/image_n/nCD014687-CMP-004.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014687.pub2/media/CDSR/CD014687/image_t/tCD014687-CMP-004.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.2</div> <div class="figure-caption"> <p>Comparison 4: Corticosteroid and local anaesthetic injection (CS+LA) versus local anaesthetic injection (LA): function, Outcome 2: Function: AOFAS (0‐100) and MFPDS (0‐100) meta‐analysis (final values) intermediate term </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014687.pub2/references#CD014687-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014687.pub2/media/CDSR/CD014687/image_n/nCD014687-CMP-004.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014687-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014687.pub2/media/CDSR/CD014687/urn:x-wiley:14651858:media:CD014687:CD014687-CMP-004.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Corticosteroid and local anaesthetic injection (CS+LA) versus local anaesthetic injection (LA): function, Outcome 3: Function: MFPDS (0‐100) (final values) long term" data-id="CD014687-fig-0011" src="/cdsr/doi/10.1002/14651858.CD014687.pub2/media/CDSR/CD014687/image_n/nCD014687-CMP-004.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014687.pub2/media/CDSR/CD014687/image_t/tCD014687-CMP-004.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.3</div> <div class="figure-caption"> <p>Comparison 4: Corticosteroid and local anaesthetic injection (CS+LA) versus local anaesthetic injection (LA): function, Outcome 3: Function: MFPDS (0‐100) (final values) long term </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014687.pub2/references#CD014687-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014687.pub2/media/CDSR/CD014687/image_n/nCD014687-CMP-004.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014687-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014687.pub2/media/CDSR/CD014687/urn:x-wiley:14651858:media:CD014687:CD014687-CMP-005.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Corticosteroid and local anaesthetic injection (CS+LA) versus local anaesthetic injection (LA): HRQoL, Outcome 1: HRQoL: EQ‐5D (0‐1) (final values) short term" data-id="CD014687-fig-0012" src="/cdsr/doi/10.1002/14651858.CD014687.pub2/media/CDSR/CD014687/image_n/nCD014687-CMP-005.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014687.pub2/media/CDSR/CD014687/image_t/tCD014687-CMP-005.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.1</div> <div class="figure-caption"> <p>Comparison 5: Corticosteroid and local anaesthetic injection (CS+LA) versus local anaesthetic injection (LA): HRQoL, Outcome 1: HRQoL: EQ‐5D (0‐1) (final values) short term </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014687.pub2/references#CD014687-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014687.pub2/media/CDSR/CD014687/image_n/nCD014687-CMP-005.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014687-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014687.pub2/media/CDSR/CD014687/urn:x-wiley:14651858:media:CD014687:CD014687-CMP-005.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Corticosteroid and local anaesthetic injection (CS+LA) versus local anaesthetic injection (LA): HRQoL, Outcome 2: HRQoL: EQ‐5D (0‐1) (final values) intermediate term" data-id="CD014687-fig-0013" src="/cdsr/doi/10.1002/14651858.CD014687.pub2/media/CDSR/CD014687/image_n/nCD014687-CMP-005.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014687.pub2/media/CDSR/CD014687/image_t/tCD014687-CMP-005.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.2</div> <div class="figure-caption"> <p>Comparison 5: Corticosteroid and local anaesthetic injection (CS+LA) versus local anaesthetic injection (LA): HRQoL, Outcome 2: HRQoL: EQ‐5D (0‐1) (final values) intermediate term </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014687.pub2/references#CD014687-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014687.pub2/media/CDSR/CD014687/image_n/nCD014687-CMP-005.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014687-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014687.pub2/media/CDSR/CD014687/urn:x-wiley:14651858:media:CD014687:CD014687-CMP-005.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Corticosteroid and local anaesthetic injection (CS+LA) versus local anaesthetic injection (LA): HRQoL, Outcome 3: HRQoL: EQ‐5D (0‐1) (final values) long term" data-id="CD014687-fig-0014" src="/cdsr/doi/10.1002/14651858.CD014687.pub2/media/CDSR/CD014687/image_n/nCD014687-CMP-005.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014687.pub2/media/CDSR/CD014687/image_t/tCD014687-CMP-005.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.3</div> <div class="figure-caption"> <p>Comparison 5: Corticosteroid and local anaesthetic injection (CS+LA) versus local anaesthetic injection (LA): HRQoL, Outcome 3: HRQoL: EQ‐5D (0‐1) (final values) long term </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014687.pub2/references#CD014687-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014687.pub2/media/CDSR/CD014687/image_n/nCD014687-CMP-005.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014687-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014687.pub2/media/CDSR/CD014687/urn:x-wiley:14651858:media:CD014687:CD014687-CMP-006.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Corticosteroid and local anaesthetic injection (CS+LA) versus local anaesthetic injection (LA): satisfaction, Outcome 1: Satisfaction: intermediate time point (6 months)" data-id="CD014687-fig-0015" src="/cdsr/doi/10.1002/14651858.CD014687.pub2/media/CDSR/CD014687/image_n/nCD014687-CMP-006.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014687.pub2/media/CDSR/CD014687/image_t/tCD014687-CMP-006.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.1</div> <div class="figure-caption"> <p>Comparison 6: Corticosteroid and local anaesthetic injection (CS+LA) versus local anaesthetic injection (LA): satisfaction, Outcome 1: Satisfaction: intermediate time point (6 months) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014687.pub2/references#CD014687-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014687.pub2/media/CDSR/CD014687/image_n/nCD014687-CMP-006.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014687-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014687.pub2/media/CDSR/CD014687/urn:x-wiley:14651858:media:CD014687:CD014687-CMP-007.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Corticosteroid and local anaesthetic injection (CS+LA) versus local anaesthetic injection (LA): adverse events, Outcome 1: Adverse events: intermediate term" data-id="CD014687-fig-0016" src="/cdsr/doi/10.1002/14651858.CD014687.pub2/media/CDSR/CD014687/image_n/nCD014687-CMP-007.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014687.pub2/media/CDSR/CD014687/image_t/tCD014687-CMP-007.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.1</div> <div class="figure-caption"> <p>Comparison 7: Corticosteroid and local anaesthetic injection (CS+LA) versus local anaesthetic injection (LA): adverse events, Outcome 1: Adverse events: intermediate term </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014687.pub2/references#CD014687-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014687.pub2/media/CDSR/CD014687/image_n/nCD014687-CMP-007.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014687-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014687.pub2/media/CDSR/CD014687/urn:x-wiley:14651858:media:CD014687:CD014687-CMP-008.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 8: Ultrasound guided corticosteroid injection (UG CS+LA) versus non‐ultrasound guided corticosteroid injection (NUG CS+LA): pain, Outcome 1: Pain: VAS (0‐100) (final values) short term" data-id="CD014687-fig-0017" src="/cdsr/doi/10.1002/14651858.CD014687.pub2/media/CDSR/CD014687/image_n/nCD014687-CMP-008.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014687.pub2/media/CDSR/CD014687/image_t/tCD014687-CMP-008.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.1</div> <div class="figure-caption"> <p>Comparison 8: Ultrasound guided corticosteroid injection (UG CS+LA) versus non‐ultrasound guided corticosteroid injection (NUG CS+LA): pain, Outcome 1: Pain: VAS (0‐100) (final values) short term </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014687.pub2/references#CD014687-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014687.pub2/media/CDSR/CD014687/image_n/nCD014687-CMP-008.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014687-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014687.pub2/media/CDSR/CD014687/urn:x-wiley:14651858:media:CD014687:CD014687-CMP-008.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 8: Ultrasound guided corticosteroid injection (UG CS+LA) versus non‐ultrasound guided corticosteroid injection (NUG CS+LA): pain, Outcome 2: Pain: VAS (0‐100) meta‐analysis (final values) intermediate term" data-id="CD014687-fig-0018" src="/cdsr/doi/10.1002/14651858.CD014687.pub2/media/CDSR/CD014687/image_n/nCD014687-CMP-008.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014687.pub2/media/CDSR/CD014687/image_t/tCD014687-CMP-008.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.2</div> <div class="figure-caption"> <p>Comparison 8: Ultrasound guided corticosteroid injection (UG CS+LA) versus non‐ultrasound guided corticosteroid injection (NUG CS+LA): pain, Outcome 2: Pain: VAS (0‐100) meta‐analysis (final values) intermediate term </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014687.pub2/references#CD014687-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014687.pub2/media/CDSR/CD014687/image_n/nCD014687-CMP-008.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014687-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014687.pub2/media/CDSR/CD014687/urn:x-wiley:14651858:media:CD014687:CD014687-CMP-008.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 8: Ultrasound guided corticosteroid injection (UG CS+LA) versus non‐ultrasound guided corticosteroid injection (NUG CS+LA): pain, Outcome 3: Pain: VAS (0‐100) meta‐analysis (final values) long term" data-id="CD014687-fig-0019" src="/cdsr/doi/10.1002/14651858.CD014687.pub2/media/CDSR/CD014687/image_n/nCD014687-CMP-008.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014687.pub2/media/CDSR/CD014687/image_t/tCD014687-CMP-008.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.3</div> <div class="figure-caption"> <p>Comparison 8: Ultrasound guided corticosteroid injection (UG CS+LA) versus non‐ultrasound guided corticosteroid injection (NUG CS+LA): pain, Outcome 3: Pain: VAS (0‐100) meta‐analysis (final values) long term </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014687.pub2/references#CD014687-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014687.pub2/media/CDSR/CD014687/image_n/nCD014687-CMP-008.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014687-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014687.pub2/media/CDSR/CD014687/urn:x-wiley:14651858:media:CD014687:CD014687-CMP-009.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 9: Ultrasound guided corticosteroid injection (UG CS+LA) versus non‐ultrasound guided corticosteroid injection (NUG CS+LA): function, Outcome 1: Function: MFPDS (17‐51) (final values) short term" data-id="CD014687-fig-0020" src="/cdsr/doi/10.1002/14651858.CD014687.pub2/media/CDSR/CD014687/image_n/nCD014687-CMP-009.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014687.pub2/media/CDSR/CD014687/image_t/tCD014687-CMP-009.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.1</div> <div class="figure-caption"> <p>Comparison 9: Ultrasound guided corticosteroid injection (UG CS+LA) versus non‐ultrasound guided corticosteroid injection (NUG CS+LA): function, Outcome 1: Function: MFPDS (17‐51) (final values) short term </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014687.pub2/references#CD014687-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014687.pub2/media/CDSR/CD014687/image_n/nCD014687-CMP-009.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014687-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014687.pub2/media/CDSR/CD014687/urn:x-wiley:14651858:media:CD014687:CD014687-CMP-009.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 9: Ultrasound guided corticosteroid injection (UG CS+LA) versus non‐ultrasound guided corticosteroid injection (NUG CS+LA): function, Outcome 2: Function: MOXFQ (0‐100) and MFPDS (17‐51) meta‐analysis (final values) intermediate term" data-id="CD014687-fig-0021" src="/cdsr/doi/10.1002/14651858.CD014687.pub2/media/CDSR/CD014687/image_n/nCD014687-CMP-009.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014687.pub2/media/CDSR/CD014687/image_t/tCD014687-CMP-009.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.2</div> <div class="figure-caption"> <p>Comparison 9: Ultrasound guided corticosteroid injection (UG CS+LA) versus non‐ultrasound guided corticosteroid injection (NUG CS+LA): function, Outcome 2: Function: MOXFQ (0‐100) and MFPDS (17‐51) meta‐analysis (final values) intermediate term </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014687.pub2/references#CD014687-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014687.pub2/media/CDSR/CD014687/image_n/nCD014687-CMP-009.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014687-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014687.pub2/media/CDSR/CD014687/urn:x-wiley:14651858:media:CD014687:CD014687-CMP-009.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 9: Ultrasound guided corticosteroid injection (UG CS+LA) versus non‐ultrasound guided corticosteroid injection (NUG CS+LA): function, Outcome 3: Function: MOXFQ (0‐100) and MFPDS (17‐51) meta‐analysis (final values) long term" data-id="CD014687-fig-0022" src="/cdsr/doi/10.1002/14651858.CD014687.pub2/media/CDSR/CD014687/image_n/nCD014687-CMP-009.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014687.pub2/media/CDSR/CD014687/image_t/tCD014687-CMP-009.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.3</div> <div class="figure-caption"> <p>Comparison 9: Ultrasound guided corticosteroid injection (UG CS+LA) versus non‐ultrasound guided corticosteroid injection (NUG CS+LA): function, Outcome 3: Function: MOXFQ (0‐100) and MFPDS (17‐51) meta‐analysis (final values) long term </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014687.pub2/references#CD014687-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014687.pub2/media/CDSR/CD014687/image_n/nCD014687-CMP-009.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014687-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014687.pub2/media/CDSR/CD014687/urn:x-wiley:14651858:media:CD014687:CD014687-CMP-010.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 10: Ultrasound guided corticosteroid injection (UG CS+LA) versus non‐ultrasound guided corticosteroid injection (NUG CS+LA): satisfaction, Outcome 1: Satisfaction: short term" data-id="CD014687-fig-0023" src="/cdsr/doi/10.1002/14651858.CD014687.pub2/media/CDSR/CD014687/image_n/nCD014687-CMP-010.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014687.pub2/media/CDSR/CD014687/image_t/tCD014687-CMP-010.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.1</div> <div class="figure-caption"> <p>Comparison 10: Ultrasound guided corticosteroid injection (UG CS+LA) versus non‐ultrasound guided corticosteroid injection (NUG CS+LA): satisfaction, Outcome 1: Satisfaction: short term </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014687.pub2/references#CD014687-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014687.pub2/media/CDSR/CD014687/image_n/nCD014687-CMP-010.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014687-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014687.pub2/media/CDSR/CD014687/urn:x-wiley:14651858:media:CD014687:CD014687-CMP-010.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 10: Ultrasound guided corticosteroid injection (UG CS+LA) versus non‐ultrasound guided corticosteroid injection (NUG CS+LA): satisfaction, Outcome 2: Satisfaction: meta‐analysis intermediate term" data-id="CD014687-fig-0024" src="/cdsr/doi/10.1002/14651858.CD014687.pub2/media/CDSR/CD014687/image_n/nCD014687-CMP-010.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014687.pub2/media/CDSR/CD014687/image_t/tCD014687-CMP-010.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.2</div> <div class="figure-caption"> <p>Comparison 10: Ultrasound guided corticosteroid injection (UG CS+LA) versus non‐ultrasound guided corticosteroid injection (NUG CS+LA): satisfaction, Outcome 2: Satisfaction: meta‐analysis intermediate term </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014687.pub2/references#CD014687-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014687.pub2/media/CDSR/CD014687/image_n/nCD014687-CMP-010.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014687-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014687.pub2/media/CDSR/CD014687/urn:x-wiley:14651858:media:CD014687:CD014687-CMP-010.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 10: Ultrasound guided corticosteroid injection (UG CS+LA) versus non‐ultrasound guided corticosteroid injection (NUG CS+LA): satisfaction, Outcome 3: Satisfaction: long term" data-id="CD014687-fig-0025" src="/cdsr/doi/10.1002/14651858.CD014687.pub2/media/CDSR/CD014687/image_n/nCD014687-CMP-010.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014687.pub2/media/CDSR/CD014687/image_t/tCD014687-CMP-010.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.3</div> <div class="figure-caption"> <p>Comparison 10: Ultrasound guided corticosteroid injection (UG CS+LA) versus non‐ultrasound guided corticosteroid injection (NUG CS+LA): satisfaction, Outcome 3: Satisfaction: long term </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014687.pub2/references#CD014687-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014687.pub2/media/CDSR/CD014687/image_n/nCD014687-CMP-010.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014687-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014687.pub2/media/CDSR/CD014687/urn:x-wiley:14651858:media:CD014687:CD014687-CMP-011.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 11: Ultrasound guided corticosteroid injection (UG CS+LA) versus non‐ultrasound guided corticosteroid injection (NUG CS+LA): adverse events, Outcome 1: Adverse events: long term" data-id="CD014687-fig-0026" src="/cdsr/doi/10.1002/14651858.CD014687.pub2/media/CDSR/CD014687/image_n/nCD014687-CMP-011.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014687.pub2/media/CDSR/CD014687/image_t/tCD014687-CMP-011.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.1</div> <div class="figure-caption"> <p>Comparison 11: Ultrasound guided corticosteroid injection (UG CS+LA) versus non‐ultrasound guided corticosteroid injection (NUG CS+LA): adverse events, Outcome 1: Adverse events: long term </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014687.pub2/references#CD014687-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014687.pub2/media/CDSR/CD014687/image_n/nCD014687-CMP-011.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014687-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014687.pub2/media/CDSR/CD014687/urn:x-wiley:14651858:media:CD014687:CD014687-CMP-012.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 12: Plantar incision neurectomy (PN) versus dorsal incision neurectomy (DN): satisfaction, Outcome 1: Satisfaction: long term" data-id="CD014687-fig-0027" src="/cdsr/doi/10.1002/14651858.CD014687.pub2/media/CDSR/CD014687/image_n/nCD014687-CMP-012.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014687.pub2/media/CDSR/CD014687/image_t/tCD014687-CMP-012.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 12.1</div> <div class="figure-caption"> <p>Comparison 12: Plantar incision neurectomy (PN) versus dorsal incision neurectomy (DN): satisfaction, Outcome 1: Satisfaction: long term </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014687.pub2/references#CD014687-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014687.pub2/media/CDSR/CD014687/image_n/nCD014687-CMP-012.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014687-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014687.pub2/media/CDSR/CD014687/urn:x-wiley:14651858:media:CD014687:CD014687-CMP-013.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 13: Plantar incision neurectomy (PN) versus dorsal incision neurectomy (DN): adverse events, Outcome 1: Adverse events: long term" data-id="CD014687-fig-0028" src="/cdsr/doi/10.1002/14651858.CD014687.pub2/media/CDSR/CD014687/image_n/nCD014687-CMP-013.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014687.pub2/media/CDSR/CD014687/image_t/tCD014687-CMP-013.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 13.1</div> <div class="figure-caption"> <p>Comparison 13: Plantar incision neurectomy (PN) versus dorsal incision neurectomy (DN): adverse events, Outcome 1: Adverse events: long term </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014687.pub2/references#CD014687-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014687.pub2/media/CDSR/CD014687/image_n/nCD014687-CMP-013.01.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD014687-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Summary of findings: corticosteroid and local anaesthetic injection (CS+LA) versus local anaesthetic injection (LA) for people with Morton's neuroma</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Corticosteroid and local anaesthetic injection (CS+LA) versus local anaesthetic injection (LA) for people with Morton's neuroma</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> Morton's neuroma </p> <p><b>Setting:</b> outpatient </p> <p><b>Intervention:</b> corticosteroid and local anaesthetic injection (CS+LA) </p> <p><b>Comparison:</b> local anaesthetic injection (LA) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="bottom"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="bottom"> <p><b>Relative effect</b> <br/><b>(95% CI)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="bottom"> <p><b>Number of participants</b> <br/><b>(studies)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="bottom"> <p><b>Certainty of the evidence</b> <br/><b>(GRADE)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="bottom"> <p><b>Comments</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="bottom"> <p><b>Risk with LA</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="bottom"> <p><b>Risk with CS+LA</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Pain:</b> VAS(0 to 100; a lower score indicates less pain) (change from baseline and final values) </p> <p>Follow‐up: 3 months to 6 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean VAS (0‐100) (final values) at 3 to 6 months was <b>15.10 mm</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD <b>6.31 mm lower</b><br/>(14.23 lower to 1.61 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>157<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⨁⨁◯◯<br/>Low<sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The evidence suggests that CS+LA may result in little to no difference in pain when compared with LA in people with Morton's neuroma. The MD is less than the MCID of 15 mm. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Function:</b> assessed with 2 different questionnaires (lower scores indicate improved function) (final values) </p> <p>Follow‐up: 3 months to 6 months</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>The function score in the CS+LA groups (final values) at 3 to 6 months was on average 0.30 SMDs (0.61 lower to 0.02 higher) <b>lower</b> than in the LA groups. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>157</p> <p>(2 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⨁⨁◯◯<br/>Low<sup>a,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>As a rule of thumb, a SMD of 0.2 is considered a small effect, 0.5 a moderate effect, and 0.8 a large effect. </p> <p>CS+LA may result in little to no difference in function compared to LA for people with Morton's neuroma. </p> <p>Converting the SMD back to the AOFAS (0 to 100) gives an estimated MD of ‐3.33 points (95% CI ‐6.77 to 0.22) and for the MFPDS (0 to 100) an estimated MD of ‐7.71 points (95% CI ‐15.68 to 0.51). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HRQoL:</b> EQ‐5D (0 to 1; a higher score indicates improved HRQoL) (final values) </p> <p>Follow‐up: 3 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean HRQoL (0‐1) (final values) at 3 months was <b>0.57 points</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD <b>0.07 points higher</b><br/>(0.03 lower to 0.17 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>122<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⨁⨁⨁◯<br/>Moderate<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CS+LA probably results in little to no difference in HRQoL compared to LA in people with Morton's neuroma. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Satisfaction:</b> Modified Johnson Scale (dichotomised into satisfied and dissatisfied) </p> <p>Follow‐up: 6 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>58 per 100</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>63 per 100</b><br/>(36 to 100) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.08</b><br/>(0.63 to 1.85) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⨁⨁◯◯<br/>Low<sup>d,e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CS+LA may not increase satisfaction compared to LA in people with Morton's neuroma.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Adverse events</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Unable to calculate</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Unable to calculate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 9.84</b> </p> <p>(1.28 to 75.56)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>157<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⨁◯◯◯<br/>Very low<sup>a,f</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>The evidence is very uncertain about the effect of CS+LA on adverse events compared to LA in people with Morton's neuroma. </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>CS+LA: mild skin atrophy (39 per 1000), hypopigmentation of the skin (39 per 1000) and plantar fat pad atrophy (26 per 1000) </p> <p>LA: none.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>AOFAS:</b> American Orthopaedic Foot and Ankle Society Clinical Rating Lesser Metatarsophalangeal‐Interphalangeal Scale; <b>CI:</b> confidence interval; <b>CS+LA:</b> corticosteroid and local anaesthetic injection; <b>EQ‐5D:</b> EuroQol 5 Dimension Instrument; <b>HRQoL:</b> health‐related quality of life; <b>LA:</b> local anaesthetic injection; <b>MCID:</b> minimum clinically important difference; <b>MD:</b> mean difference; <b>MFPDS:</b> Manchester Foot Pain and Disability Schedule; <b>OIS:</b> optimal information size; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio; <b>SMD:</b> standardised mean difference; <b>VAS:</b> visual analogue scale </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty</b>: we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><b>Explanations</b> </p> <p><sup>a</sup>Downgraded once for study limitations: high risk of bias (missing outcome data) in one study.<br/><sup>b</sup>Downgraded once for imprecision: CI included the possibility of no effect.<br/><sup>c</sup>Downgraded once for imprecision: wide CI which crossed both the small (0.2) and moderate (0.5) effect sizes.<br/><sup>d</sup>Downgraded once for study limitations: high risk of bias (missing outcome data).<br/><sup>e</sup>Downgraded once for imprecision: less than OIS (OIS = 186 participants) and a CI that included the possibility of no effect.<br/><sup>f</sup>Downgraded twice for serious imprecision: less than OIS (OIS = 4638 participants) and a wide CI. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Summary of findings: corticosteroid and local anaesthetic injection (CS+LA) versus local anaesthetic injection (LA) for people with Morton's neuroma</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014687.pub2/full#CD014687-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD014687-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Summary of findings: ultrasound‐guided injection of corticosteroid and local anaesthetic (UG CS+LA) versus non‐ultrasound‐guided injection of corticosteroid and local anaesthetic (NUG CS+LA) for people with Morton's neuroma</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Ultrasound‐guided injection of corticosteroid and local anaesthetic (UG CS+LA) versus non‐ultrasound‐guided injection of corticosteroid and local anaesthetic (NUG CS+LA) for people with Morton's neuroma</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> Morton's neuroma </p> <p><b>Setting:</b> outpatient </p> <p><b>Intervention:</b> ultrasound‐guided injection of corticosteroid and local anaesthetic (UG CS+LA) </p> <p><b>Comparison:</b> non‐ultrasound‐guided injection of corticosteroid and local anaesthetic (NUG CS+LA) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="bottom"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="bottom"> <p><b>Relative effect</b> <br/><b>(95% CI)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="bottom"> <p><b>Number of participants</b> <br/><b>(studies)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="bottom"> <p><b>Certainty of the evidence</b> <br/><b>(GRADE)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="bottom"> <p><b>Comments</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="bottom"> <p><b>Risk with NUG CS+LA</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="bottom"> <p><b>Risk with UG CS+LA</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Pain:</b> VAS (0 to 100; a lower score indicates less pain) (final values) </p> <p>Follow‐up: 6 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean VAS (0‐100) (final values) at 6 months was <b>47.00 mm</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD <b>15.01 mm lower</b><br/>(27.88 lower to 2.14 lower) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>116<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⨁⨁⨁◯<br/>Moderate<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>UG CS+LA probably reduces pain when compared with NUG CS+LA for people with Morton's neuroma. The MD is less than the MCID of 15 mm. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Function:</b> assessed with 2 different questionnaires (lower scores indicate improved function) (final values) </p> <p>Follow‐up: 6 months</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>The function score in the UG CS+LA groups (final values) at 6 months was on average 0.47 SMDs (0.84 lower to 0.10 lower) <b>lower</b> than in the NUG CS+LA groups. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>116</p> <p>(2 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⨁⨁⨁◯<br/>Moderate<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>As a rule of thumb, a SMD of 0.2 is considered a small effect, 0.5 a moderate effect, and 0.8 a large effect. </p> <p>The evidence suggests UG CS+LA probably increases function when compared with NUG CS+LA for people with Morton's neuroma. </p> <p>Converting the SMD back to the MOXFQ (0 to 100) gives an estimated MD of ‐21.95 points (95% CI ‐39.23 to ‐4.67), and for the MFPDS (17 to 51) an estimated MD of ‐5.12 points (95% CI ‐9.16 to ‐1.90). The effect sizes for both are small to moderate, but we are unaware of a MCID for the MOXFQ or MFPDS. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HRQoL</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>Outcome not measured.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Satisfaction:</b> 4‐point Likert scale (dichotomised into satisfied and dissatisfied) </p> <p>Follow‐up: 3 months to 6 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>45 per 100</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>77 per 100</b><br/>(54 to 100) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.71</b><br/>(1.19 to 2.44) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>114<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⨁⨁◯◯<br/>Low<sup>c,d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>UG CS+LA may increase satisfaction when compared with NUG CS+LA for people with Morton's neuroma. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Adverse events</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>13 per 100</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>5 per 100</b> </p> <p>(2 to 18)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.42</b> </p> <p>(0.12 to 1.39)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>116<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⨁⨁◯◯<br/>Low<sup>e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>UG CS+LA may result in little to no difference in adverse events when compared with NUG CS+LA for people with Morton's neuroma. </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>Adverse events: depigmentation or fat atrophy, or both:</p> <p>UG CS+LA (40 per 1000);</p> <p>NUG CS+LA (127 per 1000).</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval; <b>HRQoL:</b> health‐related quality of life; <b>MCID:</b> minimal clinically important difference; <b>MD:</b> mean difference; <b>MFPDS:</b> Manchester Foot Pain and Disability Schedule; <b>MOXFQ:</b> Manchester–Oxford Foot Questionnaire; <b>NUG CS+LA:</b> non‐ultrasound‐guided injection of corticosteroid and local anaesthetic; <b>OIS:</b> optimal information size; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio; <b>SMD:</b> standardised mean difference; <b>UG CS+LA:</b> ultrasound‐guided injection of corticosteroid and local anaesthetic; <b>VAS:</b> visual analogue scale </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><b>Explanations</b> </p> <p><sup>a</sup>Downgraded once for imprecision: wide CI (&gt; 10 mm).<br/><sup>b</sup>Downgraded once for imprecision: less than OIS (OIS = 128 participants) and wide CI which crossed both small (0.2) and large (0.8) effect sizes.<br/><sup>c</sup>Downgraded once for study limitations: some concerns risk of bias (measurement of the outcome) in both studies.<br/><sup>d</sup>Downgraded once for imprecision: less than OIS (OIS = 128 participants).<br/><sup>e</sup>Downgraded twice for serious imprecision: less than OIS (OIS = 4638 participants) and includes the possibility of no effect. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Summary of findings: ultrasound‐guided injection of corticosteroid and local anaesthetic (UG CS+LA) versus non‐ultrasound‐guided injection of corticosteroid and local anaesthetic (NUG CS+LA) for people with Morton's neuroma</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014687.pub2/full#CD014687-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD014687-tbl-0003"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Summary of findings: plantar‐incision neurectomy (PN) versus dorsal‐incision neurectomy (DN) for people with Morton's neuroma</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Plantar‐incision neurectomy (PN) versus dorsal‐incision neurectomy (DN) for people with Morton's neuroma</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> Morton's neuroma </p> <p><b>Setting:</b> outpatient </p> <p><b>Intervention:</b> plantar‐incision neurectomy (PN) </p> <p><b>Comparison:</b> dorsal‐incision neurectomy (DN) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="bottom"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="bottom"> <p><b>Relative effect</b> <br/><b>(95% CI)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="bottom"> <p><b>Number of participants</b> <br/><b>(studies)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="bottom"> <p><b>Certainty of the evidence</b> <br/><b>(GRADE)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="bottom"> <p><b>Comments</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="bottom"> <p><b>Risk with DN</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="bottom"> <p><b>Risk with PN</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Pain:</b> VAS(0 to 100; lower score indicates less pain) </p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>Pain data reported in a format we could not analyse.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Function:</b> restrictions in daily activities (4‐item Likert scale) </p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>Function data reported in a format we could not analyse.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HRQoL</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>Outcome not reported.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Satisfaction:</b> 4‐item Likert scale (dichotomised into satisfied and dissatisfied) </p> <p>Follow‐up: mean 34 months (range 28 to 42)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>83 per 100</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>88 per 100</b><br/>(72 to 100) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.06</b><br/>(0.87 to 1.28) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>73<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⨁⨁◯◯<br/>Low<sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PN may result in little to no difference in satisfaction when compared with DN for people with Morton's neuroma. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>15 per 100</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>12 per 100</b><br/>(4 to 37) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.95</b><br/>(0.32 to 2.85) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>75<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⨁⨁◯◯<br/>Low<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PN may result in little to no difference in adverse events when compared with DN for people with Morton's neuroma. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval; <b>DN:</b> dorsal‐incision neurectomy; <b>HRQoL:</b> health‐related quality of life; <b>OIS:</b> optimal information size; <b>PN:</b> plantar‐incision neurectomy; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio; <b>VAS:</b> visual analogue scale </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><b>Explanations</b> </p> <p><sup>a</sup>Downgraded once for study limitations: some concerns about risk of bias (measurement of the outcome) due to use of an unvalidated 4‐point Likert scale with two active treatment groups and no reported blinding.<br/><sup>b</sup>Downgraded once for imprecision: less than OIS (OIS = 186 participants) and a CI that included the possibility of no effect.<br/><sup>c</sup>Downgraded twice for serious imprecision: less than OIS (OIS = 398 participants) to rule out risk difference with adverse events between intervention groups and CI failed to exclude values for important harms by crossing the line of no effect. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Summary of findings: plantar‐incision neurectomy (PN) versus dorsal‐incision neurectomy (DN) for people with Morton's neuroma</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014687.pub2/full#CD014687-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD014687-tbl-0004"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Shockwave therapy (SWT) versus sham SWT: short term (up to 1 month)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.1 Pain: VAS (0‐100) (final values): short term (up to 1 month) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐7.10 [‐20.10, 5.90]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.2 Function: AOFAS (0‐100) (final values): short term (up to 1 month) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.30 [‐8.38, 14.98]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.3 Satisfaction (short term) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.43 [0.89, 13.15]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Shockwave therapy (SWT) versus sham SWT: short term (up to 1 month)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014687.pub2/references#CD014687-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD014687-tbl-0005"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Shockwave therapy (SWT) versus sham SWT: adverse events</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.1 Adverse events: short term <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Shockwave therapy (SWT) versus sham SWT: adverse events</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014687.pub2/references#CD014687-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD014687-tbl-0006"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Corticosteroid and local anaesthetic injection (CS+LA) versus local anaesthetic injection (LA): pain</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.1 Pain: VAS (0‐100) meta‐analysis (change from baseline and final values) short‐term results <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>157</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.67 [‐11.76, 4.41]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.2 Pain: VAS (0‐100) meta‐analysis (change from baseline and final values) intermediate‐term results <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>157</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐6.31 [‐14.23, 1.61]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.3 Pain: VAS (0‐100) (final values) long‐term results <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>118</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.40 [‐9.59, 12.39]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Corticosteroid and local anaesthetic injection (CS+LA) versus local anaesthetic injection (LA): pain</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014687.pub2/references#CD014687-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD014687-tbl-0007"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Corticosteroid and local anaesthetic injection (CS+LA) versus local anaesthetic injection (LA): function</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.1 Function: AOFAS (0‐100) and MFPDS (0‐100) meta‐analysis (final values) short term <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>157</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.50 [‐0.82, ‐0.18]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.2 Function: AOFAS (0‐100) and MFPDS (0‐100) meta‐analysis (final values) intermediate term <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>157</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.30 [‐0.61, 0.02]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.3 Function: MFPDS (0‐100) (final values) long term <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>118</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.30 [‐4.25, 14.85]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Corticosteroid and local anaesthetic injection (CS+LA) versus local anaesthetic injection (LA): function</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014687.pub2/references#CD014687-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD014687-tbl-0008"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Corticosteroid and local anaesthetic injection (CS+LA) versus local anaesthetic injection (LA): HRQoL</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.1 HRQoL: EQ‐5D (0‐1) (final values) short term <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>122</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.03 [‐0.07, 0.13]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.2 HRQoL: EQ‐5D (0‐1) (final values) intermediate term <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>122</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.07 [‐0.03, 0.17]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.3 HRQoL: EQ‐5D (0‐1) (final values) long term <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>118</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.03 [‐0.14, 0.08]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Corticosteroid and local anaesthetic injection (CS+LA) versus local anaesthetic injection (LA): HRQoL</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014687.pub2/references#CD014687-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD014687-tbl-0009"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Corticosteroid and local anaesthetic injection (CS+LA) versus local anaesthetic injection (LA): satisfaction</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.1 Satisfaction: intermediate time point (6 months) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.08 [0.63, 1.85]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Corticosteroid and local anaesthetic injection (CS+LA) versus local anaesthetic injection (LA): satisfaction</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014687.pub2/references#CD014687-tbl-0009">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD014687-tbl-0010"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">Corticosteroid and local anaesthetic injection (CS+LA) versus local anaesthetic injection (LA): adverse events</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.1 Adverse events: intermediate term <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>157</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>9.84 [1.28, 75.56]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">Corticosteroid and local anaesthetic injection (CS+LA) versus local anaesthetic injection (LA): adverse events</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014687.pub2/references#CD014687-tbl-0010">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD014687-tbl-0011"> <div class="table-heading"><span class="table-label">Comparison 8.</span> <span class="table-title">Ultrasound guided corticosteroid injection (UG CS+LA) versus non‐ultrasound guided corticosteroid injection (NUG CS+LA): pain</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8.1 Pain: VAS (0‐100) (final values) short term <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>72</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐29.00 [‐41.63, ‐16.37]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8.2 Pain: VAS (0‐100) meta‐analysis (final values) intermediate term <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>116</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐15.01 [‐27.88, ‐2.14]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8.3 Pain: VAS (0‐100) meta‐analysis (final values) long term <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>116</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐15.46 [‐26.02, ‐4.90]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 8.</span> <span class="table-title">Ultrasound guided corticosteroid injection (UG CS+LA) versus non‐ultrasound guided corticosteroid injection (NUG CS+LA): pain</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014687.pub2/references#CD014687-tbl-0011">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD014687-tbl-0012"> <div class="table-heading"><span class="table-label">Comparison 9.</span> <span class="table-title">Ultrasound guided corticosteroid injection (UG CS+LA) versus non‐ultrasound guided corticosteroid injection (NUG CS+LA): function</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9.1 Function: MFPDS (17‐51) (final values) short term <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>72</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐6.80 [‐11.25, ‐2.35]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9.2 Function: MOXFQ (0‐100) and MFPDS (17‐51) meta‐analysis (final values) intermediate term <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>116</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.47 [‐0.84, ‐0.10]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9.3 Function: MOXFQ (0‐100) and MFPDS (17‐51) meta‐analysis (final values) long term <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>116</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.52 [‐0.94, ‐0.10]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 9.</span> <span class="table-title">Ultrasound guided corticosteroid injection (UG CS+LA) versus non‐ultrasound guided corticosteroid injection (NUG CS+LA): function</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014687.pub2/references#CD014687-tbl-0012">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD014687-tbl-0013"> <div class="table-heading"><span class="table-label">Comparison 10.</span> <span class="table-title">Ultrasound guided corticosteroid injection (UG CS+LA) versus non‐ultrasound guided corticosteroid injection (NUG CS+LA): satisfaction</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10.1 Satisfaction: short term <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>72</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.02 [1.28, 3.17]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10.2 Satisfaction: meta‐analysis intermediate term <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>114</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.71 [1.19, 2.44]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10.3 Satisfaction: long term <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>68</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.82 [1.17, 2.83]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 10.</span> <span class="table-title">Ultrasound guided corticosteroid injection (UG CS+LA) versus non‐ultrasound guided corticosteroid injection (NUG CS+LA): satisfaction</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014687.pub2/references#CD014687-tbl-0013">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD014687-tbl-0014"> <div class="table-heading"><span class="table-label">Comparison 11.</span> <span class="table-title">Ultrasound guided corticosteroid injection (UG CS+LA) versus non‐ultrasound guided corticosteroid injection (NUG CS+LA): adverse events</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11.1 Adverse events: long term <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>116</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.42 [0.12, 1.39]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 11.</span> <span class="table-title">Ultrasound guided corticosteroid injection (UG CS+LA) versus non‐ultrasound guided corticosteroid injection (NUG CS+LA): adverse events</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014687.pub2/references#CD014687-tbl-0014">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD014687-tbl-0015"> <div class="table-heading"><span class="table-label">Comparison 12.</span> <span class="table-title">Plantar incision neurectomy (PN) versus dorsal incision neurectomy (DN): satisfaction</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12.1 Satisfaction: long term <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>73</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.06 [0.87, 1.28]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 12.</span> <span class="table-title">Plantar incision neurectomy (PN) versus dorsal incision neurectomy (DN): satisfaction</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014687.pub2/references#CD014687-tbl-0015">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD014687-tbl-0016"> <div class="table-heading"><span class="table-label">Comparison 13.</span> <span class="table-title">Plantar incision neurectomy (PN) versus dorsal incision neurectomy (DN): adverse events</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13.1 Adverse events: long term <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>75</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.32, 2.85]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 13.</span> <span class="table-title">Plantar incision neurectomy (PN) versus dorsal incision neurectomy (DN): adverse events</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014687.pub2/references#CD014687-tbl-0016">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-1"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 3.2 Pain: VAS (0‐100) meta‐analysis (change from baseline and final values) intermediate‐term results</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr class="study-data"> <td> <p>Lizano‐Diez 2017</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col6" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col10" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col12" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>A computer‐based randomisation process was employed by using a specific computer program that was accessible only to the pharmacy department providing the medications. No baseline imbalance. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were blinded but those delivering the intervention were aware of intervention received. There were no deviations from intervention. Data was analysed with participants in the groups to which they were assigned. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Six participants (14.6%) were lost to follow‐up without reasons and difference in proportions between intervention groups with four (20.0%) from the steroid and two (9.5%) from the anaesthetic group. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Pain VAS (range: 0 mm to 100 mm). Consistent measurements were made for both intervention groups. Participants (assessors) were blinded to intervention received. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No pre‐registered method (registry or protocol) available. No protocol to cross‐check. Only one pain outcome reported. No evidence of selective reporting. No information as type of analyses not specified in a trial registry entry. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Six participants (14.6%) were lost to follow‐up without reasons and difference in proportions between intervention groups with four (20.0%) from the steroid and two (9.5%) from the anaesthetic group. No pre‐registered method (registry or protocol) available. </p> </td> </tr> <tr class="study-data"> <td> <p>Thomson 2013</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col10" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Telephone call to the York Telephone Randomisation Service, which used permuted blocks with varying block size. No baseline imbalance except MFPDS pain‐related (P = 0.04). </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were unaware of intervention received up to 3 months but unblinded after 3 months. Radiologist delivering the intervention was aware of the intervention received. There were no deviations from the intended intervention. Data was analysed with participants in the groups to which they were assigned. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Five participants (3.8%) were lost to follow‐up. Four (6.3%) from the intervention group and one (1.5%) from the control group. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Pain VAS (range: 0 mm to 100 mm). Consistent measurements were made for both intervention groups. Participants (assessors) were blinded to intervention received. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Protocol registered. Not enough information in the protocol on a statistical plan and no published statistical plan found. All outcome measures from protocol reported. Both raw and mean adjusted analysis reported. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Protocol registered. Not enough information in the protocol on a statistical plan and no published statistical plan found. </p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 3.2 Pain: VAS (0‐100) meta‐analysis (change from baseline and final values) intermediate‐term results</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014687.pub2/references#riskOfBias2Table-1">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-2"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 4.2 Function: AOFAS (0‐100) and MFPDS (0‐100) meta‐analysis (final values) intermediate term</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr class="study-data"> <td> <p>Lizano‐Diez 2017</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col6" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col8" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col10" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col12" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>A computer‐based randomisation process was employed by using a specific computer program that was accessible only to the pharmacy department providing the medications. No baseline imbalance. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were blinded but those delivering the intervention were aware of intervention received. There were no deviations from intervention. Data was analysed with participants in the groups to which they were assigned. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Six participants (14.6%) were lost to follow‐up without reasons and difference in proportions between intervention groups with four (20.0%) from the steroid and two (9.5%) from the anaesthetic group. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>American Orthopaedic Foot &amp; Ankle Society (AOFAS) clinical rating system test (metatarsophalangeal and interphalangeal score). Range: 0 to 100, where 100 means no functional limitations. The AOFAS does not endorse the scale due to insufficient reliability and validity. Consistent measurements were made for both intervention groups. Participants and researcher who collected the data were blinded to intervention received. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No pre‐registered method (registry or protocol) available. No protocol to cross‐check. Only one function outcome reported. No evidence of selective reporting. No information as type of analyses not specified in a trial registry entry. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Six participants (14.6%) were lost to follow‐up without reasons and difference in proportions between intervention groups with four (20.0%) from the steroid and two (9.5%) from the anaesthetic group. The AOFAS has not been validated. No pre‐registered method (registry or protocol) available. </p> </td> </tr> <tr class="study-data"> <td> <p>Thomson 2013</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col10" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Telephone call to the York Telephone Randomisation Service, which used permuted blocks with varying block size. No baseline imbalance except MFPDS pain‐related (P = 0.04). </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were unaware of intervention received up to 3 months but unblinded after 3 months. Radiologist delivering the intervention was aware of the intervention received. There were no deviations from the intended intervention. Data was analysed with participants in the groups to which they were assigned. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Five participants (3.8%) were lost to follow‐up. Four (6.3%) from the intervention group and one (1.5%) from the control group. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Manchester Foot Pain and Disability Schedule walking/doing (range: 0 to 100, where 0 is best score). Consistent measurements were made for both intervention groups. Participants (assessors) were blinded to intervention received. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Protocol registered. Not enough information in the protocol on a statistical plan and no published statistical plan found. All outcome measures from protocol reported. Both raw and mean adjusted analysis reported. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Protocol registered. Not enough information in the protocol on a statistical plan and no published statistical plan found. </p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 4.2 Function: AOFAS (0‐100) and MFPDS (0‐100) meta‐analysis (final values) intermediate term</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014687.pub2/references#riskOfBias2Table-2">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-3"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 5.2 HRQoL: EQ‐5D (0‐1) (final values) intermediate term</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr class="study-data"> <td> <p>Thomson 2013</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col10" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Telephone call to the York Telephone Randomisation Service, which used permuted blocks with varying block size. No baseline imbalance except MFPDS pain‐related (P = 0.04). </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were unaware of intervention received up to 3 months but unblinded after 3 months. Radiologist delivering the intervention was aware of the intervention received. There were no deviations from the intended intervention. Data was analysed with participants in the groups to which they were assigned. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Five participants (3.8%) were lost to follow‐up. Four (6.3%) from the intervention group and one (1.5%) from the control group. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>EQ‐5D (range: 0 to 1, where 1 is best health). Consistent measurements were made for both intervention groups. Participants (assessors) were blinded to intervention received. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Protocol registered. Not enough information in the protocol on a statistical plan and no published statistical plan found. All outcome measures from protocol reported. Both raw and mean adjusted analysis reported. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Protocol registered. Not enough information in the protocol on a statistical plan and no published statistical plan found. </p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 5.2 HRQoL: EQ‐5D (0‐1) (final values) intermediate term</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014687.pub2/references#riskOfBias2Table-3">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-4"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 6.1 Satisfaction: intermediate time point (6 months)</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr class="study-data"> <td> <p>Lizano‐Diez 2017</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col6" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col8" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col10" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col12" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>A computer‐based randomisation process was employed by using a specific computer program that was accessible only to the pharmacy department providing the medications. No baseline imbalance. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were blinded but those delivering the intervention were aware of intervention received. There were no deviations from intervention. Data was analysed with participants in the groups to which they were assigned. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Six participants (14.6%) were lost to follow‐up without reasons and difference in proportions between intervention groups with four (20.0%) from the steroid and two (9.5%) from the anaesthetic group. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Johnson scale modified from four to five statement unvalidated Likert scale. Consistent measurements were made for both intervention groups. Participants (assessors) were blinded to intervention received. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No pre‐registered method (registry or protocol) available. No protocol to cross‐check. Only one satisfaction outcome reported. No evidence of selective reporting. No information as type of analyses not specified in a trial registry entry. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Six participants (14.6%) were lost to follow‐up without reasons and difference in proportions between intervention groups with four (20.0%) from the steroid and two (9.5%) from the anaesthetic group. Johnson scale is an unvalidated 5 statement Likert scale. No pre‐registered method (registry or protocol) available. </p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 6.1 Satisfaction: intermediate time point (6 months)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014687.pub2/references#riskOfBias2Table-4">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-5"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 7.1 Adverse events: intermediate term</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr class="study-data"> <td> <p>Lizano‐Diez 2017</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col6" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col10" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col12" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>A computer‐based randomisation process was employed by using a specific computer program that was accessible only to the pharmacy department providing the medications. No baseline imbalance. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were blinded but those delivering the intervention were aware of intervention received. There were no deviations from intervention. Data was analysed with participants in the groups to which they were assigned. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Six participants (14.6%) were lost to follow‐up without reasons and difference in proportions between intervention groups with four (20.0%) from the steroid and two (9.5%) from the anaesthetic group. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No documentation of adverse events in the methods but adverse events reported in the results. Nothing to suggest data collection was not consistant between the groups. Participants and the researcher who collected the data were blinded to intervention received. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No prespecified analysis plan. Unlikely there would be multiple eligible outcomes or analyses for adverse events. Only one reported in the results. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Six participants (14.6%) were lost to follow‐up without reasons and difference in proportions between intervention groups with four (20.0%) from the steroid and two (9.5%) from the anaesthetic group. No documentation of adverse events in the methods but adverse events reported in the results. No prespecified analysis plan. Unlikely there would be multiple eligible outcomes or analyses for adverse events. Only one reported in the results. </p> </td> </tr> <tr class="study-data"> <td> <p>Thomson 2013</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Telephone call to the York Telephone Randomisation Service, which used permuted blocks with varying block size. No baseline imbalance except MFPDS pain‐related (P = 0.04). </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were unaware of intervention received up to 3 months but unblinded after 3 months. Radiologist delivering the intervention was aware of the intervention received. There were no deviations from the intended intervention. Data was analysed with participants in the groups to which they were assigned. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Five participants (3.8%) were lost to followup. Four (6.3%) from the intervention group and one (1.5%) from the control group. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The research team monitored adverse events throughout the trial. Nothing to suggest data collection was not consistant between the groups. Participants and researcher were blinded to intervention received. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Protocol registered. Data analysed in accordance with protocol (document adverse events). Only one outcome for adverse events reported in protocol and results. Only one analysis for adverse events reported in results. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were unaware of intervention received up to 3 months but unblinded after 3 months. Radiologist delivering the intervention was aware of the intervention received. Five participants (3.8%) were lost to followup. Four (6.3%) from the intervention group and one (1.5%) from the control group. </p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 7.1 Adverse events: intermediate term</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014687.pub2/references#riskOfBias2Table-5">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-6"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 8.2 Pain: VAS (0‐100) meta‐analysis (final values) intermediate term</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr class="study-data"> <td> <p>Mahadevan 2016</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col10" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Clustered Data. <b>Domain 1a: Randomisation process</b> : Participants were randomised per foot using block sizes of six with opaque sealed envelops that were sequentially opened at the time of the intervention. The local research and development department performed the block randomisation. There was no baseline imbalance that would suggest a problem with randomisation. <b>Domain 1b: Timing of identification or recruitment</b>: Participants were the cluster where bilateral symptomatic neuroma were identified during recruitment before randomisation. There was no baseline imbalance that would suggest differential identification or recruitment of participants. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Clustered Data. Participants were aware they were enroled in a trial but were unaware of the intervention received. Those delivering the intervention were aware of the intervention received. There were no deviations from intended interventions and the analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Clustered Data. Three participants (four feet including one cluster) declined intervention following recruitment. One participant (one foot) was lost to follow‐up. 45 of 50 feet (90%) were included at the intermediate follow‐up. While there are documented reasons for withdrawal, the intervention arm for these participants and feet are not identified but unlikely to bias the result. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Clustered Data. The outcome measure was appropriate and unlikely to differ between intervention groups. Outcome assessors (participants) were aware a trial was taking place but were blinded to the intervention allocation. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Clustered Data. No pre‐registered protocol.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Clustered Data. No pre‐registered protocol.</p> </td> </tr> <tr class="study-data"> <td> <p>Santiago 2022</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col8" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col10" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Epidat 4.1, the sampling module, was used to generate a series of random numbers indicating in which group each participant should be included. A researcher not involved in the diagnosis or treatment of the participant guarded the generated list. Not clear if the randomisation sequence was concealed from the researcher recruiting trial participants. No baseline imbalance for age and pain. Gender reported overall but not per intervention arm. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participant blinding not recorded for intervention received. Those delivering the intervention were aware of intervention received. There were no interventions from the intended intervention. Data was analysed with participants in the groups to which they were assigned. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Four participants (5.3%) were lost to follow‐up. Three (8.3%) from the NUG and one (2.6%) from the UG. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Pain VAS (range: 0 to 10). Consistent measurements were made for both intervention groups. Participant reported outcome with two active treatment groups and no reported blinding. While there is potential for participants to be influenced, it is unlikely due to similar therapeutic mechanisms for both interventions. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Protocol registered. Not enough information in the protocol on a statistical plan and no published statistical plan found. All outcome measures from protocol reported. No information as type of analyses not specified in a trial registry entry. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participant blinding not recorded for intervention received. Those delivering the intervention were aware of intervention received. Participant reported outcome with two active treatment groups and no reported blinding. While there is potential for participants to be influenced, it is unlikely due to similar therapeutic mechanisms for both interventions. Protocol registered. Not enough information in the protocol on a statistical plan and no published statistical plan found. </p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 8.2 Pain: VAS (0‐100) meta‐analysis (final values) intermediate term</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014687.pub2/references#riskOfBias2Table-6">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-7"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 9.2 Function: MOXFQ (0‐100) and MFPDS (17‐51) meta‐analysis (final values) intermediate term</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr class="study-data"> <td> <p>Mahadevan 2016</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col10" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Clustered Data. <b>Domain 1a: Randomisation process</b> : Participants were randomised per foot using block sizes of six with opaque sealed envelops that were sequentially opened at the time of the intervention. The local research and development department performed the block randomisation. There was no baseline imbalance that would suggest a problem with randomisation. <b>Domain 1b: Timing of identification or recruitment</b>: Participants were the cluster where bilateral symptomatic neuroma were identified during recruitment before randomisation. There was no baseline imbalance that would suggest differential identification or recruitment of participants. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Clustered Data. Participants were aware they were enroled in a trial but were unaware of the intervention received. Those delivering the intervention were aware of the intervention received. There were no deviations from intended interventions and the analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Clustered Data. Three participants (four feet including one cluster) declined intervention following recruitment. One participant (one foot) was lost to follow‐up. 45 of 50 feet (90%) were included at the intermediate follow‐up. While there are documented reasons for withdrawal, the intervention arm for these participants and feet are not identified but unlikely to bias the result. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Clustered Data. The outcome measure was appropriate and unlikely to differ between intervention groups. Outcome assessors (participants) were aware a trial was taking place but were blinded to the intervention allocation. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Clustered Data. No pre‐registered protocol.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Clustered Data. No pre‐registered protocol.</p> </td> </tr> <tr class="study-data"> <td> <p>Santiago 2022</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col8" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col10" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Epidat 4.1, the sampling module, was used to generate a series of random numbers indicating in which group each participant should be included. A researcher not involved in the diagnosis or treatment of the participant guarded the generated list. Not clear if the randomisation sequence was concealed from the researcher recruiting trial participants. No baseline imbalance for age and pain. Gender reported overall but not per intervention arm. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participant blinding not recorded for intervention received. Those delivering the intervention were aware of intervention received. There were no interventions from the intended intervention. Data was analysed with participants in the groups to which they were assigned. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Four participants (5.3%) were lost to follow‐up. Three (8.3%) from the NUG and one (2.6%) from the UG. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Manchester Foot Pain and Disability Schedule (range: 17 to 51, where higher scores indicate greater severity). Consistent measurements were made for both intervention groups. Participant reported outcome with two active treatment groups and no reported blinding. While there is potential for participants to be influenced, it is unlikely due to similar therapeutic mechanisms for both interventions. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Protocol registered. Not enough information in the protocol on a statistical plan and no published statistical plan found. All outcome measures from protocol reported. No information as type of analyses not specified in a trial registry entry. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participant blinding not recorded for intervention received. Those delivering the intervention were aware of intervention received. Participant reported outcome with two active treatment groups and no reported blinding. While there is potential for participants to be influenced, it is unlikely due to similar therapeutic mechanisms for both interventions. Protocol registered. Not enough information in the protocol on a statistical plan and no published statistical plan found. </p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 9.2 Function: MOXFQ (0‐100) and MFPDS (17‐51) meta‐analysis (final values) intermediate term</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014687.pub2/references#riskOfBias2Table-7">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-8"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 10.2 Satisfaction: meta‐analysis intermediate term</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr class="study-data"> <td> <p>Mahadevan 2016</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col8" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col10" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Clustered Data. <b>Domain 1a: Randomisation process</b> : Participants were randomised per foot using block sizes of six with opaque sealed envelops that were sequentially opened at the time of the intervention. The local research and development department performed the block randomisation. There was no baseline imbalance that would suggest a problem with randomisation. <b>Domain 1b: Timing of identification or recruitment</b>: Participants were the cluster where bilateral symptomatic neuroma were identified during recruitment before randomisation. There was no baseline imbalance that would suggest differential identification or recruitment of participants. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Clustered Data. Participants were aware they were enroled in a trial but were unaware of the intervention received. Those delivering the intervention were aware of the intervention received. There were no deviations from intended interventions and the analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Clustered Data. Three participants (four feet including one cluster) declined intervention following recruitment. One participant (one foot) was lost to follow‐up. 45 of 50 feet (90%) were included at the intermediate follow‐up. While there are documented reasons for withdrawal, the intervention arm for these participants and feet are not identified but unlikely to bias the result. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Clustered Data. The outcome measure is a commonly used but unvalidated four point Likert scale. Unlikely to differ between intervention groups. Outcome assessors (participants) were aware a trial was taking place but were blinded to the intervention allocation. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Clustered Data. No pre‐registered protocol.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Clustered Data. The outcome measure is a commonly used but unvalidated four point Likert scale. No pre‐registered protocol. </p> </td> </tr> <tr class="study-data"> <td> <p>Santiago 2022</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col8" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col10" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Epidat 4.1, the sampling module, was used to generate a series of random numbers indicating in which group each participant should be included. A researcher not involved in the diagnosis or treatment of the participant guarded the generated list. Not clear if the randomisation sequence was concealed from the researcher recruiting trial participants. No baseline imbalance for age and pain. Gender reported overall but not per intervention arm. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participant blinding not recorded for intervention received. Those delivering the intervention were aware of intervention received. There were no interventions from the intended intervention. Data was analysed with participants in the groups to which they were assigned. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Four participants (5.3%) were lost to follow‐up. Three (8.3%) from the NUG and one (2.6%) from the UG. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Unvalidated four statement Likert scale. Consistent measurements were made for both intervention groups. Participant reported outcome with two active treatment groups and no reported blinding. While there is potential for participants to be influenced, it is unlikely due to similar therapeutic mechanisms for both interventions. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Protocol lists EQ‐5D but a four statement Likert scale used in study. No information as type of analyses not specified in a trial registry entry. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participant blinding not recorded for intervention received. Those delivering the intervention were aware of intervention received. Unvalidated four statement Likert scale. Participant reported outcome with two active treatment groups and no reported blinding. While there is potential for participants to be influenced, it is unlikely due to similar therapeutic mechanisms for both interventions. Protocol lists EQ‐5D but a four statement Likert scale used in study. No information as type of analyses not specified in a trial registry entry. </p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 10.2 Satisfaction: meta‐analysis intermediate term</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014687.pub2/references#riskOfBias2Table-8">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-9"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 11.1 Adverse events: long term</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr class="study-data"> <td> <p>Mahadevan 2016</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col8" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col10" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Clustered Data. <b>Domain 1a: Randomisation process</b> : Participants were randomised per foot using block sizes of six with opaque sealed envelops that were sequentially opened at the time of the intervention. The local research and development department performed the block randomisation. There was no baseline imbalance that would suggest a problem with randomisation. <b>Domain 1b: Timing of identification or recruitment</b>: Participants were the cluster where bilateral symptomatic neuroma were identified during recruitment before randomisation. There was no baseline imbalance that would suggest differential identification or recruitment of participants. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Clustered Data. Participants were aware they were enrolled in a trial but were unaware of the intervention received. Those delivering the intervention were aware of the intervention received. When a patient requested further treatment (failure), outcome measures at that point were recorded and analysed. Intervention arms identified for event counts of the dichotomised outcome. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Clustered Data. Three participants (four feet including one cluster) declined intervention following recruitment. One participant (one foot) was lost to follow‐up. 45 of 50 feet (90%) were included at the intermediate follow‐up. While there are documented reasons for withdrawal, the intervention arm for these participants and feet are not identified but unlikely to bias the result. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Clustered Data. Method discusses treatment failure (where participant requested further treatment) but does not mention adverse events. Adverse events (complications) are discussed in results. Nothing to suggest data collection was not consistant between the groups. Participants consented to participate in the trial and nothing to suggest individuals who collected the data were not aware that a trial was taking place. Participants were blinded to intervention received but no mention of blinding for the individuals who collected the data. While outcome could have been influenced by knowledge of intervention received it is unlikely due to two similar active intervention arms. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No prespecified analysis plan. Unlikely there would be multiple eligible outcomes or analyses for adverse events. Only one reported in the results. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Clustered Data. Method discusses treatment failure (where participant requested further treatment) but does not mention adverse events. Adverse events (complications) are discussed in results. Nothing to suggest data collection was not consistant between the groups. Participants consented to participate in the trial and nothing to suggest individuals who collected the data were not aware that a trial was taking place. Participants were blinded to intervention received but no mention of blinding for the individuals who collected the data. While outcome could have been influenced by knowledge of intervention received it is unlikely due to two similar active intervention arms. No prespecified analysis plan. Unlikely there would be multiple eligible outcomes or analyses for adverse events. Only one reported in the results. </p> </td> </tr> <tr class="study-data"> <td> <p>Santiago 2022</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col8" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col10" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Epidat 4.1, the sampling module, was used to generate a series of random numbers indicating in which group each participant should be included. A researcher not involved in the diagnosis or treatment of the participant guarded the generated list. Not clear if the randomisation sequence was concealed from the researcher recruiting trial participants. No baseline imbalance for age and pain. Gender reported overall but not per intervention arm. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participant blinding not recorded for intervention received. Those delivering the intervention were aware of intervention received. There were no interventions from the intended intervention. Data was analysed with participants in the groups to which they were assigned. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Four participants (5.3%) were lost to followup. Three (8.3%) from the NUG and one (2.6%) from the UG. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No documentation of adverse events in the methods but adverse events reported in the results. Nothing to suggest data collection was not consistant between the groups. Participant and researcher reported outcome with two active treatment groups and no reported blinding for participants but researcher was blinded to intervention arms. While outcome could have been influenced it is unlikely due to two similar active intervention arms. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Adverse events not listed as an outcome in the registered protocol but reported in the results. Unlikely there would be multiple eligible outcomes or analyses for adverse events. Only one reported in the results. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No documentation of adverse events in the methods but adverse events reported in the results. Nothing to suggest data collection was not consistant between the groups. Participant and researcher reported outcome with two active treatment groups and no reported blinding for participants but researcher was blinded to intervention arms. While outcome could have been influenced it is unlikely due to two similar active intervention arms. Adverse events not listed as an outcome in the registered protocol but reported in the results. Unlikely there would be multiple eligible outcomes or analyses for adverse events. Only one reported in the results. </p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 11.1 Adverse events: long term</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014687.pub2/references#riskOfBias2Table-9">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-10"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 12.1 Satisfaction: long term</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr class="study-data"> <td> <p>Akermark 2013</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col8" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col10" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were grouped by a random code sorted by block and patient but blinding of person recruiting participants not reported which may result in ability to predict assignments successfully, based on previous assignments. No baseline imbalance. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were aware of intervention received. There were no deviations from intervention that were inconsistent with what could occur outside the trial context. Data was analysed with participants in the groups to which they were assigned. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Two participants (4.9%) from the dorsal group underwent reoperation with plantar incision by 12 months. Outcome data included as poor results. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Unvalidated four‐step Likert scale for overall satisfaction with the results of surgery (range: excellent, good, fair, and poor). Consistent measurements were made for both intervention groups. Participant reported outcome with 2 active treatment groups and no reported blinding. While there is potential for participants to be influenced, it is unlikely due to similar therapeutic mechanisms for both interventions. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No pre‐registered method (registry or protocol) available. Only one satisfaction outcome reported. No evidence of selective reporting. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Due to participant reported outcome with two active treatment groups and no reported blinding. No pre‐registered method (registry or protocol) available. </p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 12.1 Satisfaction: long term</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014687.pub2/references#riskOfBias2Table-10">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-11"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 13.1 Adverse events: long term</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr class="study-data"> <td> <p>Akermark 2013</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col8" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col10" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were grouped by a random code sorted by block and patient but blinding of person recruiting participants not reported which may result in ability to predict assignments successfully, based on previous assignments. No baseline imbalance. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were aware of intervention received. There were no deviations from intervention that were inconsistent with what could occur outside the trial context. Data was analysed with participants in the groups to which they were assigned. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Two participants (4.9%) from the dorsal group underwent reoperation with plantar incision by 12 months. Outcome data included as poor results. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Method discusses treatment failure (poor result of surgery, persistent pain requiring reoperation) but does not mention adverse events. Adverse events (complications) are discussed in results. Nothing to suggest data collection was not consistent between the groups. Participants and study assessors aware of intervention received. While outcome could have been influenced it is unlikely due to two similar active intervention arms. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No prespecified analysis plan. Unlikely there would be multiple eligible outcomes or analyses for adverse events. Only one reported in the results. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Method discusses treatment failure (poor result of surgery, persistent pain requiring reoperation) but does not mention adverse events. Adverse events (complications) are discussed in results. Nothing to suggest data collection was not consistent between the groups. Participants and study assessors aware of intervention received. While outcome could have been influenced it is unlikely due to two similar active intervention arms. No prespecified analysis plan. Unlikely there would be multiple eligible outcomes or analyses for adverse events. Only one reported in the results. </p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 13.1 Adverse events: long term</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014687.pub2/references#riskOfBias2Table-11">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD014687.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="de#CD014687-note-0005">Deutsch</a> </li> <li class="section-language"> <a class="" href="es#CD014687-note-0012">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD014687-note-0009">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD014687-note-0010">Français</a> </li> <li class="section-language"> <a class="" href="ms#CD014687-note-0008">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="pl#CD014687-note-0011">Polski</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD014687-note-0006">简体中文</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD014687-note-0007">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738735355000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738735355000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD014687\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD014687\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD014687\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD014687\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD014687\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD014687\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD014687\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD014687\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD014687\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD014687\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD014687\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD014687\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD014687\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD014687\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD014687\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD014687\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD014687\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD014687\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=tkZQC4GK&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD014687.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD014687.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD014687.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD014687.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD014687.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740716585229"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD014687.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740716585233"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD014687.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918da3057e709379',t:'MTc0MDcxNjU4NS4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 